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GENETIC MUTATION UNDERLYING 
ORTHOSTATIC INTOLERANCE AND -continued 
DIAGNOSTIC AND THERAPEUTIC 
METHODS RELATING THERETO Table of Abbreviations 
5 RCR repair chain reaction 
CROSS REFERENCE TO RELATED SbP systolic blood pressure 
SSCP single strand conformation polymorphism 
SDA strand displacement activation 
REF Restriction endonuclease fingerprinting 
APPLICATIONS 
This application is based on and claims priority to U.S. 
Provisional Application Ser. No. 601173,682, filed Dec. 29, 10 
1999, and to U.S. Provisional Application Ser. No. 601175, 
456, filed Jan. 11, 2000, each of which are herein incorpo- 
rated by reference in their entirety. 
BACKGROUND ART 
Orthostatic intolerance (01) is a syndrome characterized 
15 by adrenergic symptoms brought on by upright posture. 
Usually, there is a heart rate increase of at least 30 bpm on 
standing without significant orthostatic hypotension. Jacob 
et al., Circulation (1997). Females are disproportionately 
affected and patients usually present in the second to fourth 
20 decade of life. Low et al., Neurology (1995). This dysauto- 
nomic syndrome is quite common and may have been first 
described as Da Costa’s syndrome more than 100 years ago. 
Jordan et al., Chin J.  Physiol (1997); Novak et al., JAut  N 
molecules useful for analyzing novel norepinephrine (NE) 25 tion: Mechanisms, Manifestations and Treatment (1 987). It 
transporter variants, to peptides encoded by these molecules, has been re-recomized Over the years as heart, 
a newly identified NE transporter polymorphism, Among drome. It also bears many similarities to chronic fatigue 
such are methods for determining the susceptibility of syndrome. Because of the prominent feature of orthostatic 
current popular name. Rosen et al., Am JMed  (1982). biological sample from the subject. 
These features and their improvement with salt and vol- 
ume replacement are consistent with hypovolemia and a 
secondary sympathetic activation. However, most patients 
35 are not hypovolemic. Excessive venous pooling with upright 
posture, hypersensitivity of veins to alpha-adrenoreceptor 
GRANT STATEMENT 
n i S  work was supported by NIH grants MH58921, p o l  
HL56693 and ~ ~ 0 0 0 9 5 ,  and by NASA grant NAS 9 19483, 
Thus, the U,S, G~~~~~~~~ has certain rights in the inven- 
tion. 
TECHNICAL FIELD 
The present invention relates to isolated po~ynuc~eotide sYst ( l  996); Streeten, Orthostatic Of the circuza- 
and to the diagnostic and therapeutic thereof relating to asthenia, and prolapse syn- 
a subject to orthostatic intolerance based on an analysis o f a  30 tachycardia, postural tachycardia syndrome is a 
Table of Abbreviations 
ggonists and decreased autonomic latencies in the lower 
extremities are consistent with partial autonomic denerva- 
tion as another mechanism which could cause secondary 
40 sympathetic activation. However, increased heart rate, 
plasma norepinephrine and muscle sympathetic nerve activ- 
ity (MSNA) even in the supine position coupled with widely 
oscillating heart rate with upright posture and disparities 
among heart rate, plasma norepinephrine and MSNA 
45 responses to upright tilt are more consistent with fmdamen- 
tally disordered autonomic regulation. Novak et al., JAut  N 
Syst (1996); Furlan et al., Circulation (1998); Shannonet al., 
Circulation (1998); Puddu et al., Am Heart J (1983); Pas- 
temac et al., Am JMed  (1982); Coghlan et al., Am JMed  
Thus far, most explanations of the physiological and 
biochemical abnormalities in 0 1  have focused on alterations 
in norepinephrine release (i.e., compensatory, excessive, or 
disordered). Streeten et al., J L a b  Clin Med (1988); Furlan 
55 et al., Circulation (1998); Novak et al., Stroke (1998). An 
alternative explanation is an abnormality in synaptic nore- 
pinephrine clearance. Approximately 80-90% of norepi- 
nephrine released into many synapses can be cleared by 
neuronal re-uptake via the presynaptic norepinephrine trans- 
60 porter (NET), while the remaining 1 6 2 0 %  spills over into 
the circulation or extraneuronal tissue, as disclosed by Esler 
et al., Physiol Rev (1990). 
To date, attempts to identify a genetic basis within the NE 
transporter gene for 0 1  or other NE transport impairment 
65 have not been undertaken. It is further noted that drugs 
inhibiting NET (e.g., cocaine, amphetamines, tricyclic anti- 
depressants) cause features typical of 0 1  (i.e., tachycardia, 
50 (1979). 
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orthostatic symptoms, and elevated plasma catecholamines). 
Thus, exploration of impaired NET function, including 
exploration of a genetic basis for such impaired NET func- 
tion, would provide important information about the bio- 
logical and addictive effects of these drugs. 
What is needed, then, is further characterization of the 
structure of the NE transporter gene generally and in 0 1  
patients. Since the NE transporter plays a pivotal role in 
norepinephrine uptake at the synaptic cleft, further charac- 
terization of the structure and role of the NE transporter gene 10 
would meet a long-felt need in the art for diagnostic and 
therapeutic methods associated with NE transporter-medi- 
ated biological functions. 
to and associated with the NE transporter polymorphism 
and/or sub-optimal NE transporter function. 
Some of the objects of the invention having been stated 
hereinabove, other objects will become evident as the 
5 description proceeds, when taken in connection with the 
accompanying Drawings and Examples as best described 
hereinbelow. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 1A-1C depict continuous blood pressure (BP) and 
heart rate (HR) recordings. Beat-by-beat BP as determined 
by photoplethysmography and continuous HR recording 
illustrates spontaneous excursions of up to 50 mmHg and 25 
15 bpm respectively in the proband (FIG. 1A) and her identical 
twin (FIG. 1B). With tilt (FIG. lC), BP and HR volatility is 
A method of screening for sub-optimal NE transporter- intensified. 
mediated physiological responses function in a subject is FIGS. 2A-2F depict evaluation of norepinephrine trans- 
disclosed. The method comprises: (a) obtaining a biological porter (NET) mutation, DNA sequencing (FIG, 2A) identi- 
sample from the subject; and (b) detecting a Polymorphism 2o fied the presence of both C and G nucleotides (arrows) in 
of a NE transporter gene in the biological sample from the both the sense and antisense DNA indicating heterozygosity 
subject, the Presence of the Polymorphism indicating that at this locus. This C to G nucleotide change results in an 
the susceptibility of the subject to sub-optimal NET-medi- alanine to proline change in amino acid 457 (A457P). FIG. 
ated physiological responses. In accordance with a preferred 2B shows the position of the A457p mutation within NET, 
embodiment of the present invention, detection of the poly- 25 This mutation occurs in transmembrane domain 9 which is 
morphism is employed with respect to determining the highly conserved among the related murine and bovine 
susceptibility of a subject to orthostatic intolerance (01). NETS and the frog epinephrine transporter (ET)  as Seen in 
Preferably, the polymorphism of the NE transporter FIG. 2C. FIG. 2D shows that compared to the wild type 
polypeptide comprises a G to C transversion in exon 9 of the NET, the A457P mutation results in significant impairment 
NE transporter gene. Preferably, the G to C transversion 30 of NE uptake in transiently transfected Chinese Hamster 
further comprises a change in the triplet code from GCAI Ovary cells which is not significantly different from the 
GCCIGCGIGCU to CCAICCCICCGICCU, which encodes a nonspecific uptake observed in cells transfected with the 
NE transporter polypeptide having a proline moiety at amino vector alone. FIGS. 2E and 2F evaluated the presence of the 
acid residue 457 instead of an alanine moiety. mutant (P) and wild type (A) alleles within the family of the 
acid probes and antibodies suitable for use in carrying out FIGS. 3A-3F depict supine and upright heart rate and 
the methods of the present invention and for use in detecting plasma catecholamines in the proband's family. Heart rate 
the polypeptides and polynucleotides of the present inven- (HR) and plasma concentrations of norepinephrine (NE) and 
tion are also disclosed herein. Methods for preparing the its intraneuronal metabolite dihydroxyphenylglycol 
polynucleotides and polypeptides of the present invention 40 (DHPG) in family members with (Ap) and without (AA) the 
are also disclosed herein. A457P mutation. Supine HR (FIG. 3A) was similar in AA 
In a further embodiment, this invention pertains to diag- and AP individuals. Upright HR (FIG. 3B) and NE (FIG. 
nostic methods based upon a polymorphism of a NE trans- 3D) were significantly greater in AP family members than in 
porter gene as described herein. Such diagnostic methods AA individuals. Supine NE (FIG. 3C) trended toward higher 
include detection of NE transporter deficiencies and disor- values in AP individuals but did not reach statistical signifi- 
ders related thereto based upon a comparison of NE trans- cance. The ratio of DHPG to NE was significantly lower in 
porter function related data to data observed in patients AP individuals both supine and upright with impairment of 
having the NE transporter polymorphism disclosed here. NE reuptake. (*p=O.OX, **p<0.05, ***p=O.Ol). Plasma 
It is therefore an object of the present invention to provide 5o DHPGInorepinephrine ratio was significantly greater in AA 
polynucleotide molecules that can be used in analyzing NE individuals that in AP individuals with both supine and 
transporter genes in vertebrate subjects. upright postures (FIG. 3E and FIG. 3F). 
It is also an object of the present invention to provide for FIG. 4A is a schematic depicting neuronal metabolism of 
the determination of NE transporter genotype in vertebrate norepinephrine (NE) in normal conditions. 
subjects and particularly human subjects, based on informa- 55 FIG. 4B is a schematic depicting neuronal metabolism of 
tion obtained through the analysis of nucleic acids, including norepinephrine (NE) in NET deficiency conditions. 
genomic DNA and cDNA, derived from tissues from the 
subject. DETAILED DESCRIPTION OF THE 
It is yet another object of the present invention to provide 
a ready method for determining NE transporter genotype. 
It is still a further object of the present invention to 
provide polypeptide and polynucleotide molecules for use in 
generating antibodies that distinguish between the different 
forms of NE transporter which constitute the NE transporter 
polymorphism. 
It is yet a further object of the present invention is to 
provide methods for diagnosing clinical syndromes related 
SUMMARY OF THE INVENTION 
Kits and reagents, including oligonucleotides, nucleic 35 0 1  proband (arrow). 
45 
INVENTION 
60 
Orthostatic intolerance (01) is a common syndrome char- 
acterized by lightheadedness, palpitations, fatigue, altered 
mentation, and a syncope and is often accompanied by 
postural tachycardia and elevated plasma norepinephrine. 
65 Previous studies suggest that heart rate and plasma norepi- 
nephrine are elevated out of proportion to increase in 
sympathetic outflow. The cocaine and antidepressant sensi- 
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tive L-norepinephrine transporter (NET) is responsible for 
synaptic norepinephrine inactivation. 
As shown in FIG. 4A, under normal conditions exocytotic 
release of NE from intraneuronal vesicles into the synaptic 
space where the amine can interact with post-synaptic and 
pre-synapic adrenoreceptors (a). Approximately 80% of the 
synapic NE is taken up into the neuron by NET. Approxi- 
mately 20% spills over into the circulation (b). Captured NE 
is preferentially converted to DHPG by monoamine oxidase 
(MAO); some is repackaged into synaptic vesicles (c). 
DHPG diffuses out of the neuron into the circulation (d). 
As shown in FIG. 4B, release of NE into the synaptic 
space is unaffected (e). Because of decreased NET activity, 
less than 80% of the synapic NE is taken up into the neuron 
by NET and the spillover into the circulation is greater than 
20%. Also because of decreased NET activity, NE has 
greater opportunity for interaction with adrenoreceptors (q. 
Because the reuptake of NE is decreased, DHPG production 
is decreased (g). Lower DHPG concentration in the neuron 
results in lower DHPG concentrations in the plasma and, 
subsequently, a reduced plasma DHPGiNE ration (h). 
Whether abnormal NET function might contribute to the 
pathophysiology of 01, using a battery of bedside physi- 
ological, pharmacological, biochemical, and molecular bio- 
logical tests was tested. In a proband with significant ortho- 
static symptoms and tachycardia, the present co-inventors 
found disproportionately elevated plasma norepinephrine 
with standing, impaired systemic clearance of infused 
titrated norepinephrine, impaired tyramine responsiveness, 
and a dissociation between plasma norepinephrine and 
DHPG elevation. Analysis of the norepinephrine transporter 
(SCL6A2, referred to herein as the “NE transporter” or 
“NET”) revealed the proband to be a heterozygote for an 
inactivating coding mutation in exon 9. Analysis of norepi- 
nephrine transport activity produced by the mutant cDNA in 
transfected cells demonstrated greater than 98% reduction in 
function relative to normal. Presence of the mutant allele in 
the proband’s family segregated with postural tachycardia 
and alteration in plasma catecholamine homeostasis. 
Thus, the present invention pertains to the first identifi- 
cation of a specific genetic defect in 0 1  and to the first 
identification of a disease linked to a coding alteration in a 
Na+/Cl- dependent neurotransmitter transporter. The 
present invention also pertains to the discovery that genetic 
or acquired deficits in norepinephrine inactivation underlie 
hyperadrenergic states leading to orthostatic intolerance. 
As disclosed herein is the discovery of a polymorphism of 
the norepinephrine transporter, the transport polypeptide 
that plays a role in norepinephrine reuptake at the synaptic 
cleft, among other in vivo roles. Particularly, the polymor- 
phism is characterized by an amino acid substitution, ala- 
nineiproline at amino acid 457 in the encoded NE trans- 
porter polypeptide. 
Also disclosed herein is the observation that a single 
nucleotide change in the NE transporter gene is responsible 
for the functional polymorphism of the NE transporter. 
Particularly, a G to C transversion with exon 9 of the NE 
transporter gene leads to an A457P change in the encoded 
NE transporter polypeptide. 
In light of these discoveries, manipulation of biological 
samples derived from vertebrate subjects can be effected to 
provide for the analysis of NE transporter phenotypes, for 
the generation of peptides encoded by such nucleic acid 
molecules, and for diagnostic methods relating to the NE 
transporter polymorphism. Nucleic acid molecules utilized 
6 
in these contexts may be amplified, as described below, and 
generally include RNA, genomic DNA and cDNA derived 
from RNA. 
A. Polynucleotide Screening Techniques 
In accordance with one embodiment of the present inven- 
tion, a method of screening for susceptibility to sub-optimal 
norepinephrine (NE) transport function resulting in 
decreased NE clearance in a subject is provided. The method 
comprising the steps of: (a) obtaining a nucleic acid sample 
from the subject; and (b) detecting a polymorphism of a 
norepinephrine transporter (“NE transporter” or “NET”) 
gene in the nucleic acid sample from the subject, the 
presence of the polymorphism indicating that the suscepti- 
15 bility of the subject to sub-optimal NE transport function, 
which results in decreased NE transport. In accordance with 
the present invention, detection of the polymorphism is 
particularly provided with respect to determining the sus- 
ceptibility of a subject to orthostatic intolerance (01). 
As used herein and in the claims, the term “polymor- 
phism” refers to the occurrence of two or more genetically 
determined alternative sequences or alleles in a population. 
A polymorphic marker is the locus at which divergence 
occurs. Preferred markers have at least two alleles, each 
25 occurring at frequency of greater than 1%. A polymorphic 
locus may be as small as one base pair. 
Useful nucleic acid molecules according to the present 
invention include those which will specifically hybridize to 
NE transporter sequences in the region of the G to C 
3o transversion at base 237 within exon 9 (GenBank Accession 
No. ~91127,  SEQ ID NO:15) of the NE transporter gene, 
changing the triplet code from GCA or GCC or GCG or 
GCU to CCA or CCC or CCG or CCU. This transversion 
leads to the A457P change in the encoded NE transporter 
35 polypeptide. Typically these are at least about 20 nucleotides 
in length and have the nucleotide sequence corresponding to 
the region of the G to C transversion in a cDNA (e.g. SEQ 
ID NO:3) encoding a NE transporter polypeptide and includ- 
ing exon 9 of the NE transporter gene. The cDNA sequence 
4o set forth in SEQ ID NO:1 is referred to herein as a NE 
transporter “consensus sequence”. The term “consensus 
sequence”, as used herein, is meant to refer to a nucleic acid 
or protein sequence for NET, the nucleic or amino acids of 
which are known to occur with high frequency in a popu- 
45 lation of individuals who carry the gene which codes for a 
normally functioning protein, or which nucleic acid itself 
has normal function. 
Provided nucleic acid molecules can be labeled according 
to any technique known in the art, such as with radiolabels, 
50 fluorescent labels, enzymatic labels, sequence tags, etc. 
According to another aspect of the invention, the nucleic 
acid molecules contain the G to C transversion of exon 9. 
Such molecules can be used as allele-specific oligonucle- 
otide probes to track a particular mutation, for example, 
Body samples can be tested to determine whether the NE 
transporter gene contains the G to C transversion of exon 9. 
Suitable body samples for testing include those comprising 
DNA, RNA or protein obtained from biopsies, including 
60 liver and intestinal tissue biopsies; or from blood, prenatal; 
or embryonic tissues, for example. 
In one embodiment of the invention a pair of isolated 
oligonucleotide primers are provided RB655 (SEQ ID 
NO:32) and RB667(SEQ ID NO:33). These primers are 
65 derived from NE transporter exon 9 (the location of the 
polymorphism of the present invention), and amplify a yield 
a 448 base pair (bp) product. Other primers are also derived 
5 
2o 
55 through a family of subjects. 
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from NE transporter exon 9 (the location of the polymor- erably between ten and thirty bases in length. Such oligo- 
phism of the present invention, GenBank Accession No. nucleotides can optionally further comprise a detectable 
~91127,  SEQ ID NO:15). The oligonucleotide primers are label. 
useful in diagnosis of a subject at risk for impaired or Environmental conditions conducive to synthesis include 
sub-optimal NET function and orthostatic intolerance. The 5 the presence of nucleoside triphosphates and an agent for 
primers direct amplification of a target polynucleotide prior 
to sequencing. These unique NE transporter exon 9 oligo- 
nucleotide primers were designed and produced based upon 
identification of the G to C transversion in exon 9. 
In another embodiment of the invention isolated allele 
specific oligonucleotides (e.g. SEQ ID NOS: 9 & 10) are 
provided. Sequences substantially similar thereto are also 
provided in accordance with the present invention. The 
allele specific oligonucleotides are useful in diagnosis of a 
subject at risk for impaired or sub-optimal NET function. 
These unique NE transporter exon 9 oligonucleotide primers 
were designed and produced based upon identification of the 
G to C transversion in exon 9. 
The terms “substantially complementary to” or “substan- 
tially the sequence of’ refer to sequences which hybridize to 
the sequences provided (e.g. SEQ ID NOS: 9 and 10) under 
stringent conditions andor sequences having sufficient 
homology with any of SEQ ID NOS: 9 and 10, such that the 
allele specific oligonucleotides of the invention hybridize to 
the seauence. The term “isolated” as used herein includes 
polymerization, such as DNA polymerase, and a suitable 
temperature and pH. The primer is preferably single 
stranded for maximum efficiency in amplification, but can be 
double stranded. If double stranded, the primer is first 
i o  treated to separate its strands before being used to prepare 
extension products. The primer must be sufficiently long to 
prime the synthesis of extension products in the presence of 
the inducing agent for polymerization. The exact length of 
primer will depend on many factors, including temperature, 
15 buffer, and nucleotide composition. The oligonucleotide 
primer typically contains 12-20 or more nucleotides, 
although it can contain fewer nucleotides. 
Primers of the invention are designed to be “substantially” 
complementary to each strand of the genomic locus to be 
20 amplified. This means that the primers must be sufficiently 
complementary to hybridize with their respective strands 
under conditions which allow the agent for polymerization 
to perform. In other words, the primers should have suffi- 
cient complementarity with the 5‘ and 3’ sequences flanking 
25 the transversion to hvbridize therewith and nermit amnlifi- 
oligonucleotides substantially free of other nucleic acids, cation of the genomic locus. 
proteins, lipids, carbohydrates or other materials with which Oligonucleotide primers of the invention are employed in 
they may be associated, such association being either in the amplification method which is an enzymatic chain 
cellular material or in a synthesis medium. A “target poly- reaction that produces exponential quantities of polymor- 
nucleotide” or “target nucleic acid” refers to the nucleic acid 30 phic locus relative to the number of reaction steps involved. 
sequence of interest e.g., a NE transporter-encoding poly- Typically, one primer is complementary to the negative (-) 
nucleotide. Other primers which can be used for primer strand of the polymorphic locus and the other is comple- 
hybridization are readily ascertainable to those of skill in the mentary to the positive (+) strand. Annealing the primers to 
art based upon the disclosure herein of the NE transporter denatured nucleic acid followed by extension with an 
polymorphism. 35 enzyme, such as the large fragment of DNA polymerase I 
The primers of the invention embrace oligonucleotides of (Klenow) and nucleotides, results in newly synthesized + 
sufficient length and appropriate sequence so as to provide and - strands containing the target polymorphic locus 
initiation of polymerization on a significant number of sequence. Because these newly synthesized sequences are 
nucleic acids in the polymorphic locus (See FIG. 2). Spe- also templates, repeated cycles of denaturing, primer anneal- 
cifically, the term “primer” as used herein refers to a 40 ing, and extension results in exponential production of the 
sequence comprising two or more deoxyribonucleotides or region (i.e., the target polymorphic locus sequence) defined 
ribonucleotides, preferably more than three, and more pref- by the primers. The product of the chain reaction is a discreet 
erably more than eight and most preferably at least about 20 nucleic acid duplex with termini corresponding to the ends 
nucleotides of the NE transporter gene wherein the DNA of the specific primers employed. 
seauence contains the G to C transversion within to NE 45 The oligonucleotide nrimers of the invention can be 
transporter exon 9. The allele including guanosine (G) 
within NE transporter exon 9 is referred to herein as the 
“NET-a allele”, the “A457 allele”, or the “alanine-encoding 
allele”. The allele including cytosine (C) within NE trans- 
porter exon 9 is referred to herein as the “NET-b allele”, the 
“P457 allele”, or the “proline-encoding allele”. 
An oligonucleotide that distinguishes between the NET-a 
and the NET-b alleles of the NE transporter gene, wherein 
the oligonucleotide hybridizes to a portion of the NE trans- 
porter gene that includes nucleotide 237 of exon 9 of the NE 
transporter gene when the nucleotide 237 is cytosine, but 
u 
prepared using any suitable method, such as conventional 
phosphotriester and phosphodiester methods or automated 
embodiments thereof. In one such automated embodiment, 
diethylphosphoramidites are used as starting materials and 
50 can be synthesized as described by Beaucage et al., Etra- 
hedron Letters 22:1859-1862 (1981). One method for syn- 
thesizing oligonucleotides on a modified solid support is 
described in U.S. Pat. No. 4,458,066. 
Any nucleic acid specimen, in purified or non-purified 
55 form, can be utilized as the starting nucleic acid or acids, 
providing it contains, or is suspected of containing, a nucleic 
does not hybridize with the portion of the NE transporter acid sequence containing the polymorphic locus. Thus, the 
gene when the nucleotide 237 is guanosine is also provided method can amplify, for example, DNA or RNA, including 
in accordance with the present invention. An oligonucleotide messenger RNA, wherein DNA or RNA can be single 
that distinguishes between the NET-a and the NET-b alleles 60 stranded or double stranded. In the event that RNA is to be 
of the NE transporter gene, wherein the oligonucleotide used as a template, enzymes, andor conditions optimal for 
hybridizes to a portion of the NE transporter gene that reverse transcribing the template to DNA would be utilized. 
includes nucleotide 237 of exon 9 of the NE transporter gene In addition, a DNA-RNA hybrid which contains one strand 
when the nucleotide 237 is guanosine, but does not hybridize of each can be utilized. A mixture of nucleic acids can also 
with the portion of the NE transporter gene when the 65 be employed, or the nucleic acids produced in a previous 
nucleotide 237 is cytosine is also provided in accordance amplification reaction herein, using the same or different 
with the present invention. Such oligonucleotides are pref- primers can be so utilized. The specific nucleic acid 
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sequence to be amplified, i.e., the polymorphic locus, can be The amplification products can be detected by Southern 
a fraction of a larger molecule or can be present initially as blot analysis with or without using radioactive probes. In 
a discrete molecule, so that the specific sequence constitutes one such method, for example, a small sample of DNA 
the entire nucleic acid. It is not necessary that the sequence containing a very low level of the nucleic acid sequence of 
to be amplified be present initially in a pure form; it can be 5 the polymorphic locus is amplified, and analyzed via a 
a minor fraction of a complex mixture, such as contained in Southern blotting technique or similarly, using dot blot 
whole human DNA. analysis. The use of non-radioactive probes or labels is 
DNAutilized herein can be extracted from a body sample, facilitated by the high level of the amplified signal. Alter- 
such as blood, tissue material, preferably white blood cells, natively, probes used to detect the amplified products can be 
and the like by a variety of techniques such as that described i o  directly or indirectly detectably labeled, for example, with a 
by Maniatis et. al. in Molecular Cloning: A Laboratory radioisotope, a fluorescent compound, a bioluminescent 
Manual, Cold Spring Harbor, N.Y., p 286281 (1982). If the compound, a chemiluminescent compound, a metal chelator 
extracted sample is impure, it can be treated before ampli- or an enzyme. Those of ordinary skill in the art will know of 
fication with an amount of a reagent effective to open the other suitable labels for binding to the probe, or will be able 
cells, or animal cell membranes of the sample, and to expose 15 to ascertain such, using routine experimentation. 
andor separate the strand(s) of the nucleic acid(s). This Sequences amplified by the methods of the invention can 
lysing and nucleic acid denaturing step to expose and be further evaluated, detected, cloned, sequenced, and the 
separate the strands will allow amplification to occur much like, either in solution or after binding to a solid support, by 
more readily. any method usually applied to the detection of a specific 
The deoxyribonucleotide triphosphates dATP, dCTP, 20 DNA sequence such as dideoxy sequencing, PCR, oligomer 
dGTP, and dTTP are added to the synthesis mixture, either restriction (Saiki et al., Bio/Echnology 3:lOOX-1012 
separately or together with the primers, in adequate amounts (1 985), allele-specific oligonucleotide (ASO) probe analysis 
and the resulting solution is heated to about 90-100" C. from (Comer et al., Proc. Natl. Acad. Sci. U.S.A. 80:278 (1983), 
about 1 to 10 minutes, preferably from 1 to 4 minutes. After oligonucleotide ligation assays (OLAs) (Landgren et. al., 
this heating period, the solution is allowed to cool, which is 25 Science 241: 1007, 1988), and the like. Molecular techniques 
preferable for the primer hybridization. To the cooled mix- for DNA analysis have been reviewed (Landgren et. al., 
ture is added an appropriate agent for effecting the primer Science 242:229-237, 1988). 
extension reaction (called herein "agent for polymeriza- Preferably, the method of amplifying is by PCR, as 
tion"), and the reaction is allowed to occur under conditions described herein and inU.S. Pat. Nos. 4,683,195; 4,683,202; 
known in the art. The agent for polymerization can also be 30 and 4,965,188 each of which is hereby incorporated by 
added together with the other reagents if it is heat stable. reference; and as is commonly used by those of ordinary 
This synthesis (or amplification) reaction can occur at room skill in the art. Alternative methods of amplification have 
temperature up to a temperature above which the agent for been described and can also be employed as long as the NE 
polymerization no longer functions. Thus, for example, if transporter locus amplified by PCR using primers of the 
DNA polymerase is used as the agent, the temperature is 35 invention is similarly amplified by the alternative means. 
generally no greater than about 40" C. Most conveniently the Such alternative amplification systems include but are not 
reaction occurs at room temperature. limited to self-sustained sequence replication, which begins 
The agent for polymerization can be any compound or with a short sequence of RNA of interest and a T7 promoter. 
system which will function to accomplish the synthesis of Reverse transcriptase copies the RNA into cDNA and 
primer extension products, including enzymes. Suitable 40 degrades the RNA, followed by reverse transcriptase poly- 
enzymes for this purpose include, for example, E. coli DNA merizing a second strand of DNA. 
polymerase I, Klenow fragment of E. coli DNApolymerase, Another nucleic acid amplification technique is nucleic 
polymerase muteins, reverse transcriptase, other enzymes, acid sequence-based amplification (NASBATM) which uses 
including heat-stable enzymes (Le., those enzymes which reverse transcription and T7 RNA polymerase and incorpo- 
perform primer extension after being subjected to tempera- 45 rates two primers to target its cycling scheme. NASBATM 
tures suficiently elevated to cause denaturation), such as amplification can begin with either DNA or RNA and finish 
Taq polymerase. Suitable enzyme will facilitate combination with either, and amplifies to about 10' copies within 60 to 90 
of the nucleotides in the proper manner to form the primer minutes. 
extension products which are complementary to each poly- Alternatively, nucleic acid can be amplified by ligation 
morphic locus nucleic acid strand. Generally, the synthesis 50 activated transcription (LAT). LAT works from a single- 
will be initiated at the 3' end of each primer and proceed in stranded template with a single primer that is partially 
the 5' direction along the template strand, until synthesis single-stranded and partially double-stranded. Amplification 
terminates, producing molecules of different lengths. is initiated by ligating a cDNA to the promoter olignucle- 
The newly synthesized strand and its complementary otide and within a few hours, amplification is about 10' to 
nucleic acid strand will form a double-stranded molecule 55 about lo9 fold. The QB replicase system can be utilized by 
under hybridizing conditions described above and this attaching an RNA sequence called MDV-1 to RNA comple- 
hybrid is used in subsequent steps of the method. In the next mentary to a DNA sequence of interest. Upon mixing with 
step, the newly synthesized double-stranded molecule is a sample, the hybrid RNA finds its complement among the 
subjected to denaturing conditions using any of the proce- specimen's mRNAs and binds, activating the replicase to 
dures described above to provide single-stranded molecules. 60 copy the tag-along sequence of interest. 
The steps of denaturing, annealing, and extension product Another nucleic acid amplification technique, ligase chain 
synthesis can be repeated as often as needed to amplify the reaction (LCR), works by using two differently labeled 
target polymorphic locus nucleic acid sequence to the extent halves of a sequence of interest which are covalently bonded 
necessary for detection. The amount of the specific nucleic by ligase in the presence of the contiguous sequence in a 
acid sequence produced will accumulate in an exponential 65 sample, forming a new target. The repair chain reaction 
fashion. PCR. A Practical Approach, ILR Press, Eds. (RCR) nucleic acid amplification technique uses two 
McPherson et al. (1992). complementary and target-specific oligonucleotide probe 
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pairs, thermostable polymerase and ligase, and DNA nucle- A kit in accordance with the present invention can further 
otides to geometrically amplify targeted sequences. A 2-base comprise a reagent or reagents for extracting a nucleic acid 
gap separates the oligo probe pairs, and the RCR fills and sample from a biological sample obtained from a subject. 
joins the gap, mimicking normal DNA repair. Any such reagent or reagents as would be readily apparent 
Nucleic acid amplification by strand displacement a&- to one of ordinary skill in the art falls within the scope of the 
vation (SDA) utilizes a short primer containing a recognition present invention. By way of particular example, a suitable 
site for HincII with short overhang on the 5‘ end which binds lysis buffer for the tissue along with a suspension of glass 
to target DNA. A DNA polymerase fills in the part of the beads for capturing the nucleic acid sample and an elution 
primer opposite the overhang with sulfur-containing adenine buffer for eluting the nucleic acid sample off of the glass 
analogs. HincII is added but only cuts the unmodified DNA 10 beads comprise means for extracting a nucleic acid sample 
strand. A DNA polymerase that lacks 5‘ exonuclease activity from a biological sample obtained from a subject. 
enters at the cite of the nick and begins to polymerize, Other examples include commercially available, such as 
displacing the initial primer strand downstream and building the GENOMIC ISOLATION KIT A.S.A.P.TM (Boehringer 
a new one which serves as more primer. Mannheim, Indianapolis, Ind.), Genomic DNA Isolation 
SDA produces greater than about a 107-fold amplification l5 System (GIBCO BRL, Gaithersburg, Md.1, ELU-QUIKTM 
in 2 hours at 370 c, Unlike PCR and LCR, SDA does not DNA Purification Kit (Schleicher & Schuell, Keene, N.H.), 
require instrumented temperature cycling. Another amplifi- DNA Extraction Kit (Stratagene, La J o k  Calif.), TURBO- 
cation system useful in the method of the invention is the QB GENTM Isolation Kit (InVitrOgen, San Diego, Calif.), and the 
Replicase System. Although PCR is the preferred method of like. Use of these kits according to the manufacturer's 
amplification if the invention, these other methods can also 20 instructions is generally acceptable for purification of DNA 
be used to amplify the NE transporter locus as described in prior to practicing the methods of the present invention. 
the method of the invention. Thus, the term “amplification B, Definitions Affecting NE Transporter-Encoding poly- 
technique” as used herein and in the claims is meant to nucleotide and NET Transporter Polypeptides Encoded by 
Same encompass all the foregoing methods. 
In accordance with the present invention, purified and 
5 
In another embodiment of the invention a method is 25 
provided for diagnosing Or identifying a isolated NE transporter-encoding polynucleotides and NE 
predisposition Or higher transporter polypeptides encoded by Same are provided. A 
a acid Of a from a by dideoxy otide comprises a NE transporter encoding polynucleotide 
sequencing, preferably amp1ification Of the target 30 which includes a G to C transversion at base 237 within exon 
nucleic acid. 9 of the NE transporter gene which changes the triplet code 
In another embodiment of the invention a method is from GCA or GCC or GCG or GCU to CCA or ccc or CCG 
provided for diagnosing a subject having a predisposition or or CCu and leads to the A457P change in the encoded NE 
higher susceptibility to (at risk Of) impaired sub-optimal 35 transporter polypeptide. The encoded NE transporter 
NET function, comprising contacting a target nucleic acid of polypeptide comprising the A457P change is also particu- 
a sample from a subject With a reagent that detects the larly provided. Thus, allelic variant polynucleotides and 
Presence ofthe NE transporter PolYmorphism and detecting polypeptides encoded by same are provided in accordance 
the reagent. with the present invention. Further, a biologically active NE 
Another method comprises contacting a target nucleic 4o transporter polypeptide is also provided in accordance with 
acid of a sample from a subject with a reagent that detects the present invention, as is a NE transporter-encoding poly- 
the presence of the G to C transversion at base 237, within nucleotide encoding such a NE transporter polypeptide. 
exon 9, and detecting the transversion. A number of hybrid- Exemplary biological activities include the biological activ- 
ization methods are well known to those skilled in the art. ity of mediating NE uptake and the biological activity of 
Many of them are useful in carrying out the invention. 
The materials for use in the method of the invention are The provided NE transporter-encoding polynucleotides 
ideally suited for the preparation of a diagnostic kit. Such a and polypeptides have broad utility given the biological 
kit can comprise a carrier being compartmentalized to significance of NE uptake, as is known in the art. By way of 
receive in close confinement one or more containers such as example, the NE transporter-encoding polynucleotides and 
vials, tubes, and the like, each of the container comprising 50 polypeptides are useful in the preparation of screening 
one of the separate elements to be used in the method. For assays and assay kits that are used to detect the presence of 
example, one of the containers can comprise a reagent or the proteins and nucleic acids of this invention in biological 
reagents for amplifying NE transporter DNA, the reagent or samples, and in the detection and analysis of polymorphic 
reagents comprising the necessary enzyme(s) and oligo- sequences and polypeptides encoded by such sequences, as 
nucleotide primers for amplifying said target DNA from the 55 disclosed herein. 
subject. Preferably, the provided NE transporter polynucleotides 
The oligonucleotide primers include primers having a and polypeptides are isolated from vertebrate and inverte- 
sequence of NET exon 9 selected from the group including, brate sources. Thus, homologs of NE transporter, including, 
but not limited to: SEQ ID NO: 15, or primer sequences but not limited to, mammalian, yeast and bacterial homologs 
substantially complementary or substantially homologous 60 are provided in accordance with the present invention. 
thereto. The target flanking 5‘ and 3’ polynucleotide Preferred mammalian homologs of NE transporter members 
sequence of NET exon 9 has substantially the sequence set include, but are not limited to, bovine, rat, mouse and human 
forth in SEQ ID NO:15, and sequences substantially homologs. 
complementary or homologous thereto. Other oligonucle- The terms “NE transporter gene product”, “NE trans- 
otide primers for amplifying NE transporter are readily 65 porter protein” and “NE transporter polypeptide” refer to 
ascertainable to those of skill in the art given the disclosure proteins having amino acid sequences which are substan- 
of the present invention presented herein. tially identical to the native amino acid sequences in NE 
having a 
to (at risk Of) 
impaired sub-optimal NET function, comprising sequencing particularly provided NE transporter-encoding polynucle- 
45 cross-reacting with an anti-NE transporter antibody. 
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transporter and which are biologically active in that they are the shorter of the two sequences. The preferred default 
capable of mediating NE uptake, or cross-reacting with parameters for the GAP program include: (1) a unitary 
anti-NE transporter antibodies raised against a NE trans- comparison matrix (containing a value of 1 for identities and 
porter polypeptide. 0 for non-identities) of nucleotides and the weighted com- 
The terms “NE transporter gene product”, “NE trans- 5 parison matrix of Gribskov et al., Nucl. Acids. Res. 14:6745 
porter protein” and “NE transporter polypeptide” also (1986), as described by Schwartz et al., eds., Atlas ofprotein 
include analogs of NE transporter molecules which exhibit Sequence and Structure, National Biomedical Research 
at least some biological activity in common with native NE Foundation, pp.357-358 (1979); (2) a penalty of 3.0 for each 
transporter gene products. Furthermore, those skilled in the gap and an additional 0.01 penalty for each symbol and each 
art of mutagenesis will appreciate that other analogs, as yet 10 gap; and (3) no penalty for end gaps. Other comparison 
undisclosed or undiscovered, can be used to construct NE techniques are described in the Examples. 
transporter analogs. There is no need for an “NE transporter The term “homology” describes a mathematically based 
gene product”, “NE transporter protein” or “NE transporter comparison of sequence similarities which is used to iden- 
polypeptide” to comprise all, or substantially all of the tify genes or proteins with similar functions or motifs. 
amino acid sequence of a native NE transporter gene prod- 15 Accordingly, the term “homology” is synonymous with the 
uct. Shorter or longer sequences are anticipated to be of use term “similarity” and “percent similarity” as defined above. 
in the invention. Thus, the term “NE transporter gene Thus, the phrases “substantial homology” or “substantial 
product” also includes fusion or recombinant NE transporter similarity” have similar meanings. 
polypeptides and proteins. Methods of preparing such pro- B.2. Nucleic Acid Sequences 
teins are described herein. In certain embodiments, the invention concerns the use of 
The terms “NE transporter-encoding polynucleotide”, NE transporter genes and gene products that include within 
“NE transporter gene”, “NE transporter gene sequence” and their respective sequences a sequence which is essentially 
“NE transporter gene segment” refer to any DNA sequence that of a NE transporter gene, or the corresponding protein. 
encoding a NE transporter gene product, NE transporter 25 gene”, means that the sequence substantially corresponds to 
protein or NE transporter polypeptide as defined above. The a portion of a NE transporter polypeptide or NE transporter 
terms also refer to RNA, or antisense sequences, compatible encoding polynucleotide and has relatively few bases or 
polynucleotide”, “NE transporter gene”, “NE transporter tical to those of a NE transporter protein or NE transporter 
gene sequence” and “NE transporter gene segment” can also 30 gene, (or a biologically functional equivalent of, when 
20 
that is substantially identical to a polynucleotide sequence The term “a sequence essentially as that ofa  NE transporter 
with such DNA sequences. A “NE transporter-encoding amino acids (whether DNA or protein) which are not iden- 
comprise any combination of associated control sequences. 
The term “substantially identical”, when used to define 
referring to proteins), The term ‘‘biologically functional 
equivalent” is well understood in the art and is further 
either a NE transporter gene product or NE transporter defined in detail herein. Accordingly, sequences which have 
amino acid sequence, or a NE transporter gene or NE between about 70% and about 80%; or more preferably, 
transporter nucleic acid sequence, means that a particular 35 between about 81% and about 90%; or even more prefer- 
sequence, for example, a mutant sequence, varies from the ably, between about 91% and about 99%; of amino acids 
sequence of a natural NE transporter by one or more which are identical or functionally equivalent to the amino 
deletions, substitutions, or additions, the net effect of which acids of a NE transporter protein or NE transporter gene, 
is to retain at least some of biological activity of NE will be sequences which are ‘‘essentially the same”. 
transporter. Alternatively, DNA analog sequences are “sub- 40 NE transporter gene products and NE transporter genes 
stantially identical” to specific DNA sequences disclosed which have functionally equivalent codons are also covered 
herein if: (a) the DNA analog sequence is derived from by the invention. The term “functionally equivalent codon” 
coding regions ofthe natural NE transporter gene; Or (b) the is used herein to refer to codons that encode the same amino 
DNA analog sequence is capable of hybridization of DNA acid, such as the ACG and AGU codons for serine. Thus, 
sequences of (a) under moderately stringent conditions and 45 when referring to the sequence examples presented in SEQ 
which encode biologically active NE transporter gene prod- ID No’s: 1-4 and 11-14, applicants provide substitution of 
uct; Or (C) the DNAsequences are degenerative as a result of functionally equivalent codons of Table 1 into the sequence 
the genetic code to the DNA analog sequences defined in (a) examples of SEQ ID ~ 0 ’ ~ :  1-4 and 11-14. Thus, applicants 
and/or (b). Substantially identical analog Proteins Will be are in possession of amino acid and nucleic acids sequences 
greater than about 60% identical to the corresponding 50 which include such substitutions but which are not set forth 
sequence of the native protein. Sequences having lesser 
degrees of similarity but comparable biological activity are 
considered to be equivalents. In determining nucleic acid TABLE 1 
sequences, all subject nucleic acid sequences capable of 
encoding substantially similar amino acid sequences are 55 
considered to be substantially similar to a reference nucleic 
acid sequence, regardless of differences in codon sequences. 
Percent similarity can be determined, for example, by 
herein in their entirety for convenience, 
T a b l e  of t h e  G e n e t i c  Code 
Amino A c i d s  Codons 
B. 1. Percent Similarity A l a n i n e  A l a  A GCA GCC GCG GCU 
Cys C UGC UGU comparing sequence information using the GAP computer 60 Cysteine 
program, available from the University of Wisconsin A s p a r t i c  Ac id  D GAC GAU 
Geneticist Computer Group. The GAP program utilizes the 
alignment method of Needleman et al., J.  Mol. Biol. 48:443 G1umatic acid G1u E GAA GAG 
(1970), as revised by Smith et al., Adv. Appl. Math. 2:482 Phenylalanine Phe uuc uuu 
(1981). Briefly, the GAP program defines similarity as the 65 
which are similar, divided by the total number of symbols in 
number of aligned symbols (i.e. nucleotides or amino acids) G l y c i n e  G l y  G GGA GGC GGG GGU 
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TABLE l-continued 
T a b l e  of t h e  G e n e t i c  C o d e  
A m i n o  A c i d s  C o d o n s  
H i s t i d i n e  
I s o l e u c i n e  
L y s i n e  
L e u c i n e  
Methionine 
A s p a r a g i n e  
P r o l i n e  
G l u t a m i n e  
A r g i n i n e  
S e r i n e  
T h r e o n i n e  
V a l i n e  
T r y p t o p h a n  
T y r o s i n e  
H i s  H 
I l e  I 
L y s  K 
L e u  L 
M e t  M 
A s n  N 
P r o  P 
G l n  Q 
A r g  R 
S e r  S 
T h r  T 
V a l  V 
T r p  W 
T y r  Y 
CAC CAU 
AUA AUC AUU 
AAA AAG 
UUA UUG CUA CUC CUG CUU 
AU G 
AAC AAU 
CCA CCC CCG CCU 
CAA CAG 
AGA AGG CGA CGC CGG CGU 
ACG AGU UCA UCC UCG UCU 
ACA ACC ACG ACU 
GUA GUC GUG GUU 
UGG 
UAC UAU 
It will also be understood that amino acid and nucleic acid 
sequences can include additional residues, such as additional 
N- or C-terminal amino acids or 5‘ or 3’ sequences, and yet 
still be essentially as set forth in one of the sequences 
disclosed herein, so long as the sequence meets the criteria 
set forth above, including the maintenance of biological 
protein activity where protein expression is concerned. The 
addition of terminal sequences particularly applies to nucleic 
acid sequences which can, for example, include various 
non-coding sequences flanking either of the 5‘ or 3’ portions 
of the coding region or can include various internal 
sequences, i.e., introns, which are known to occur within 
genes. 
The present invention also encompasses the use of DNA 
segments which are complementary, or essentially comple- 
mentary, to the sequences set forth in the specification. 
Nucleic acid sequences which are “complementary” are 
those which are base-pairing according to the standard 
Watson-Crick complementarity rules. As used herein, the 
term “complementary sequences” means nucleic acid 
sequences which are substantially complementary, as can be 
assessed by the same nucleotide comparison set forth above, 
or as defined as being capable of hybridizing to the nucleic 
acid segment in question under relatively stringent condi- 
tions such as those described herein. Aparticular example of 
a provided complementary nucleic acid segment is an anti- 
sense oligonucleotide. 
Nucleic acid hybridization will be affected by such con- 
ditions as salt concentration, temperature, or organic sol- 
vents, in addition to the base composition, length of the 
complementary strands, and the number of nucleotide base 
mismatches between the hybridizing nucleic acids, as will 
be readily appreciated by those skilled in the art. Stringent 
temperature conditions will generally include temperatures 
in excess of 30” C., typically in excess of 37” C., and 
preferably in excess of 45” C. Stringent salt conditions will 
ordinarily be less than 1,000 mM, typically less than 500 
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mM, and preferably less than 200 mM. However, the com- 
bination of parameters is much more important than the 
measure of any single parameter. (See e.g., Wetmur & 
Davidson, J. Mol. Biol. 31:349-370 (1968)). 
Probe sequences can also hybridize specifically to duplex 
DNAunder certain conditions to form triplex or other higher 
order DNA complexes. The preparation of such probes and 
suitable hybridization conditions are well known in the art. 
As used herein, the term “DNA segment” refers to a DNA 
molecule which has been isolated free of total genomic DNA 
of a particular species. Furthermore, a DNA segment encod- 
ing a NE transporter polypeptide refers to a DNA segment 
which contains NE transporter coding sequences, yet is 
isolated away from, or purified free from, total genomic 
DNA of a source species, such as Homo sapiens. Included 
within the term “DNA segment” are DNA segments and 
smaller fragments of such segments, and also recombinant 
vectors, including, for example, plasmids, cosmids, phages, 
viruses, and the like. 
Similarly, a DNA segment comprising an isolated or 
purified NE transporter gene refers to a DNA segment 
including NE transporter coding sequences isolated substan- 
tially away from other naturally occurring genes or protein 
encoding sequences. In this respect, the term “gene” is used 
for simplicity to refer to a functional protein, polypeptide or 
peptide encoding unit. As will be understood by those in the 
art, this functional term includes both genomic sequences 
and cDNA sequences. “Isolated substantially away from 
other coding sequences” means that the gene of interest, in 
this case, the NE transporter gene, forms the significant part 
of the coding region of the DNA segment, and that the DNA 
segment does not contain large portions of naturally-occur- 
ring coding DNA, such as large chromosomal fragments or 
other functional genes or cDNA coding regions. Of course, 
this refers to the DNA segment as originally isolated, and 
does not exclude genes or coding regions later added to the 
segment by the hand of man. 
In particular embodiments, the invention concerns iso- 
lated DNA segments and recombinant vectors incorporating 
DNA sequences which encode a NE transporter polypeptide 
that includes within its amino acid sequence an amino acid 
sequence of any of SEQ ID NOs:2, 4, 12 and 14. In other 
particular embodiments, the invention concerns isolated 
DNA segments and recombinant vectors incorporating DNA 
sequences which encode a protein that includes within its 
amino acid sequence the amino acid sequence of a NE 
transporter polypeptide corresponding to human tissues. 
It will also be understood that this invention is not limited 
to the particular nucleic acid and amino acid sequences of 
SEQ ID NO’s:1-4 and 11-14. Recombinant vectors and 
isolated DNA segments can therefore variously include the 
NE transporter polypeptide-encoding region itself, include 
coding regions bearing selected alterations or modifications 
in the basic coding region, or include encoded larger 
polypeptides which nevertheless include NE transporter 
polypeptide-encoding regions or can encode biologically 
functional equivalent proteins or peptides which have vari- 
ant amino acid sequences. 
In certain embodiments, the invention concerns isolated 
DNA segments and recombinant vectors which encode a 
protein or peptide that includes within its amino acid 
sequence an amino acid sequence essentially as set forth in 
any of SEQ ID NOs:2, 4, 12 and 14. Naturally, where the 
DNA segment or vector encodes a full length NE transporter 
gene product, the most preferred nucleic acid sequence is 
that which is essentially as set forth in any of SEQ ID NOS: 
1,3,  11 and 13 and which encode a protein that exhibits NE 
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uptake-modulating activity, as can be determined by, for 
example, assays to detect NE uptake, as disclosed herein in 
the Examples. also useful. 
SEQ ID NO:2, 4, 12 and 14,, that the sequence 5 biologically functional equivalent NE transporter proteins 
corresponds to a portion an amino acid and peptides. Such sequences can rise as a consequence of codon redundancy and functional equivalency which are sequence either of SEQ ID NOs:2, 4, 12 and 14 and has known to occur naturally within nucleic acid sequences and relatively few amino acids which are not identical to, or a the proteins thus encoded, Alternatively, functionally 
biologically functional equivalent of, the amino acids of an equivalent proteins or peptides can be created via the 
The term “biologically functional equivalent” is well under- changes in the protein can be engineered, based on 
stood in the art and is further defined in detail herein. considerations of the properties of the amino acids being 
AccordiWlY, sequences, which have between about 70% exchanged, e.g. substitution of Ile and Leu at amino acid 2 
and about 80%; ormorepreferably, between about 81% and 15 in SEQ ID NOs:11-14. Changes designed by man can be 
about 90%; or even more preferably, between about 91% introduced through the application of site-directed mutagen- 
and about 99%; of amino acids which are identical or esis techniques, e.g., to introduce improvements to the 
functionally equivalent to the amino acids in any of SEQ ID antigenicity of the protein or to test NE transporter mutants 
NOS: 2, 4, 12 and 14, will be sequences which “a sequence in order to examine NE transport activity, or other activity 
essentially as set forth in SEQ ID NOs:2, 4, 12 and 14”. 
in certain cases. DNA segments with total lengths of about 
1,000, 500, 200, 100 and about 50 base pairs in length are 
The term “a sequence essentially as set forth in any of The DNA segments Of the present invention encompass 
amino acid sequence of any of SEQ ID NOs:2, 4, 12 and 14. application of recombinant DNA technology, in which 
20 at the molecular level. 
In particular embodiments, the invention concerns gene 
and 
If desired, One can prepare fusion proteins and 
peptides, e.g., where the NE transporter coding region is therapy methods that use isolated DNA segments 
aligned within the same expression unit with other proteins 
or peptides having desired functions, such as for purification 
25 or immunodetection purposes (e.g., proteins which can be 
ing regions, respectively), 
recombinant vectors incorporating DNA sequences which 
encode a protein that includes within its amino acid 
4, 12 and 14, SEQ ID NOs:2, 4, 12 and 14 including 
sequences which are derived from human tissue. In other 
sequence an amino acid sequence Of any Of SEQ ID Nos:2, purified by afinity c~omatography and enzyme label cod- 
Recombinant vectors form important further aspects of 
particular embodiments, the invention the present invention, particularly useful vectors are those 
DNA sequences and recombinant DNA vectors incorporat- 30 vectors in which the coding portion ofthe DNA segment is 
ing DNA sequences which encode a protein that positioned under the control of a promoter, The promoter 
within its amino acid sequence the amino acid sequence of can be in the form of the promoter which is naturally 
associated with the NE transporter gene, e.g., in mammalian the NE transporter protein from human hepatic tissue. 
In certain other embodiments, the invention concerns tissues, as can be obtained by isolating the 5‘ non-coding 
isolated DNA segments and recombinant vectors that 35 sequences located upstream of the coding segment or exon, 
include within their sequence a nucleic acid sequence essen- for using recombinant cloning and/or PCR tech- 
tially as set forth in any of SEQ ID NO: 1, 3, 11 and 13. The nology, in connection with the compositions disclosed 
term “a sequence essentially as set forth in any of SEQ ID herein, 
NO:1, 3, 11 and 13” is used in the same sense as described other embodiments, certain advantages will be gained 
above and means that the nucleic acid sequence substantially 40 by positioning the coding DNA segment under the control of 
corresponds to a Portion of any of SEQ ID NOs:l, 3, 11 and a recombinant, or heterologous, promoter. As used herein, a 
13, respectively, and has relatively few COdons which are not recombinant or heterologous promoter is intended to refer to 
identical, or functionally equivalent, to the codons of any of a promoter that is not normally associated with a NE 
SEQ ID NOs:l, 3, 11 and 13, respectively. Again, DNA transporter gene in its natural environment. Such promoters 
segments which encode gene Products exhibiting NE trans- 45 can include promoters isolated from bacterial, viral, eukary- 
port activity, cross-reactivity with an anti-NE transporter otic, or mammalian cells, ~ ~ t u ~ ~ l l ~ ,  it will be important to 
antibody, Or other biological activity of the NE transporter employ a promoter that effectively directs the expression of 
gene Product Will be most Preferred. The term ‘‘functiona1lY the DNA segment in the cell type chosen for expression. The 
equivalent codon” is used herein to refer to codons that use of promoter and cell type for protein 
encode the Same amino acid, such as the Six COdons for 50 expression is generally known to those of skill in the art of 
arginine Or serine, and also to refer to Codons that encode molecular biology, for example, see Sambrook et al., 1989, 
biologically equivalent amino acids (see Table 1). incorporated herein by reference. The promoters employed 
The nucleic acid segments of the present invention, can be constitutive, or inducible, and can be used under the 
regardless of the length of the coding sequence itself, can be appropriate conditions to direct high level expression of the 
combined with other DNA sequences, such as promoters, 55 introduced DNA segment, such as is advantageous in the 
enhancers, polyadenylation signals, additional restriction large-scale production of recombinant proteins or peptides. 
enzyme sites, multiple cloning sites, other coding segments, Appropriate promoter systems provided for use in high-level 
and the like, such that their overall length can vary consid- expression include, but are not limited to, the vaccina virus 
erably. It is therefore provided that a nucleic acid fragment promoter and the baculovirus promoter. 
of almost any length can be employed, with the total length 60 In an alternative embodiment, the present invention pro- 
preferably being limited by the ease of preparation and use vides an expression vector comprising a polynucleotide that 
in the intended recombinant DNA protocol. For example, encodes a NE transporter polypeptide having NE transport 
nucleic acid fragments can be prepared which include a activity, cross-reacting with an anti-NE transporter antibody, 
short stretch complementary to a nucleic acid sequence set or other biological activity in accordance with the present 
for in any of SEQ ID NOS: 1, 3, 11 and 13 respectively, such 65 invention. Also preferably, an expression vector of the 
as about 10 nucleotides, and which are up to 10,000 or 5,000 present invention comprises a polynucleotide that encodes a 
base pairs in length, with segments of 3,000 being preferred human NE transporter gene product. More preferably, an 
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expression vector of the present invention comprises a 
polynucleotide that encodes a polypeptide comprising an 
amino acid residue sequence of any of SEQ ID NOs:2,4, 12 
and 14. More preferably, an expression vector of the present 
invention comprises a polynucleotide comprising the nucle- 
otide base sequence of any of SEQ ID NO:1, 3, 11 and 13. 
Even more preferably, an expression vector of the inven- 
tion comprises a polynucleotide operatively linked to an 
enhancer-promoter. More preferably still, an expression 
vector of the invention comprises a polynucleotide opera- 
tively linked to a prokaryotic promoter. Alternatively, an 
expression vector of the present invention comprises a 
polynucleotide operatively linked to an enhancer-promoter 
that is a eukaryotic promoter, and the expression vector 
further comprises a polyadenylation signal that is positioned 
3’ of the carboxy-terminal amino acid and within a tran- 
scriptional unit of the encoded polypeptide. 
In yet another embodiment, the present invention pro- 
vides a recombinant host cell transfected with a polynucle- 
otide that encodes a NE transporter polypeptide having NE 
porter polynucleotides and polypeptides found in other 
vertebrates, particularly warm blooded vertebrates, and 
more particularly bovine, mouse and rat. 
As mentioned above, in connection with expression 
5 embodiments to prepare recombinant NE transporter pro- 
teins and peptides, it is provided that longer DNA segments 
will most often be used, with DNA segments encoding the 
entire NE transporter protein, functional domains or cleav- 
age products thereof, being most preferred. However, it will 
i o  be appreciated that the use of shorter DNA segments to 
direct the expression of NE transporter peptides or epitopic 
core regions, such as can be used to generate anti-NE 
transporter antibodies, also falls within the scope of the 
invention. 
DNA segments which encode peptide antigens from about 
15 to about 50 amino acids in length, or more preferably, 
from about 15 to about 30 amino acids in length are 
particularly useful. DNA segments encoding peptides will 
generally have a minimum coding length in the order of 
20 about 45 to about 150, or to about 90 nucleotides. DNA 
15 
transport activity, cross-reactivity with an anti-NE trans- segments encoding full length proteins can have a minimum 
porter antibody, or other biological activity in accordance coding length on the order of about 4,500 to about 4,600 
with the present invention. SEQ ID NO’s: 1 4  and 11-14 set nucleotides for a protein in accordance with any of SEQ ID 
forth nucleotide and amino acid sequences from an exem- NOS: 2, 4, 12 and 14. 
plary vertebrate, human. Also provided by the present inven- 25 Naturally, the present invention also encompasses DNA 
tion are homologous or biologically equivalent polynucle- segments which are complementary, or essentially comple- 
otides and NE transporter polypeptides found in other mentary, to the sequences set forth in any of SEQ ID NO’s: 
vertebrates, including bovine, mouse and rat. 1,3, 11 and 13. The terms “complementary” and “essentially 
Preferably, a recombinant host cell of the present inven- complementary” are defined above. Excepting intronic or 
tion is transfected with the polynucleotide that encodes 30 flanking regions, details of which are disclosed graphically 
human NE transporter polypeptide. More preferably, a in FIG. 2, and allowing for the degeneracy of the genetic 
recombinant host cell of the present invention is transfected code, sequences which have between about 70% and about 
with the polynucleotide sequence of any of SEQ ID NOs:l, 80%; or more preferably, between about 81% and about 
3, 11 and 13. Even more preferably, a host cell of the 90%; or even more preferably, between about 91% and 
invention is a eukaryotic host cell. Still more preferably, a 35 about 99%; of nucleotides which are identical or function- 
recombinant host cell of the present invention is a vertebrate ally equivalent (i.e. encoding the same amino acid) of 
cell. Preferably, a recombinant host cell of the invention is nucleotides in any of SEQ ID NOs:l, 3, 11 and 13 will be 
a mammalian cell. sequences which are “a sequence essentially as set forth in 
In another aspect, a recombinant host cell of the present any of SEQ ID NOS: 1, 3, 11 and 13”. Sequences which are 
invention is a prokaryotic host cell. Preferably, a recombi- 40 essentially the same as those set forth in any of SEQ ID 
nant host cell of the invention is a bacterial cell, preferably NOs:l, 3, 11 and 13 can also be functionally defined as 
a strain of Escherichia coli. More preferably, a recombinant sequences which are capable of hybridizing to a nucleic acid 
host cell comprises a polynucleotide under the transcrip- segment containing the complement in any of SEQ ID 
tional control of regulatory signals functional in the recom- NOs:l, 3, 11 and 13 under relatively stringent conditions. 
binant host cell, wherein the regulatory signals appropriately 45 Suitable relatively stringent hybridization conditions are 
control expression of the NE transporter polypeptide in a described herein and will be well known to those of skill in 
manner to enable all necessary transcriptional and post- the art. 
transcriptional modification. B.3. Biologically Functional Equivalents 
In yet another embodiment, the present invention pro- As mentioned above, modification and changes can be 
vides a method of preparing a NE transporter polypeptide 50 made in the structure of the NE transporter proteins and 
comprising transfecting a cell with polynucleotide that peptides described herein and still obtain a molecule having 
encodes a NE transporter polypeptide having NE transport like or otherwise desirable characteristics. For example, 
activity, cross-reacting with an anti-NE transporter antibody, certain amino acids can be substituted for other amino acids 
or other biological activity in accordance with the present in a protein structure without appreciable loss of interactive 
invention, to produce a transformed host cell; and maintain- 55 capacity with structures such as, for example, in the nucleus 
ing the transformed host cell under biological conditions of a cell. Since it is the interactive capacity and nature of a 
suficient for expression of the polypeptide. More preferably, protein that defines that protein’s biological functional activ- 
the transformed host cell is a eukaryotic cell. More prefer- ity, certain amino acid sequence substitutions can be made 
ably still, the eukaryotic cell is a vertebrate cell. Alterna- in a protein sequence (or, of course, its underlying DNA 
tively, the host cell is a prokaryotic cell. More preferably, the 60 coding sequence) and nevertheless obtain a protein with like 
prokaryotic cell is a bacterial cell of Escherichia coli. Even or even countervailing properties (e.g., antagonistic v. ago- 
more preferably, a polynucleotide transfected into the trans- nistic). Thus, various changes can be made in the sequence 
formed cell comprises a nucleotide base sequence of any of of the NE transporter proteins and peptides (or underlying 
SEQ ID NOs:l, 3, 11 and 13. SEQ ID NO’s:1-4 and 11-14 DNA) without appreciable loss of their biological utility or 
set forth nucleotide and amino acid sequences for an exem- 65 activity. 
plary vertebrate, human. Also provided by the present inven- It is also well understood by the skilled artisan that, 
tion are homologues or biologically equivalent NE trans- inherent in the definition of a biologically functional equiva- 
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lent protein or peptide, is the concept that there is a limit to 
the number of changes that can be made within a defined 
portion of the molecule and still result in a molecule with an 
acceptable level of equivalent biological activity. Biologi- 
cally functional equivalent peptides are thus defined herein 
as those peptides in which certain, not most or all, of the 
amino acids can be substituted. Of course, a plurality of 
distinct proteinsipeptides with different substitutions can 
easily be made and used in accordance with the invention. 
It is also well understood that where certain residues are 
shown to be particularly important to the biological or 
structural properties of a protein or peptide, e.g., residues in 
active sites, such residues can not generally be exchanged. 
This is the case in the present invention, where if any 
changes, for example, in the phosphorylation domains of a 
NE transporter polypeptide, could result in a loss of an 
aspect of the utility of the resulting peptide for the present 
invention. 
Amino acid substitutions, such as those which might be 
employed in modifying the NE transporter proteins and 
peptides described herein, are generally based on the relative 
similarity of the amino acid side-chain substituents, for 
example, their hydrophobicity, hydrophilicity, charge, size, 
and the like. An analysis of the size, shape and type of the 
amino acid side-chain substituents reveals that arginine, 
lysine and histidine are all positively charged residues; that 
alanine, glycine and serine are all a similar size; and that 
phenylalanine, tryptophan and tyrosine all have a generally 
similar shape. Therefore, based upon these considerations, 
arginine, lysine and histidine; alanine, glycine and serine; 
and phenylalanine, tryptophan and tyrosine; are defined 
herein as biologically functional equivalents. 
In making such changes, the hydropathic index of amino 
acids can be considered. Each amino acid has been assigned 
a hydropathic index on the basis of their hydrophobicity and 
charge characteristics, these are: isoleucine (+4.5); valine 
(+4.2); leucine (+3.8); phenylalanine (+2 3); cysteineicys- 
tine (+2.5); methionine (+1.9); alanine (+1.8); glycine 
(-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); 
tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate 
(-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); 
lysine (-3.9); and arginine (-4.5). 
The importance of the hydropathic amino acid index in 
conferring interactive biological function on a protein is 
generally understood in the art (Kyte & Doolittle, J.  Mol. 
Biol. 157: 105-132 (1 982), incorporated herein by refer- 
ence). It is known that certain amino acids can be substituted 
for other amino acids having a similar hydropathic index or 
score and still retain a similar biological activity. In making 
changes based upon the hydropathic index, the substitution 
of amino acids whose hydropathic indices are within 22 of 
the original value is preferred, those which are within 21 of 
the original value are particularly preferred, and those within 
20.5 of the original value are even more particularly pre- 
ferred. 
It is also understood in the art that the substitution of like 
amino acids can be made effectively on the basis of hydro- 
philicity. U.S. Pat. No. 4,554,101, incorporated herein by 
reference, states that the greatest local average hydrophilic- 
ity of a protein, as governed by the hydrophilicity of its 
adjacent amino acids, correlates with its immunogenicity 
and antigenicity, i.e. with a biological property of the 
protein. It is understood that an amino acid can be substi- 
tuted for another having a similar hydrophilicity value and 
still obtain a biologically equivalent protein. 
As detailed in U.S. Pat. No. 4,554,101, the following 
hydrophilicity values have been assigned to amino acid 
22 
residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0+1); 
glutamate (+3.0+1); serine (+0.3); asparagine (+0.2); 
glutamine (+0.2); glycine (0); threonine (-0.4); proline 
(-0.521); alanine (-0.5); histidine (-0.5); cysteine (-1.0); 
5 methionine (-1.3); valine (-1.5); leucine (-1 3); isoleucine 
(-1 3); tyrosine (-2.3); phenylalanine (-2.5); tryptophan 
In making changes based upon similar hydrophilicity 
values, the substitution of amino acids whose hydrophilicity 
10 values are within 22 of the original value is preferred, those 
which are within 21 of the original value are particularly 
preferred, and those within 20.5 of the original value are 
even more particularly preferred. 
While discussion has focused on functionally equivalent 
l5 polypeptides arising from amino acid changes, it will be 
appreciated that these changes can be effected by alteration 
of the encoding DNA, taking into consideration also that the 
genetic code is degenerate and that two or more codons can 
code for the same amino acid. 
(-3.4). 
2o B.4. Sequence Modification Techniques 
Modifications to the NE transporter proteins and peptides 
described herein can be carried out using techniques such as 
site directed mutagenesis. Site-specific mutagenesis is a 
25 technique useful in the preparation of individual peptides, or 
biologically functional equivalent proteins or peptides, 
through specific mutagenesis of the underlying DNA. The 
technique further provides a ready ability to prepare and test 
sequence variants, for example, incorporating one or more 
3o of the foregoing considerations, by introducing one or more 
nucleotide sequence changes into the DNA. Site-specific 
mutagenesis allows the production of mutants through the 
use of specific oligonucleotide sequences which encode the 
DNA sequence of the desired mutation, as well as a sufficient 
35 number of adjacent nucleotides, to provide a primer 
sequence of sufficient size and sequence complexity to form 
a stable duplex on both sides of the deletion junction being 
traversed. Typically, a primer of about 17 to 30 nucleotides 
in length is preferred, with about 5 to 10 residues on both 
In general, the technique of site-specific mutagenesis is 
well known in the art as exemplified by publications (e.g., 
Adelman et al., 1983). As will be appreciated, the technique 
typically employs a phage vector which exists in both a 
45 single stranded and double stranded form. Typical vectors 
useful in site-directed mutagenesis include vectors such as 
the M13 phage (Messing et al., 1981). These phage are 
readily commercially available and their use is generally 
well known to those skilled in the art. Double stranded 
50 plasmids are also routinely employed in site directed 
mutagenesis which eliminates the step of transferring the 
gene of interest from a plasmid to a phage. 
In general, site-directed mutagenesis in accordance here- 
with is performed by first obtaining a single-stranded vector 
55 or melting apart the two strands of a double stranded vector 
which includes within its sequence a DNA sequence which 
encodes, for example, a human NE transporter polypeptide. 
An oligonucleotide primer bearing the desired mutated 
sequence is prepared, generally synthetically, for example 
60 by the method of Crea et al. (1978). This primer is then 
annealed with the single-stranded vector, and subjected to 
DNA polymerizing enzymes such as E. coli polymerase I 
Klenow fragment, in order to complete the synthesis of the 
mutation-bearing strand. Thus, a heteroduplex is formed 
65 wherein one strand encodes the original non-mutated 
sequence and the second strand bears the desired mutation. 
This heteroduplex vector is then used to transform appro- 
4o sides of the junction of the sequence being altered. 
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priate cells, such as E. coli cells, and clones are selected an upstream promoter region, a promoter region or a pro- 
which include recombinant vectors bearing the mutated moter of a generalized eukaryotic RNA Polymerase I1 
sequence arrangement. transcription unit. 
The preparation of sequence variants of the selected gene Another type of discrete transcription regulatory sequence 
using site-directed mutagenesis is provided as a means of 5 element is an enhancer. An enhancer provides specificity of 
producing potentially useful NE transporter polypeptide or time, location and expression level for a particular encoding 
other species having NE transport activity and is not meant region (e.g., gene). A major function of an enhancer is to 
to be limiting as there are other ways in which sequence increase the level of transcription of a coding sequence in a 
variants of these peptides can be obtained. For example, cell that contains one or more transcription factors that bind 
recombinant vectors encoding the desired genes can be 10 to that enhancer. Unlike a promoter, an enhancer can func- 
treated with mutagenic agents to obtain sequence variants tion when located at variable distances from transcription 
(see, e.g., a method described by Eichenlaub, 1979) for the start sites so long as a promoter is present. 
mutagenesis of plasmid DNA using hydroxylamine. As used herein, the phrase “enhancer-promoter’’ means a 
B.5. Other Structural Equivalents composite unit that contains both enhancer and promoter 
In addition to the NE transporter peptidy1 compounds 15 elements. An enhancer-promoter is operatively linked to a 
described herein, the inventors also provide that other steri- coding sequence that  codes at least one gene Product. As 
cally similar compounds can be formulated to mimic the key used herein, the Phrase ‘‘operatively 1inked’’ that an 
portions of the peptide structure. Such compounds can be enhancer-promoter is u m ~ c t e d  to a coding sequence in 
hence are also functional equivalents. The generation of a 20 controlled and regulated by that enhancer-promoter. Tech- 
structural functional equivalent can be achieved by the niques for operatively linking an enhancer-promoter to a 
techniques of modeling and chemical design known to those coding sequence are well known in the art. As is also well 
of skill in the art, It will be understood that all such sterically known in the art, the precise orientation and location relative 
similar constructs fall within the scope of the present inven- to a coding sequence n h s e  transcription is controlled, is 
tion. 25 dependent inter alia upon the specific nature of the enhancer- 
promoter. Thus, a TATA box minimal promoter is typically 
C. Introduction of Gene Products located from about 25 to about 30 base pairs upstream of a 
Where the gene itself is employed to introduce the gene transcription initiation site and an upstream promoter ele- 
Products, a convenient method of introduction Will be ment is typically located from about 100 to about 200 base 
through the use of a recombinant vector which incorporates 30 pairs upstream of a transcription initiation site. In contrast, 
the desired gene, together with its associated control an enhancer can be located downstream from the initiation 
sequences. The preparation of recombinant vectors is well site and can be at a considerable distance from that site, 
known to those of skill in the art and described in many ~n enhancer-promoter used in a vector construct of the 
references, such a% for example, Sambrook et al. (19x91, present invention can be any enhancer-promoter that drives 
specifically incorporated herein by reference. 35 expression in a cell to be transfected. By employing an 
In vectors, it is understood that the DNA coding enhancer-promoter with well-known properties, the level 
sequences to be expressed, in this case those encoding the and pattern of gene product expression can be optimized. 
NE transporter gene products, are positioned adjacent to and For introduction of, for example, the human NE trans- 
under the control of a promoter. It is understood in the art porter gene including allelic variations thereof, it is pro- 
that to bring a coding sequence under the Control of such a 40 posed that one will desire to preferably employ a vector 
Promoter, One generally Positions the 5‘ endofthetranscrip- construct that will deliver the desired gene to the affected 
tion initiation site of the transcriptional reading frame of the cells, This will, of course, generally require that the con- 
gene Product to be expressed between about 1 and about 50 struct be delivered to the targeted cells, for example, mam- 
nucleotides ‘‘downstream” of 6 %  3’ Of) the Chosen Pro- malian cardiac cells. It is proposed that this can be achieved 
moter. One can also desire to incorporate into the transcrip- 45 most preferably by introduction ofthe desired gene through 
tional unit ofthe vector an appropriate PolYadenYlation site the use of a viral vector to carry the NE transporter sequence 
(e.!&, 5 ’ - u T U - 3 ’ ) ,  if one was not contained within the to efficiently infect the cells. These vectors will preferably be 
Original inserted DNA. Typically, these PolYAaddition sites an adenoviral, a retroviral, a vaccinia viral vector or adeno- 
are Placed about 30 to 2000 nucleotides ‘‘downstream” of associated virus. These vectors are preferred because they 
the Coding sequence at a Position Prior to transcription 50 have been successfully used to deliver desired sequences to 
termination. cells and tend to have a high infection efficiency. Suitable 
While use of the control sequences of the specific gene vector-NE transporter gene constructs are adapted for 
(i.e., a NE transporter promoter for a NE transporter gene) administration as pharmaceutical compositions, as described 
will be preferred, there is no reason why other control herein below. 
sequences could not be employed, SO long as they are 55 Commonly used viral promoters for expression vectors 
compatible with the genotype of the cell being treated. Thus, are derived from polyoma, cytomegalovirus, Adenovirus 2, 
one can mention other useful promoters by way of example, and Simian Virus 40 (SV40). The early and late promoters 
including, e%., an SV4O early promoter, a long terminal of SV40 virus are particularly useful because both are 
repeat promoter from retrovirus, an actin promoter, a heat obtained easily from the virus as a fragment which also 
shock promoter, a metallothionein promoter, and the like. 60 contains the SV40 viral origin of replication. Smaller or 
As is known in the art, a promoter is a region of a DNA larger SV40 fragments can also be used, provided there is 
molecule typically within about 100 nucleotide pairs in front included the approximately 250 bp sequence extending from 
of (upstream of) the point at which transcription begins (Le., the Hind I11 site toward the Bgl I site located in the viral 
a transcription start site). That region typically contains origin of replication. Further, it is also possible, and often 
several types of DNA sequence elements that are located in 65 desirable, to utilize promoter or control sequences normally 
similar relative positions in different genes. As used herein, associated with the desired gene sequence, provided such 
the term “promoter” includes what is referred to in the art as control sequences are compatible with the host cell systems. 
used in the Same manner as the peptides ofthe invention and such a way that the transcription of that coding sequence is 
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The origin of replication can be provided either by comprising the steps of: (a) delivering to the cell an effective 
construction of the vector to include an exogenous origin, amount of a DNA molecule comprising a polynucleotide 
such as can be derived from SV40 or other viral (e.g., that encodes a NE transporter polypeptide that modulates 
Polyoma, Adeno, VSV, BPV) source, or can be provided by NE transport; and (b) maintaining the cell under conditions 
the host cell chromosomal replication mechanism. If the 5 sufficient for expression of said polypeptide. 
vector is integrated into the host cell chromosome, the latter Delivery is preferably accomplished by injecting the DNA 
is often sufficieiit. molecule into the cell. Where the cell is in a subject 
Where a NE transporter gene itself is employed it will be delivering is preferably administering the DNA molecule 
most convenient to simply use a wild type NE transporter into the circulatory system of the subject. In a preferred 
gene directly. Preferably, the NE transporter gene comprises 10 embodiment, administering comprises the steps of: (a) pro- 
the alanine encoding allele such that amino acid 457 of the viding a vehicle that contains the DNA molecule; and (b) 
encoded polypeptide comprises alanine. Additionally, it is administering the vehicle to the subject. 
provided that certain regions of a NE transporter gene can be A vehicle is preferably a cell transformed or transfected 
employed exclusively without employing an entire wild type with the DNA molecule or a transfected cell derived from 
NE transporter gene or an entire allelic variant thereof. It is 15 such a transformed or transfected cell. An exemplary and 
proposed that it will ultimately be preferable to employ the preferred transformed or transfected cell is a hepatic cell. 
smallest region needed to modulate NE transport so that one Means for transforming or transfecting a cell with a DNA 
is not introducing unnecessary DNA into cells which receive molecule of the present invention are set forth above. 
a NE transporter gene construct. Techniques well known to Alternatively, the vehicle is a virus or an antibody that 
those of skill in the art, such as the use of restriction 20 specifically infects or imunoreacts with an antigen of the 
enzymes, will allow for the generation of small regions of an tumor. Retroviruses used to deliver the constructs to the host 
exemplary NE transporter gene. The ability of these regions target tissues generally are viruses in which the 3’-LTR 
to modulate NE transport can easily be determined by the (linear transfer region) has been inactivated. That is, these 
assays reported in the Examples. In general, techniques for are enhancerless 3’-LTR’s, often referred to as SIN (self- 
assessing the modulation of NE transport are known in the 25 inactivating viruses) because after productive infection into 
art. the host cell, the 3’-LTR is transferred to the 5‘-end and both 
viral LTR’s are inactive with respect to transcriptional 
activity, A use of these viruses well known to those skilled 
prepare a transgenic non-human animal which expresses a in the art is to clone genes for which the regulatory elements 
NE transporter gene of the Present invention or in which 30 of the cloned gene are inserted in the space between the two 
C. 1. Transgenic Animals 
It is also within the scope of the present invention to 
expression of a NE transporter gene is “knocked-out”. The LTR’s. An advantage of a viral infection system is that it 
present invention provides transgenic non-human animals allows for a very high level of infection into the appropriate 
that express either the A457 form of NE transporter or the recipient cell. 
P457 form of NE transporter. A preferred transgenic animal Antibodies have been used to target and deliver DNA 
is a mouse. 35 molecules. An N-terminal modified poly-L-lysine (NPLL)- 
Techniques for the Preparation of transgenic animals are antibody conjugate readily forms a complex with plasmid 
known in the art. Exemplary techniques are described in DNA. A complex of monoclonal antibodies against a cell 
US.  Pat. No. 5,489,742 (traWFnic rats); US.  pat. Nos. surface thrombomodulin conjugated with NPLL was used to 
4,736,866, 5,550,316, 5,614,396, 5,625,125 and 5,648,061 target a foreign plasmid DNA to an antigen-expressing 
(transgenic mice); US.  Pat. No. 5,573,933 (transgenic Pigs); 40 mouse lung endothelial cell line and mouse lung. Those 
US.  pat. No. 5,162,215 ( t r~sgenic  avian species) and US.  targeted endothelial cells expressed the product encoded by 
Pat. No. 5,741,957 (transgenic bovine species), the entire that foreign DNA, 
contents of each of which are herein incorporated by refer- It is also envisioned that this embodiment of the present 
ence. invention can be practiced using alternative viral or phage 
with respect to an e x e m P k  m&Od for the Preparation 45 vectors, including retroviral vectors and vaccinia viruses 
of a transgenic mouse, cloned recombinant Or synthetic whose genome has been manipulated in alternative ways so 
DNA sequences Or DNA encoding a NE trans- as to render the virus non-pathogenic. Methods for creating 
porter gene product are injected into fertilized mouse eggs. such a viral mutation are set forth in detail in U.S. Pat. No. 
The injected eggs are implanted in Pseudo Pregnant females 4,769,331, incorporated herein by reference. 
and are grown to term to provide transgenic mice whose 50 a human NE transporter- 
cells express a NE transporter gene product. Preferably, the encoding polynucleotide or a NE transporter-encoding poly- 
injected sequences are constructed having Promoter nucleotide homolog from another warm-blooded vertebrate 
sequences connected SO as to express the desired Protein in is introduced into isolated cardiac cells or other relevant 
cardiac cells of the transgenic mouse. cells. The re-injection of the transgene-carrying cells into the 
55 heart or other relevant tissues provides a treatment for 
susceptibility to impaired NET function, orthostatic intoler- 
D. Pharmaceutical Compositions 
In a preferred embodiment, the present inveritionprovides 
pharmaceutical compositions comprising a polypeptide or 
polynucleotide of the present invention and a physiologi- 
cally acceptable carrier. More preferably, a pharmaceutical 
composition comprises a polynucleotide that encodes a 
A composition of the present invention is typically admin- 
istered orally or parenterally in dosage unit formulations 
B~ way of specific 
C.2. Gene Therapy 
NE transporter genes can be used for gene therapy in 
therapy methods, including liposomal transfection of nucleic 
acids into host cells, are described in U.S. Pat. Nos. 5,279, 
833; 5,286,634; 5,399,346; 5,646,008; 5,651,964; 5,641, 60 
484; and 5,643,567, the contents of each of which are herein 
incorporated by reference. 
Briefly, NE transporter gene therapy directed toward 
modulation of NE transport in a target cell is described. 
Target cells include but are not limited cardiac cells. In one 6 5  biologically active NE transporter polypeptide. 
embodiment, a therapeutic method of the present invention 
provides a method for modulating of NE transport in a cell 
accordance with the Present invention. Exemplary gene ance, or other relevant diseases in human and animals. 
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containing standard, well-known nontoxic physiologically 
acceptable carriers, adjuvants, and vehicles as desired. The 
term “parenteral” as used herein includes intravenous, intra- 
muscular, intra-arterial injection, or infusion techniques. 
Injectable preparations, for example sterile injectable 
aqueous or oleaginous suspensions, are formulated accord- 
ing to the known art using suitable dispersing or wetting 
agents and suspending agents. The sterile injectable prepa- 
ration can also be a sterile injectable solution or suspension 
in a nontoxic parenterally acceptable diluent or solvent, for 
example, as a solution in 1,3-butanediol. 
Among the acceptable vehicles and solvents that can be 
employed are water, Ringer’s solution, and isotonic sodium 
chloride solution. In addition, sterile, fixed oils are conven- 
tionally employed as a solvent or suspending medium. For 
this purpose any bland fixed oil can be employed including 
synthetic mono-or di-glycerides. In addition, fatty acids such 
as oleic acid find use in the preparation of injectables. 
Preferred carriers include neutral saline solutions buffered 
with phosphate, lactate, Tris, and the like. Of course, in the 
case of a pharmaceutical composition provided in use in 
gene therapy, one purifies the vector sufficiently to render it 
essentially free of undesirable contaminants, such as defec- 
tive interfering adenovirus particles or endotoxins and other 
pyrogens such that it does not cause any untoward reactions 
in the individual receiving the vector construct. A preferred 
means of purifying the vector involves the use of buoyant 
density gradients, such as cesium chloride gradient centrifu- 
gation. 
A transfected cell can also serve as a carrier. By way of 
example, a liver cell can be removed from an organism, 
transfected with a polynucleotide of the present invention 
using methods set forth above and then the transfected cell 
returned to the organism (e.g. injected intra-vascularly). 
D.l. Dosages 
As used herein, an “effective” dose refers to one that is 
administered in doses tailored to each individual patient 
manifesting symptoms of NE transport deficiency sufficient 
to cause an improvement therein. After review of the dis- 
closure herein of the present invention, one of ordinary skill 
in the art can tailor the dosages to an individual patient, 
taking into account the particular formulation and method of 
administration to be used with the composition as well as 
patient height, weight, severity of symptoms, and stage of 
the disorder to be treated. 
An effective dose and a therapeutically effective dose are 
generally synonymous. However, compounds can be admin- 
istered to patients having reduced symptoms or even admin- 
istered to patients as a preventative measure. Hence, the 
composition can be effective in therapeutic treatment even in 
the absence of symptoms of the disorder. 
Aunit dose can be administered, for example, 1 to 4 times 
per day. Most preferably, the unit dose is administered twice 
a day (BID). The dose depends on the route of administra- 
tion and the formulation of a composition containing the 
compound or compounds. Further, it will be appreciated by 
one of ordinary skill in the art after receiving the disclosure 
of the present invention that it can be necessary to make 
routine adjustments or variations to the dosage depending on 
the combination of agents employed, on the age and weight 
of the patient, and on the severity of the condition to be 
treated. 
Such adjustments or variations, as well as evaluation of 
when and how to make such adjustments or variations, are 
well known to those of ordinary skill in the art of medicine. 
Evaluation parameters and techniques can vary with the 
patient and the severity of the disease. Particularly useful 
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evaluative techniques for NE transport include NE clear- 
ance, tyramine administration and other standard tests such 
as are disclosed in the Examples. 
D.2. Gene Therapy Vector Construct Dosing. 
Maximally tolerated dose (MTD) of vector construct 
when administered directly into the affected tissue is deter- 
mined. Primary endpoints are: 1) the rate of transduction in 
abnormal andor normal cells, 2) the presence and stability 
of this vector in the systemic circulation and in affected 
10 cells, and 3) the nature of the systemic (fever, myalgias) and 
local (infections, pain) toxicities induced by the vector. A 
secondary endpoint is the clinical efficacy of the vector 
construct. 
For example, a 4 ml serum-free volume of viral (e.g. 
15 adenoviral, retroviral, etc.) vector construct (containing up 
to 5x107 viral particles in AIM V media) is administered 
daily per session. During each session, 1 ml of medium 
containing the appropriate titer of vector construct is 
injected into 4 regions of the affected tissue for a total of 4 
20 ml per session in a clinical examination room. This is 
repeated daily for 4 days (4 sessions). This 16 ml total 
inoculum volume over 4 days is proportionally well below 
the one safely tolerated by nude mice (0.5 m1120 g body 
weight). 
Patient evaluation includes history and physical exami- 
nation prior to initiation of therapy and daily during the 4 
day period of vector construct injection. Toxicity grading is 
done using the ECOG Common Toxicity Criteria. CBC, 
SMA-20, urinalysis, and conventional studies are performed 
5 
25 
30 daily during this period. 
D.3. Dose Escalation and MTD. 
Patients are treated with 3x106 viral particlesx4. Once 
they have all recovered from all grade 2 or less toxicities 
(except alopecia), and as long as grade 3-4 toxicity is not 
35 encountered, a subsequent dose level is initiated in patients. 
As one grade 3 or 4 toxicity occurs at a given dose level, a 
minimum of 6 patients are enrolled at that level. As only 1 
of 6 patients has grade 3 or 4 toxicity, dose escalation 
continues. The MTD of vector construct is defined as the 
40 dose where 2 of 6 patients experience grade 3 or 4 toxicity. 
If 2 of 3, or if 3 of 6 patients experience grade 3 or 4 toxicity, 
the MTD is defined as the immediately lower dose level. 
The following escalation schema is followed: 1) level 1, 
3x106 viral particles; 2) level 2, lx107; 3) level 3, 3x107; 4) 
45 level 4, 5x107. Patients with measurable disease are evalu- 
ated for a clinical response to vector construct. Histology 
and local symptoms are followed. NE clearance, tyramine 
administration and other standard tests such as are disclosed 
in the Examples are employed. 
E. Generation of Antibodies 
In still another embodiment, the present invention pro- 
vides an antibody immunoreactive with a polypeptide or 
polynucleotide of the present invention. Preferably, an anti- 
55 body of the invention is a monoclonal antibody. Techniques 
for preparing and characterizing antibodies are well known 
in the art (See e.g. Antibodies: A Laboratoy Manual, E. 
Howell and D. Lane, Cold Spring Harbor Laboratory, 1988). 
More preferred antibodies distinguish between the different 
60 forms of NE transporter polypeptides (e.g. SEQ ID NOs:2 
and 4) that comprise the NE transporter polymorphism. 
Briefly, a polyclonal antibody is prepared by immunizing 
an animal with an immunogen comprising a polypeptide or 
polynucleotide of the present invention, and collecting anti- 
65 sera from that immunized animal. A wide range of animal 
species can be used for the production of antisera. Typically 
an animal used for production of anti-antisera is a rabbit, a 
50 
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mouse, a rat, a hamster or a guinea pig. Because of the sis. Where aminopterin or methotrexate is used, the media is 
relatively large blood volume of rabbits, a rabbit is a supplemented with hypoxanthine and thymidine as a source 
preferred choice for production of polyclonal antibodies. of nucleotides. Where azaserine is used, the media is supple- 
As is well known in the art, a given polypeptide or mented with hypoxanthine. 
polynucleotide can vary in its immunogenicity. It is often 5 This culturing provides a population of hybridomas from 
necessary therefore to couple the immunogen (e.g., a which specific hybridomas are selected. Typically, selection 
polypeptide or polynucleotide) of the present invention) of hybridomas is performed by culturing the cells by single- 
with a carrier. Exemplary and preferred carriers are keyhole clone dilution in microtiter plates, followed by testing the 
limpet hemocyanin (KLH) and bovine serum albumin individual clonal supernatants for reactivity with an antigen- 
(BSA). Other albumins such as ovalbumin, mouse serum i o  polypeptides. The selected clones can then be propagated 
albumin or rabbit serum albumin can also be used as 
carriers. 
Techniques and reagents for conjugating a polypeptide or 
a polynucleotide to a carrier protein are well known in the 
art and include glutaraldehyde, m-maleimidobencoyl-N-hy- 
droxysuccinimide ester, carbodiimide and bis-biazotized 
benzidine. 
As is also well known in the art, immunogencity to a 
particular immunogen can be enhanced by the use of non- 
specific stimulators of the immune response known as 
adjuvants. Exemplary and preferred adjuvants include com- 
plete Freund’s adjuvant, incomplete Freund’s adjuvants and 
aluminum hydroxide adjuvant. 
The amount of immunogen used of the production of 
polyclonal antibodies varies, inter alia, upon the nature of 
the immunogen as well as the animal used for immunization. 
A variety of routes can be used to administer the immuno- 
gen, e.g. subcutaneous, intramuscular, intradermal, intrave- 
nous and intraperitoneal. The production of polyclonal anti- 
bodies is monitored by sampling blood of the immunized 
indefinitely to provide the monoclonal antibody. 
By way of specific example, to produce an antibody of the 
present invention, mice are injected intraperitoneally with 
between about 1-200 pg of an antigen comprising a 
15 polypeptide of the present invention. B lymphocyte cells are 
stimulated to grow by injecting the antigen in association 
with an adjuvant such as complete Freund’s adjuvant (a 
nonspecific stimulator of the immune response containing 
killed Mycobacterium tuberculosis). At some time (e.g., at 
20 least two weeks) after the first injection, mice are boosted by 
injection with a second dose of the antigen mixed with 
incomplete Freund’s adjuvant. 
A few weeks after the second injection, mice are tail bled 
and the sera titered by immunoprecipitation against radio- 
25 labeled antigen. Preferably, the process of boosting and 
titering is repeated until a suitable titer is achieved. The 
spleen of the mouse with the highest titer is removed and the 
spleen lymphocytes are obtained by homogenizing the 
spleen with a syringe. Typically, a spleen from an immu- 
30 nized mouse contains approximately 5x107 to 2x10’ lym- 
animal at various points following immunization. When a phocytes. 
desired level of immunogenicity is obtained, the immunized Mutant lymphocyte cells known as myeloma cells are 
animal can be bled and the serum isolated and stored. obtained from laboratory animals in which such cells have 
In another aspect, the present invention provides a method been induced to grow by a variety of well-known methods. 
of producing an antibody immunoreactive with a NE trans- 35 Myeloma cells lack the salvage pathway of nucleotide 
porter polypeptide, the method comprising the steps of (a) biosynthesis. Because myeloma cells are tumor cells, they 
transfecting recombinant host cells with a polynucleotide can be propagated indefinitely in tissue culture, and are thus 
that encodes that polypeptide; (b) culturing the host cells denominated immortal. Numerous cultured cell lines of 
under conditions sufficient for expression of the polypeptide; myeloma cells from mice and rats, such as murine NS-1 
(c) recovering the polypeptide; and (d) preparing antibodies 40 myeloma cells, have been established. 
to the polypeptide. Preferably, the NE transporter polypep- Myeloma cells are combined under conditions appropri- 
tide is capable of mediating NE transport, cross-reacting ate to foster fusion with the normal antibody-producing cells 
with anti-NE transporter antibody, or other biological activ- from the spleen of the mouse or rat injected with the 
ity in accordance with the present invention. Even more antigedpolypeptide of the present invention. Fusion condi- 
preferably, the present invention provides antibodies pre- 45 tions include, for example, the presence of polyethylene 
pared according to the method described above. glycol. The resulting fused cells are hybridoma cells. Like 
A monoclonal antibody of the present invention can be myeloma cells, hybridoma cells grow indefinitely in culture. 
readily prepared through use of well-known techniques such Hybridoma cells are separated from unfused myeloma 
as those exemplified in U.S. Pat. No. 4,196,265, herein cells by culturing in a selection medium such as HAT media 
incorporated by reference. Typically, a technique involves 50 (hypoxanthine, aminopterin, thymidine). Unfused myeloma 
first immunizing a suitable animal with a selected antigen cells lack the enzymes necessary to synthesize nucleotides 
(e.g., a polypeptide or polynucleotide of the present inven- from the salvage pathway because they are killed in the 
tion) in a manner sufficient to provide an immune response. presence of aminopterin, methotrexate, or azaserine. 
Rodents such as mice and rats are preferred animals. Spleen Unfused lymphocytes also do not continue to grow in tissue 
cells from the immunized animal are then fused with cells of 55 culture. Thus, only cells that have successfully fused (hybri- 
an immortal myeloma cell. Where the immunized animal is doma cells) can grow in the selection media. 
a mouse, a preferred myeloma cell is a murine NS-1 Each of the surviving hybridoma cells produces a single 
myeloma cell. antibody. These cells are then screened for the production of 
The fused spleedmyeloma cells are cultured in a selective the specific antibody immunoreactive with an antiged 
medium to select fused spleedmyeloma cells from the 60 polypeptide of the present invention. Single cell hybridomas 
parental cells. Fused cells are separated from the mixture of are isolated by limiting dilutions of the hybridomas. The 
non-fused parental cells, for example, by the addition of hybridomas are serially diluted many times and, after the 
agents that block the de novo synthesis of nucleotides in the dilutions are allowed to grow, the supernatant is tested for 
tissue culture media. Exemplary and preferred agents are the presence of the monoclonal antibody. The clones pro- 
aminopterin, methotrexate, and azaserine. Aminopterin and 65 ducing that antibody are then cultured in large amounts to 
methotrexate block de novo synthesis of both purines and produce an antibody of the present invention in convenient 
pyrimidines, whereas azaserine blocks only purine synthe- quantity. 
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By use of a monoclonal antibody of the present invention, 
specific polypeptides and polynucleotide of the invention 
can be recognized as antigens, and thus identified. Once 
identified, those polypeptides and polynucleotide can be 
isolated and purified by techniques such as antibody-affinity 
chromatography. In antibody-affinity chromatography, a 
monoclonal antibody is bound to a solid substrate and 
exposed to a solution containing the desired antigen. The 
antigen is removed from the solution through an immuno- 
specific reaction with the bound antibody. The polypeptide 
or polynucleotide is then easily removed from the substrate 
and purified. 
F. Detection Methods 
Alternatively, the present invention provides a method of 
detecting a polypeptide of the present invention, wherein the 
method comprises immunoreacting the polypeptides with 
antibodies prepared according to the methods described 
above to form antibody-polypeptide conjugates, and detect- 
ing the conjugates. 
In yet another embodiment, the present invention pro- 
vides a method of detecting messenger RNA transcripts that 
encode a polypeptide of the present invention, wherein the 
method comprises hybridizing the messenger RNA tran- 
scripts with polynucleotide sequences that en code the 
polypeptide to form duplexes; and detecting the duplex. 
Alternatively, the present invention provides a method of 
detecting DNA molecules that encode a polypeptide of the 
present invention, wherein the method comprises hybridiz- 
ing DNA molecules with a polynucleotide that encodes that 
polypeptide to form duplexes; and detecting the duplexes. 
The detection and screening assays disclosed herein can 
be also used as a part of a diagnostic method. Human NE 
transporter-encoding polynucleotides as well as their protein 
products can be readily used in clinical setting to diagnose 
susceptibility to orthostatic intolerance and to other heritable 
NE transporter-related diseases in humans. 
F.l. Screening Assays for a Polypeptide of the Present 
Invention 
The present invention provides a method of screening a 
biological sample for the presence of a NE transporter 
polypeptide. Preferably, the NE transporter polypeptide pos- 
sesses NE transport activity, cross-reactivity with an anti-NE 
transporter antibody, or other biological activity in accor- 
dance with the present invention. A biological sample to be 
screened can be a biological fluid such as extracellular or 
intracellular fluid or a cell or tissue extract or homogenate. 
A biological sample can also be an isolated cell (e.g., in 
culture) or a collection of cells such as in a tissue sample or 
histology sample. A tissue sample can be suspended in a 
liquid medium or fixed onto a solid support such as a 
microscope slide. Hepatic tissues comprise particularly con- 
templated tissues. 
Preferably, antibodies which distinguish between the 
A457 NE transporter polypeptide and the P457 NE trans- 
porter polypeptide are provided. Such antibodies can com- 
prise polyclonal antibodies but are preferably monoclonal 
antibodies prepared as described hereinabove. 
In accordance with a screening assay method, a biological 
sample is exposed to an antibody immunoreactive with the 
polypeptide whose presence is being assayed. Typically, 
exposure is accomplished by forming an admixture in a 
liquid medium that contains both the antibody and the 
candidate polypeptide. Either the antibody or the sample 
with the polypeptide can be affixed to a solid support (e.g., 
a column or a microtiter plate). 
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The biological sample is exposed to the antibody under 
biological reaction conditions and for a period of time 
sufficient for antibody-polypeptide conjugate formation. 
Biological reaction conditions include ionic composition 
5 and concentration, temperature, pH and the like. 
Ionic composition and concentration can range from that 
of distilled water to a 2 molal solution of NaCl. Preferably, 
osmolality is from about 100 mosmolsil to about 400 
mosmolsil and, more preferably from about 200 mosmolsil 
i o  to about 300 mosmolsil. Temperature preferably is from 
about 4" C. to about 100" C., more preferably from about 
15" C. to about 50" C. and, even more preferably from about 
25" C. to about 40" C. pH is preferably from about a value 
of 4.0 to a value of about 9.0, more preferably from about 
15 a value of 6.5 to a value of about 8.5 and, even more 
preferably from about a value of 7.0 to a value of about 7.5. 
The only limit on biological reaction conditions is that the 
conditions selected allow for antibody-polypeptide conju- 
gate formation and that the conditions do not adversely 
Exposure time will vary inter alia with the biological 
conditions used, the concentration of antibody and polypep- 
tide and the nature of the sample (e.g., fluid or tissue 
sample). Techniques for determining exposure time are well 
25 known to one of ordinary skill in the art. Typically, where the 
sample is fluid and the concentration of polypeptide in that 
sample is about 10-lOM, exposure time is from about 10 
minutes to about 200 minutes. 
The presence of polypeptide in the sample is detected by 
30 detecting the formation and presence of antibody-polypep- 
tide conjugates. Techniques for detecting such antibody- 
antigen (e.g., receptor polypeptide) conjugates or complexes 
are well known in the art and include such procedures as 
centrifugation, affinity chromatography and the like, binding 
35 of a secondary antibody to the antibody-candidate receptor 
complex. 
In one embodiment, detection is accomplished by detect- 
ing an indicator affixed to the antibody. Exemplary and well 
known such indicators include radioactive labels (e.g., 32P, 
40 lZ5I, 14C), a second antibody or an enzyme such as horse 
radish peroxidase. Techniques for affixing indicators to 
antibodies are well known in the art. Commercial kits are 
available. 
20 affect either the antibody or the polypeptide. 
F.2. Screening Assay for Anti-Polypeptide Antibody 
In another aspect, the present invention provides a method 
of screening a biological sample for the presence of anti- 
bodies immunoreactive with a NE transporter polypeptide. 
Optionally, the NE transporter polypeptide has NE transport 
activity, cross-reactivity with an anti-NE transporter anti- 
50 body, or other biological activity in accordance with the 
present invention. 
In accordance with such a method, a biological sample is 
exposed to a NE transporter polypeptide under biological 
conditions and for a period of time sufficient for antibody- 
55 polypeptide conjugate formation and the formed conjugates 
are detected. Autoimmune antibodies associated with 
acquired impaired NET function are particularly contem- 
plated for detection. 
Thus, binding substances comprising a NE transporter 
60 polypeptide as described herein have selective binding activ- 
ity with an antibody epitope (antigen recognition specific- 
ity). This binding specificity can be employed for detecting 
and/or purifying the antibody or fragment thereof. The term 
"fragment" thus refers any fragment of the antibody, such as 
A NE transporter polypeptide is prepared as described 
herein above. The polypeptide is then conjugated to, or 
45 
65 Fab and F(ab'), fragments. 
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labeled with, a material that will enable visualization of the 
presence of the NE transporter polypeptide. 
The NE transporter polypeptide can thus be used in a 
variety of applications to detect antibodies or antibody 
fragments. For example, fluoresceinated, alkaline phos- 
phatase labeled, peroxidase labeled, or biotinylated NE 
transporter polypeptides are used in indirect cytochemical 
assays to detect antibody binding to cells and tissues in 
histological or flow cytometric assays. Such detection can be 
used in a variety of research or clinical contexts. 
Similarly, immobilized NE transporter polypeptides can 
be used to precipitate immune complexes in radioimmune 
and other quantitative immune or antigen capture assays. 
Such immunoprecipitation assays where immune complexes 
of radiolabeled antigens are captured on immobilized NE 
transporter polypeptides of the present invention have wide 
application in the art. 
By way of elaboration, the NE transporter polypeptides 
are used to detect the presence of antibodies and fragments 
thereof, in solutions, or on surfaces exposed to antibodies, or 
fragments thereof, by a variety of techniques. Techniques 
which are used include: enzyme-linked immunosorbent 
assay (ELISA), radioimmunoassay (RIA), immunoblot 
analysis, immunofluorescent assay (IFA), immunohis- 
tochemistry, immunoelectron microscopy (IEM), and immu- 
noilluminescence. Each technique utilizes conjugates 
including NE transporter polypeptides to visualize the bind- 
ing of the conjugate to antibody molecules or fragments 
thereof. 
Commonly used conjugates include, but are not limited 
to, enzymes such as biotin, horseradish peroxidase, alkaline 
phosphatase (O'Sullivan et al. (1978) FEBS Letters 95:31 l), 
acid phosphatase, beta-galactosidase (Ishikawa et al. (1 978) 
Scand. J. Zmmunol. 8:43) and luciferase; radioisotopes such 
as lZ5I, 35S, 14C, and 3H; fluorescent dyes such as fluores- 
cein, rhodamine, dichlorotriazinylaminofluorescein (DTAF; 
Blakeslee et al., J.  Zmmunol Meth. 13:320 (1977)), ferritin 
(Carlsson et al. (1978) Biochem. J. 173:723), fluoroscene 
isothiocyanste (FITC; McKinney et al. (1966) Anal. Bio- 
chem. 14:421), sulforhodamine 101 acid chloride (Texas 
Red) and tetra-methyrhodamine isothiocyanate (TRITC; 
Amante et al., J. Zmmunol. Meth., 1:289 (1972)); colloidal 
gold particles (Horisberger et al., Histochem. 82:219 
(1985)); and the like. Effective procedures for such conju- 
gations are generally conventional, as described by Harlow 
et al., 1988, Antibodies: a laboratoy manual, Cold Spring 
Harbor Laboratory, Cold Spring Harbor, N.Y. 
The protein conjugate is stored in appropriate buffers until 
needed. Colloidal gold conjugates can be maintained in 
Tris-based stabilizing buffer, such as those described in 
Robinson et al., (1984) Znfect. Zmmun. 46:361-366. For 
other conjugates, the buffer would typically be phosphate- 
buffered saline, pH 7.2 (PBS). However, physiological buff- 
ers such as Tris- or borate-buffered saline (TBS or BBS) in 
pH ranging from 6.5 to 8.0, or non-saline buffers such as 
acetates, bicarbonates, or citrates within this pH range can 
be utilized. 
When needed to detect the presence of antibodies or 
fragments thereof in a preparation, the NE transporter 
polypeptide conjugate can be first diluted in an appropriate 
buffer. The extent of dilution varies according to the conju- 
gate and sensitivity required, and is normally determined 
empirically for a given conjugate preparation and detection 
method. Dilutions typically range from 1 : 10 to 1 : 10,000. 
After dilution the conjugate is incubated with a sample 
suspected of containing antibodies or fragments thereof. The 
incubation should proceed for about 15-60 minutes at room 
34 
temperature, or about 4-16 hours at about 4" C., during 
which time from one to ten (optimally) NE transporter 
polypeptide molecules will bind to any antibodies or frag- 
ments thereof present. Following incubation, the sample is 
5 washed twice for about 5-10 minutes each with dilution 
buffer or with buffer which is compatible with the visual- 
ization conditions (if different). The presence of bound NE 
transporter polypeptide can then be detected or visualized by 
chromogenic assay, radioactivity, illuminescence, fluores- 
i o  cence, flow cytometry or electron density, as appropriate for 
the conjugate. 
Thus, a method for detecting an antibody or fragment 
thereof, in a sample suspected of an antibody or fragment 
thereof, is provided in accordance with the present inven- 
15 tion. The method comprises: (a) contacting the sample with 
a binding substance comprising a NE transporter polypep- 
tide under conditions favorable to binding an antibody or 
fragment thereof, to the binding substance to form a com- 
plex therebetween; and (b) detecting the complex by means 
20 of a label conjugated to the binding substance or by means 
of a labeled reagent that specifically binds to the complex 
subsequent to its formation. 
In the detection method of the present invention, the 
binding substance can be immobilized on a solid substrate. 
25 In such case, the detecting step (b) comprises: (i) contacting 
the complex with a reagent conjugated with a detectable 
label wherein the reagent specifically binds to the antibody 
or fragment thereof, and (ii) detecting the detectable label. 
In the detection method of the present invention, the 
30 binding substance can be conjugated with a detectable label. 
In such case, the detecting step (b) comprises: (i) separating 
the complex from unbound labeled binding substance; and 
(ii) detecting the detectable label which is present in the 
complex or which is unbound. 
The detection method of the present invention can further 
comprise: (i) contacting the complex with a reagent immo- 
bilized on a solid substrate to form immobilized complex 
thereon wherein the reagent binds the antibody or fragment, 
4o present in the complexes; and (ii) separating the immobi- 
lized complex from the remaining mixture. 
F.3. Screening Assay for Polynucleotide That Encodes a 
NE Transporter Polypeptide of the Present Invention 
A nucleic acid molecule and, particularly a probe mol- 
45 ecule, can be used for hybridizing as an oligonucleotide 
probe to a nucleic acid source suspected of encoding a NE 
transporter polypeptide of the present invention. Optimally, 
the NE transporter polypeptide has NE transport activity, 
cross-reactivity with an anti-NE transporter antibody, or 
50 other biological activity in accordance with the present 
invention. The probing is usually accomplished by hybrid- 
izing the oligonucleotide to a DNA source suspected of 
possessing a NE transporter gene. In some cases, the probes 
constitute only a single probe, and in others, the probes 
55 constitute a collection of probes based on a certain amino 
acid sequence or sequences of the polypeptide and account 
in their diversity for the redundancy inherent in the genetic 
code. 
A suitable source of DNA for probing in this manner is 
60 capable of expressing a polypeptide of the present invention 
and can be a genomic library of a cell line of interest. 
Alternatively, a source of DNA can include total DNA from 
the cell line of interest. Once the hybridization method of the 
invention has identified a candidate DNA segment, one 
65 confirms that a positive clone has been obtained by further 
hybridization, restriction enzyme mapping, sequencing a n d  
or expression and testing. 
35 
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Alternatively, such DNA molecules can be used in a Of course, for some applications, for example, where one 
number of techniques including their use as: (1) diagnostic desires to prepare mutants employing a mutant primer strand 
tools to detect normal and abnormal DNA sequences in hybridized to an underlying template or where one seeks to 
DNA derived from patient's cells, such as a NE transporter isolate polypeptide coding sequences from related species, 
polymorphism described herein; (2) tools for detecting and 5 functional equivalents, or the like, less stringent hybridiza- 
isolating other members of the polypeptide family and tion conditions are typically needed to allow formation of 
related polypeptides from a DNA library potentially con- the heteroduplex. Under such circumstances, one employs 
taining such sequences; (3) primers for hybridizing to conditions such as 0.15M4.9M salt, at temperatures rang- 
related sequences for the purpose of amplifying those ing from about 20" C. to about 55" C., including particularly 
sequences; (4) primers for altering native NE transporter i o  temperatures of about 25" C., about 37" C., about 45" C., and 
DNA sequences; as well as other techniques which rely on about 50" C. Cross-hybridizing species can thereby be 
the similarity of the DNA sequences to those of the DNA readily identified as positively hybridizing signals with 
segments herein disclosed. respect to control hybridizations. In any case, it is generally 
As set forth above, in certain aspects, DNA sequence appreciated that conditions can be rendered more stringent 
information provided by the invention allows for the prepa- 15 by the addition of increasing amounts of formamide, which 
ration of relatively short DNA (or RNA) sequences (e.g., serves to destabilize the hybrid duplex in the same manner 
probes) that specifically hybridize to encoding sequences of as increased temperature. Thus, hybridization conditions can 
a selected NE transporter gene. In these aspects, nucleic acid be readily manipulated, and thus will generally be a method 
probes of an appropriate length are prepared based on a of choice depending on the desired results. 
consideration of the encoding sequence for a polypeptide of 20 In certain embodiments, it is advantageous to employ a 
this invention. The ability of such nucleic acid probes to nucleic acid sequence of the present invention in combina- 
specifically hybridize to other encoding sequences lend them tion with an appropriate means, such as a label, for deter- 
particular utility in a variety of embodiments. Most impor- mining hybridization. A wide variety of appropriate indica- 
tantly, the probes can be used in a variety of assays for tor means are known in the art, including radioactive, 
detecting the presence of complementary sequences in a 25 enzymatic or other ligands, such as avidinhotin, which are 
given sample. However, other uses are envisioned, including capable of giving a detectable signal. In preferred embodi- 
the use of the sequence information for the preparation of ments, one likely employs an enzyme tag such a urease, 
mutant species primers, or primers for use in preparing other alkaline phosphatase or peroxidase, instead of radioactive or 
genetic constructions. other environmentally undesirable reagents. In the case of 
To provide certain of the advantages in accordance with 30 enzyme tags, calorimetric indicator substrates are known 
the invention, a preferred nucleic acid sequence employed which can be employed to provide a means visible to the 
for hybridization studies or assays includes probe sequences human eye or spectrophotometrically, to identify specific 
that are complementary to at least a 14 to 40 or so long hybridization with complementary nucleic acid-containing 
nucleotide stretch of a nucleic acid sequence of the present samples. 
invention, such as a sequence shown in any of SEQ ID 35 In general, it is envisioned that the hybridization probes 
NOs:l, 3, 11 and 13. A size of at least 14 nucleotides in described herein are useful both as reagents in solution 
length helps to ensure that the fragment is of sufficient length hybridization as well as in embodiments employing a solid 
to form a duplex molecule that is both stable and selective. phase. In embodiments involving a solid phase, the sample 
Molecules having complementary sequences over stretches containing test DNA (or RNA) is adsorbed or otherwise 
greater than 14 bases in length are generally preferred, 40 affixed to a selected matrix or surface. This fixed, single- 
though, to increase stability and selectivity of the hybrid, stranded nucleic acid is then subjected to specific hybrid- 
and thereby improve the quality and degree of specific ization with selected probes under desired conditions. The 
hybrid molecules obtained. One will generally prefer to selected conditions depend inter alia on the particular cir- 
design nucleic acid molecules having gene-complementary cumstances based on the particular criteria required (de- 
stretches of 14 to 20 nucleotides, or even longer where 45 pending, for example, on the G+C contents, type of target 
desired. Such fragments can be readily prepared by, for nucleic acid, source of nucleic acid, size of hybridization 
example, directly synthesizing the fragment by chemical probe, etc.). Following washing of the hybridized surface so 
means, by application of nucleic acid reproduction technol- as to remove nonspecifically bound probe molecules, spe- 
ogy, such as the PCR technology 0fU.S. Pat. No. 4,683,202, cific hybridization is detected, or even quantified, via the 
herein incorporated by reference, or by introducing selected 50 label. 
sequences into recombinant vectors for recombinant pro- F.4. Assay Kits 
duction. In another aspect, the present invention provides diagnos- 
Accordingly, a nucleotide sequence of the present inven- tic assay kits for detecting the presence of a polypeptide of 
tion can be used for its ability to selectively form duplex the present invention in biological samples, where the kits 
molecules with complementary stretches of the gene. 55 comprise a first container containing a first antibody capable 
Depending on the application envisioned, one employs of immunoreacting with the polypeptide, with the first 
varying conditions of hybridization to achieve varying antibody present in an amount sufficient to perform at least 
degrees of selectivity of the probe toward the target one assay. Preferably, the assay kits of the invention further 
sequence. For applications requiring a high degree of selec- comprise a second container containing a second antibody 
tivity, one typically employs relatively stringent conditions 60 that immunoreacts with the first antibody. More preferably, 
to form the hybrids. For example, one selects relatively low the antibodies used in the assay kits of the present invention 
salt andor high temperature conditions, such as provided by are monoclonal antibodies. Even more preferably, the first 
0.02M-0.15M salt at temperatures of about 50" C. to about antibody is affixed to a solid support. More preferably still, 
70" C. including particularly temperatures of about 55" C., the first and second antibodies comprise an indicator, and, 
about 60" C. and about 65" C. Such conditions are particu- 65 preferably, the indicator is a radioactive label or an enzyme. 
larly selective, and tolerate little, if any, mismatch between The present invention also provides a diagnostic kit for 
the probe and the template or target strand. screening agents. Such a kit can contain a polypeptide of the 
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present invention. The kit can contain reagents for detecting 0 to about 90 pgl24 hrs. Thus, these data can be used in 
an interaction between an agent and a receptor of the present accordance with the present invention to detect impaired NE 
invention. The provided reagent can be radiolabeled. The kit transport and disorders related thereto. 
can contain a known radiolabelled agent capable of binding In accordance with the present invention, the ratio of 
or interacting with a receptor of the present invention. 5 DHPG to NE in blood is also used to detect impaired NE 
In an alternative aspect, the present invention provides transport and disorders related thereto. DHPG is a metabo- 
diagnostic assay kits for detecting the presence, in biological lite of NE, resulting from the enzymatic action of monoam- 
samples, of a polynucleotide that encodes a polypeptide of ine oxidase. Since the monoamine oxidase is predominantly 
the present invention, the kits comprising a first container in the neuron itself, NE pumped back into the neuron by the 
that contains a second polynucleotide identical or comple- 10 NET is exposed to the enzyme and can be broken down into 
mentary to a segment of at least 10 contiguous nucleotide DHPG, which can then leak out into the plasma. If the NET 
bases of, as a preferred example, in any of SEQ ID Nos: 1, is not functioning appropriately or if there is a deficiency of 
3, 11 and 13. NET, not as much norepinephrine is pumped up into the 
In another embodiment, the present invention provides neuron and subsequently metabolized to DHPG. Thus, the 
diagnostic assay kits for detecting the presence, in a bio- 15 ratio of DHPG to NE in blood is less in patients with NET 
logical sample, of antibodies immunoreactive with a deficiency. This difference can appear during upright posture 
polypeptide of the present invention, the kits comprising a or with exercise. The ratio of DHPG to NE in blood is 
first container containing a NE transporter polypeptide, that determined, and the results are compared to results observed 
immunoreacts with the antibodies, with the polypeptide in patients having the NET mutation disclosed herein. Test 
present in an amount sufficient to perform at least one assay. 20 results that indicate a correlation with the results observed in 
Autoimmune antibodies associated with acquired a patient having the polymorphism disclosed herein indi- 
impaired NET function are particularly contemplated for cates the presence of a deficiency in NE transport in a patient 
detection. Preferably, the NE transporter polypeptide has NE SO screened. 
transport activity, cross-reactivity on an anti-NE transporter In accordance with the present invention, the ratio of 
antibody, or other biological activity in accordance with the 25 DHPG to normetanepkne (NMN) is also used to detect 
present invention. The reagents of the kit can be provided as impaired NE transport and dim-ders related thereto. when 
a liquid solution, attached to a solid support or as a dried NE is not Pumped into the neuron by the NE transporter, NE 
solution, the liquid solution is an aqueous solution. Prefer- enzyme called catechol-O-methYltransferase (COMT), 
ably, when the reagent provided is attached to a solid 30 which catalyzes the metabolism of NE to NMN. The 
support, the solid support can be chromatograph media or a metabolism of NE to NMN is enhanced under circumstances 
microscope slide, m e n  the reagent provided is a dry where NE transport into the neuron is impaired, and thus, a 
powder, the powder can be reconstituted by the addition of ratio of DHPG to normetanephrine (Nm) can also be used 
a suitable solvent. The solvent can be provided. to detect impaired NE transport and disorders related 
35 thereto. The ratio of DHPG to NMN is determined, and the 
G. Other Diagnostic Methods results are compared to results observed in patients having 
Provides the detection and the NET mutation disclosed herein. Test results that indicate 
diagnoses of impaired NE transport and disOrders related a correlation with the results observed in a patient having the 
thereto based on the use of standard tests associated with po~ymorphism disclosed herein indicates the presence of a 
evaluating NE transport function, such as the NE clearance 4o deficiency in NE transport in a patient so screened, 
and tyramine tests described in the Examples. Such test another aspect, the method can be used to detect 
results are Prepared, and the results are compared to results susceptibility to a NET mediated disorder in a patient. The 
observed in patients having the NET mutation disclosed detection of secondary test indicative of impaired 
herein. Test results that indicate a correlation with the results NET function can thus be used to detect susceptibility to 
observed in a Patient having the PolYmorphism disclosed 45 mental illness, hypertension, heart disease and psycho 
herein indicates the presence of a deficiency in NE transport stimulant abuse (e,g, cocaine or amphetamine abuse), Thus, 
in a patient so screened. the methods of the present invention are believed to meet a 
For example, in the NE clearance evaluations described in long felt need in the art for further characterization of NE 
the Examples, NE transport deficient Patients, 6.e. those transport impairments and predictive ability to detect sus- 
having the NET polymorphism disclosed herein) were 50 ceptibility to disorders related thereto, 
observed to have NE clearance rates ranging from about 1-2 Stated differently, the identification of the NET trans- 
liters Per minute. In contrast, NE ckarance rates are 2-3 porter mutation as set forth herein represents the first estab- 
liters per minute in normal patients. lishment of a link between genetic causes of NET deficien- 
Additionally, in the tyramine administration test disclosed ties and more indirect measures of NET deficiencies, such 
in the Examples, elevated plasma NE levels after adminis- 55 as the tyramine and NE clearance tests disclosed in the 
tration of the unit dose of tyramine were observed to range Examples presented below. This information is thus useful 
from about 1 to about 20 pgiml and more particularly from in facilitating diagnoses of approximately half a million 
about 5 to about 50 pgiml in patients having the NE patients in the United States alone who are suffering from 
transporter polymorphism disclosed herein. In contrast, disorders associated with NET deficiencies. 
plasma NE levels after administration of a unit dose of 60 
tyramine in a normal patient ranges from about 40 to about 
70 pgiml, and usually ranges from about 50 to about 60 
pgimL. The following Examples have been included to illustrate 
Urinary NE levels range from about 100 to about 500 preferred modes of the invention. Certain aspects of the 
pgi24 hrs and usually from about 200 to about 400 in the 65 following Examples are described in terms of techniques or 
patients observed to have the NET polymorphism. In con- procedures found or contemplated by the present inventors 
trast, in normal patients, urinary NE levels range from about to work well in the practice of the invention. These 
powder, Preferably, when the reagent is provided in a liquid is exposed to extraneuronal tissue which contains a different 
The Present invention 
EXAMPLES 
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rine spillover and clearance, and tyramine-mediated plasma 
catecholamine responses were compared to responses 
among subjects in a group of 10 normal volunteers (8 
females, 2 males, 3322 years). 
In seven additional siblings and the proband's mother, 
blood pressure and heart rate were determined after twenty 
minutes supine and five minutes standing. Blood was 
obtained for determination of plasma catecholamines after 
twenty minutes supine and then after thirty minutes upright. 
i o  In addition, blood was obtained from the proband, all nine 
of her siblings and her mother for DNA analysis. Plasma 
5 
Examples are exemplified through the use of standard labo- 
ratory practices of the inventors. In light of the present 
disclosure and the general level of skill in the art, those of 
skill will appreciate that the following Examples are 
intended to be exemplary only in that numerous changes, 
modification, and alterations can be employed without 
departing from the spirit and scope of the invention. 
MATERIALS AND METHODS USED IN 
EXAMPLES 
catecholamine or orthostatic vitals signs from one sister of Clinical Characteristics 
The proband was a 33-year old female with a 2o year the proband were not obtained. Her father is deceased. All 
history of exertional and orthostatic provocation of tachy- subjects gave informed 'Onsent prior to study. 
cardia, dyspnea, concentration difficulty, and syncope, She l5 was for by a modifica- 
had volatile blood tion Of a high Pressure liquid chromatographic method during or following anaesthesia 
with each of her three Caesarean sections with blood pres- 
as high as 210/180 mm Hg, Standard treatment for 
described by et al., Czin Invest (1988). urine 
for were assayed using 
syncope (fj-blockers, compression stockings, fludrocorti- methods. See et al., Czin Invest (l  988), shouP et 
sone) had been unsatisfactory, Implantation o f a  dual cham- 2o al., Czin Chem (1977). Tyramine responsiveness was deter- 
ber pacemaker seemed to decrease the frequency of syncope, pressure and heart rate after 
but symptoms of orthostatic intolerance persisted. An 
echocardiogram revealed mild mitral regurgitation and pos- 
sible mitral valve prolapse. The probands identical twin also The proband and normal controls were studied after 
had a history of mitral valve prolapse and syncope as well 25 Overnight rest. Catheters were placed in a brachial artery, the 
as multiple symptoms worsened by stress and upright pos- ipsilateral femoral vein, and bilateral antecubital veins. 
ture. Blood pressure was monitored intraarterially and heart rate 
was monitored by continuous ECG. After instrumentation Experimental Design 
Clinical Research Center at Vanderbilt University Medical was infused intraveneously at 0.9 pCi/mL/min (see Riley et 
al., Clin Sci (1991)) after a loading dose of 25 pCi over 2 Center, Nashville, Tenn. They were placed on a caffeine- min. See Esler et al., Physiol Rev (1990). After allowing 30 free, low monoamine diet containing 150 mEq Na+ and 70 
mEq K+ per day for days, All medications had been to 40 minutes to reach steady state, blood for baseline norepinephrine concentration was obtained from the artery. discontinued at least two weeks prior to admission. After 35 Norepinephrine spillover and clearance were determined fasting supine overnight, blood pressure, heart rate, and 
plasma catecholamines were measured supine and after before and during baroreflex-mediated sympathetic activa- tion with infusion of nitroprusside sufficient to decrease standing. At least two hours after breakfast standard auto- 
nomic function testing was performed as described by systolic blood pressure by 20 mmHg. 3H-NE concentration in plasma samples was determined as described by Shannon Mosqueda-Gracia, Disorders of the Autonomic Nervous 40 et al., Circulation (1999). System (1 995). Urine was collected over a 24 hour period for 
catecholamines and catecholamine metabolites. Detection of Mutations 
In the proband, and a group of normal volunteers, sys- Genomic DNA was isolated from venous blood using the 
temic norepinephrine spillover and clearance and plasma PureGene DNA Extraction Kit (Gentra Systems, Minneapo- 
norepinephrine concentrations were determined before and 45 lis, Minn.). The exons of the human NET gene (SLC6A2, 
at the maximal blood pressure increase after an intravenous McKusick # 163970) were amplified using the polymerase 
injection of 3 mg tyramine. Supine and upright blood chain reaction (PCR) with sense and antisense primers set 
pressure and heart rate, plasma catecholamines, norepineph- forth in Table 2 as follows: 
mined by assaying 
administration Of mg intravenous tyramine. 
Systemic Norepinephrine Spillover and Clearance 
The proband and her twin were admitted to the General 3o and 30 minutes recovery, tritiated norepinephrine (3H-NE) 
TABLE 2 
Primer Sets for Amplification of the Exons 
of the Human NET Gene 
Exon 1: 
RB639 (5'-aggaccggtaaagttcctctcg-3') (SEQ ID NO:16) 
RB640 (5'-tccgtgtgtattccagctcctg-3') (SEQ ID NO:17) 
Exon 2: 
RB641 (5'-gattgctgcgcgtcgcctttg-3') (SEQ ID NO:18 
RB642 (5'-ccttagatctcaccactggag-3') (SEQ ID NO:19 
Exon 3: 
RB643 (5'-catgcgacaggtcactggtg-3') (SEQ ID NO:20 
RB644 (5'-tagtgtttggctcaggtcatac-3') (SEQ ID NO:21 
Exon 4: 
RB645 (5'-agagtggccaggtcctgtct-3') (SEQ ID NO:22 
RB646 (5'-cttgcacttccagctccatctt-3') (SEQ ID NO:23 
41 
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Primer Sets for Amplification of the Exons 
of the Human NET Gene 
Exon 5: 
RB647 (5'-tggcttcagggccttgcctagag-3') 
RB648 (5'-acaagcctggcccaaggcttggt-3' 
Exon 6 :  
RB649 (5'-ctgcccatctctggttcagaccat- 
RB650 (5'-ggagagttggcttccagaccaga-3 
Exon 7: 
RB651 (5'-gtatccatgtggcagcaggagc-3' 
RB652 (5'-cacggaagagccatgcagccaa-3' 
Exon 8 :  
RB653 (5'-ctatcatgtgcagctcagaccaatgg-3') 
RB654 (5'-gtctgcaatttaaatagggccttctgg-3') 
Exon 9: 
RB655 (5'-caaggcagcctacatgagtcctgg-3') 
RB667 (5'-taacagggctgaatggaatcctcag-3') 
Exons 9 and 10: 
RB655 (5'-caaggcagcctacatgagtcctgg-3') 
RB656 (5'-ggtgcaggattctaggaggactgg-3') 
Exons 11 and 12: 
RB657 (5'-catcttgcctcactgccctgctct-3') 
RB658 (5'-catcttgcctcactgccctgctct-3') 
Exons 13 and 14: 
RB659 (5'-gctgcaggatcaaatagcaggtgg-3') 
RB660 (5'-tgctcctctcctctgagctaacag-3') 
Exon 15: 
RB746 (5'-ggaggtgcttggagatcatttgg-3') 
RB747 (5'-gcttcagtctcacattagcgagg-3') 
(SEQ ID NO:24 
(SEQ ID NO:25 
(SEQ ID NO:26 
(SEQ ID NO:27 
(SEQ ID NO:28 
(SEQ ID NO:29 
(SEQ ID NO:30 
(SEQ ID NO:31 
(SEQ ID NO:32 
(SEQ ID NO:33 
(SEQ ID NO:32 
(SEQ ID NO:34 
(SEQ ID NO:35 
(SEQ ID NO:36 
(SEQ ID NO:37 
(SEQ ID NO:38 
(SEQ ID NO:39 
(SEQ ID NO:40 
Amplified products (60 ng) were directly sequenced using tgtgt-3') and RB584 (SEQ ID N0:X) (5'-gtggttgtggtcagcat- 
PCR primers with AmpliTaqB-FS fluorescent dideoxy chain catc-3'). DNA from multiple isolates of mutant clones were 
terminators (Perkin Elmer, Wellesley, Mass.) using 25 cycles purified (Qiagen Inc., Santa Clarita, Calif.) to test for the 
of 96" C. for 30 sec, 50" C. for 15 sec, and 60" C. for 4 min. 40 impact of the A457P mutation on transporter activity. 
After ethanol precipitation, the reactions were analyzed on hNET, hNET A457P, and pcDNA3 plasmids were tran- 
an AB1 310TM automated DNA sequencer (Vanderbilt Uni- siently tranfected in parallel into Chinese Hamster Ovary 
versity Center for Molecular Neuroscience DNA Sequenc- (CHO; American Type Culture Collection, Manasas, Va., 
ing Core, Nashville, Tern.). Sequences were compared to accession no. CCL-61) cells using lipofectamine (Gibco- 
the hNET genomic sequences reported in GenBank (Acces- 45 BRL, Grand Island, N.Y.) according to manufacturer's pro- 
sionnumbers x91117 to ~91127)  and the sequences reported tocols. CHO cells were cultured at 37" C. in 5% CO, in 
by Porzgen and colleagues (Porzgen et al., Biochimica et Dulbelco's Minimum Essential Medium with 10% fetal 
Biophysica Acta (1998)), as well as in comparison with bovine serum (Hyclone, Logan, Utah), 2 mM glutamine 
DNA from asymptomatic volunteers. (Gibco-BRL, Grand Island, N.Y.), 100 I. U./ml penicillin 
50 (Gibco-BRL, Grand Island, N.Y.), and 100 pg/ml strepto- 
mycin (Gibco-BRL, Grand Island, N.Y.). Twelve well plates Functional Analysis of Identified Coding Mutation 
DNA encoding the hNET A457P mutant was created (FalconTM 3043 plates, Becton Dickinson, N.J.) were seeded 
using QuikChangeTM Site-Directed Mutagenesis Kit (Strat- with 2 .0~2.5~105 cells per well, ~~~~~~i~~~~~~ 48 hours 
agene, La Jolla, later, the cells were transfected with the appropriate DNA 
Using the oligonucleotides RB675 (5'CC~CagtaC~tCCttCtC- 55 constructs (A457p mutant, wild type hNET, or pcDNA3) in 
cccctgttctgcataaccaag-3') (SEQ ID NO151 and RB676 (5'ct- a 1 12 DNA:lipofectamine ratio, Cells were supplemented 
tggttatgcagaacagggggagaaggaaagtactgaagg-3') (SEQ ID with fresh medium at 8 hours and then refed with fresh 
No:6). The bases indicate modified bases to medium after a subsequent 14 hours. The cells were assayed 
according to manufacturer's protocol 
introduce the g237c mutation or to introduce a Sca I restric- for 3H-NE transport activity (20 nM) 72 hours after initial 
tion site that could be used to identify mutated plasmids. 60 transfection as described by A ~ ~ ~ ~ ~ ~ & ~ ~ ~  et al,, ~ p h ~ ~ ~  
Amplified DNA was cloned into a pcDNA3 (Invitrogen, Exp (1998), 
Carlsbad, Calif.) construct containing wild type hNET 
cDNA that had been previously mutated to introduce a silent 
mutation (L438L), creating a unique Afi I1 site to facilitate Allele specific oligonucleotide hybridization (ASO) was 
subcloning of the mutated sequences back into the wild type 65 used to genotype individuals for the A457P mutation with 
construct. The subcloned region was sequenced using hNET RB704 (5'-ccttctcgccctgtt-3') (SEQ ID NO:9) hybridizing to 
oligonuceotides RB252 (SEQ ID NO:7) (5'-cattctgggctgt- the wild type allele and RB705 (5'-ccttctccccctgtt-3') (SEQ 
Genotyping of A457P Alleles 
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ID NO: 10) hybridizing to the mutant allele. The underlined 
bases identify the single nucleotide polymorphism. All 
genomic DNA was coded prior to analysis to preserve 
anonymity of the sample. Genotypes were assigned without 
knowledge of the sample's identity and then used to asso- 5 
ciate genotype with a phenotype. The combination of the low plasma DHPGinorepineph- 
rine ratio, decrease of plasma norepinephrine clearance, and Statistical Analysis blunted response to tyramine suggested a potential defect in Results are expressed as mean2SEM. Paired and unpaired NET in the proband. The presence of a similar syndrome in two tail t-tests were used for comparisons between groups 
and within one group before and after the various stimuli. Direct sequence analysis of the human norepinephrine 
Data were using PRISwM software' transporter (hNET) gene (SLC6A2) in the proband revealed (GraphPAD Software Inc., San Diego, Calif.) A p  value less no divergence from previously published sequences in exons than 0.05 was considered significant. 1 through 8 and 10 through 15. In addition, all exonic 
Example 1 15 boundaries preserved canonical gtiag donoriacceptor 
sequences. However, two novel polymorphisms were iden- 
tified within exon 9, one silent (c154a) and one missense 
(g237c) mutation. The proband is heterozygous for both the 
c154a and g237c polymorphisms 2A). The g237c 
intact, The proband and twin had volatility ofblood pressure 20 mutation results in a coding alteration of alanine to proline 
heart rate, and plasma catecholamines of the proband and domain 2B and 2c). 
her twin as compared to control subjects (Shannon et al., expression Of hNET in parallel with 
levels of dihy&oxypheny~g~yco~ (DHPG, intraneuronal 25 compromised by the A457P mutation. Chinese hamster 
Example 4 
Identification of a Functional Missense Mutation in 
hNet 
i o  her identical twin suggested a genetic origin. 
Autonomic Responses 
Autonomic reflexes in both the proband and her twin were 
and heart rate (FIG, 1). Supine and upright blood pressure, (A457p) within a conservedregion Oftransmembrane 
Circulation (1999)) are depicted in Table 3, The plasma hNETA457P that 3H-NE uptake is 
monoamine oxidase (MAO) metabolite of norepinephrine) 
(Goldstein et al,, JClin Invest (1988)) in the proband and her 
Ovary (CHo) transfected with hNET 
a >lo in norepinephrine transport 
twin were low relative to the plasma level of norepinephrine, activity over vector transfected cells. CHO cells transiently 
was approximate~y 5: while in the proband and her twin, 30 uptake activity of the wild type NET transfected cells (FIG. 
normal controls averaged 3: while in the proband and twin, devoid of transport activity in a different cell host (LLC PK1 
they were 1 : 1. Urinary norepinephrine was elevated outside 
the normal range in both the proband and her twin (Table 3). 
Example 2 
Systemic Norepinephrine Spillover and Clearance 
In normal controls, the supine DHpGinorepinephrine ratio transfected with A457P NET cDNA possessed s 2 %  Of the 
the ratio was approximately 2: 1, With standing, the ratios in 2D). 'lone' were tested and were found to be 
35 Example 5 
Segregation of A457P Mutation with Phenotype 
The proband's mother and 4 of her 8 siblings were 
Arterial norepinephrine concentration at rest was slightly 40 genotyPed by AS0 and were found to be heterozygous for 
elevated in the proband compared to controls (280 pgiml vs the mutant allele (Ap), including her twin (FIG. 2E and FIG. 
2042 18 pgiml). This greater concentration was primarily 2F). Independently, heart rates and Plasma catecholamines 
due to decreased NE clearance since, despite a lower NE were obtained from the family. supine heart rates displayed 
spillover rate in the proband (436 ngimin in the proband vs a trend toward elevation associated with the AP genotype 
514298 ngimin in controls, clearance in the proband was 45 (P=nS). However, upon standing, the heart rate was signifi- 
less than half of normal controls (1.56 vs 2.4220.25 Limin). CantlY greater in family members cawing theA457P muta- 
With nitroprusside infusion, NE spillover increased to 1072 tion (Ap) than in family members homozYgous fortheA457 
ngimin in the proband but only 745275 ngimin in control genotype (FIG. 3A and FIG. 3B). Similarly, supine 
subjects. Norepinephrine clearance did not change appre- Plasma norepinephrine tended to be greater in AP that AA 
ciably after nitroprusside in either the proband (1.76 Limin) 50 family members, whereas upright norepinephrine was S k -  
or the control group (2.3120.24 Limin). nificantly greater in AP individuals (FIG. 3C and FIG. 3D). 
Finally, the plasma DHPGinorepinephrine ratio was signifi- 
cantly greater in AA individuals that in AP individuals with 
both supine and upright postures (FIG. 3E and FIG. 3F). 
Example 3 
Response to Tyramine 55 
Example 6 
Mechanism Underlying the Loss of Transport of 
A457P 
Tyramine is an indirectly-acting amine that exerts its 
effect by releasing cytosolic norepinephrine. To cause nore- 
pinephrine release, tyramine must first be taken up into the 
neuron by NET, as described by Blakely et al., J E x p  Biol 60 
(1994), and Demanet, Cardiology (1 976). Intravenous injec- As disclosed herein above, the norepinephrine transporter 
tion of tyramine 3 mg increased systolic blood pressure (NET) is responsible for clearance of norepinephrine (NE) 
1922 mmHg and plasma norepinephrine by 56221 pgiml in from the synapse and is a target for antidepressant drugs and 
normal controls. In the proband, the same dose increased psychostimulants. A human NET (hNET; SLC6A2) coding 
systolic blood pressure similarly (118 mmHg), but the 65 mutation, A457P, linked to orthostatic Intolerance which 
elevation in plasma norepinephrine was significantly results in near complete loss of [3H]NE transport ( ~ 2 %  of 
blunted (12 pgiml). wild type (wt)) is also disclosed herein above. This Example 
US 7,094,532 B2 
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pertains to the identification of a mechanism underlying the (g237c) mutation resulting in a coding alteration of alanine 
loss of transport of A457P. Biotinylation of cell surface to proline (A457P) in a highly conserved transmembrane 
proteins and Western analysis reveal that the 8 6 1 0 0  kD region was found. Proline disrupts a-helical secondary 
form of hNET, the major species in the plasma membrane, structures permitted by alanine residues. Therefore, substi- 
is decreased in total cell extracts and in plasma membrane 5 tution of a proline for alanine in this region is envisioned to 
from COS-7 cells transfected with A457P compared to wt. disrupt permeation of norepinephrine or its coupled ions 
Competition of [1251]RTI-55 binding to membrane prepara- Na+ or C1+. Chimera studies have shown that this trans- 
tions demonstrates alterations in both antagonist and sub- membrane domain (TMD) 9 falls within a region likely to 
strate binding to A457P. Cotransfection of A457P with wt influence substrate affinity and stereoselectivity of cat- 
hNET reveals a dominant negative interaction of decreased 10 echolamine transporters (Giros et al., J Biol Chem (1994)). 
[3H]NE uptake to 5922.4% of wt alone. Subsequent functional analysis of the proband’s NET dem- 
onstrated 52% activity compared to normal NET. 
The A457P mutation is the first genetic defect identified 
in the syndrome of 01. The pathophysiology of 0 1  has 
15 elicited considerable interest in recent years, and a number 
of potential mechanisms have been suggested. Most invoke 
Using techniques described in Example 6 above, appli- a primary or secondary activation of sympathetic outflow to 
cants have also characterized additional hNET single nucle- account for the tachycardia and raised norepinephrine with 
otide polymorphisms (SNPs) that have been identified, e.g. physiological stress. Postulated mechanisms include partial 
Stober et al. (1 996) American Journal of Medical Genetics 20 dysautonomia, central hyperadrenergia, abnormal 0-adreno- 
67523-532 and Halushka et al. (1999) Nature Genetics receptor function and hypovolemia. (Novak et al., JAu t  N 
22:239-247. Characterization of these SNPs has led to the Syst (1996), Rosen et al., Am JMed (1982), Fouad et al., Ann 
observation of both loss of function as well as significant Znt Med (1986), Schodorfet al., Circulation (1998), Davies 
increases in transport in different mutants. By screening et al., Am J Med (1987), Davies et al., J Clin Endocrinol 
susceptible populations for hNET mutations and character- 25 Metab (1 991)). 
izing mutant proteins, structural components underlying NET deficiency can at least partially explain a number of 
transport function are identified and the role and prevalence clinical features in patients with 01. Elevated supine heart 
of hNET mutations in disease are illuminated. rate, elevated plasma norepinephrine associated with rela- 
tively decreased plasma DHPG, the reduced norepinephrine 
30 response to tyramine, reduced systemic norepinephrine 
clearance, and the disparity of the change in heart rate and 
The NET deficiency in this family represents the first plasma norepinephrine as compared to sympathetic nerve 
demonstration of a functional mutation in a monoamine activity with upright posture are all contemplated to be 
transporter in humans. Previously, coding polymorphisms attributed to impaired NET activity andor NET deficiency. 
have been found in hNET, but these had no effect on 35 The noradrenergic synaptic clefts in the heart rate are 
norepinephrine transport activity. See e.g. Stober et al., approximately three times narrower than the synapic clefts 
Genetics (1996). In contrast, theA457Pmutationrenders the in the vasculature. See Nevi, Anatomical Record (1968). 
transporter nonfunctional and segregates with an alteration Therefore, removal of synaptic norepinephrine in the heart 
in heart rate regulation and norepinephrine metabolism. is far more dependent on NET that it is in vascular beds. See 
Bedside physiological, pharmacological, and biochemical 40 Goldstein et al., Circulation (1 988). Thus, one would expect 
tests in the proband indicated a defect in norepinephrine a disproportionate effect on heart rate and myocardial con- 
reuptake. Supine resting heart rate was within normal range tractility as compared with blood pressure if NET were 
but about 10 bpm greater than age matched controls, as dysfunctional. That is precisely what is observed in patients 
described by Shannon et al., Hypertension (1998), and rose with 01. 
substantially with upright posture. This heart rate change 45 The above features primarily represent manifestations of 
was paralleled by an increase in plasma norepinephrine peripheral NET impairment. Central nervous system NET 
which rose almost four-fold with upright posture. impairment is considerably more complicated. Noradrener- 
The proband’s blunted plasma norepinephrine increase gic and adrenergic neurons located at several sites in the 
with tyramine, and her reduced systemic norepinephrine central nervous system (e.g. the nucleus tractus solitarii 
clearance compared to normal subjects were consistent with 50 (NTS) and the ventrolateral nuclei in the medulla) are 
impaired norepinephrine reuptake as the primary deficit. The involved in cardiovascular regulation. Increasing concentra- 
relationship of plasma DHPG and norepinephrine provided tions of norepinephrine, epinephrine, and their cogeners in 
further evidence of impaired norepinephrine reuptake. Some the NTS greatly reduce blood pressure and heart rate in the 
NE taken up into the neuron by NET reaches the vesicles rat by binding to a,-adrenoreceptors as disclosed by Gold- 
where it is stored for re-release, but much is converted to 55 berg et al., Clinical & Experimental Hypertension-Part A 
DHPG by MAO, as described in Esler et al., Physiol Rev Theoly & Practice (1982), and Tung et al., J Pharm Exp 
(1990). DGPG can then enter the circulation and serve as a They (1983). 
marker of uptake and MA0 activity (FIG. 4) (see Goldstein Agents which stimulate central a,-adrenoreceptors (e.g., 
et al., J Clin Invest (1988)). The relatively low DHPG cloridine and a-methyldopa) and thus mimic increased 
compared to norepinephrine in the plasma of the proband 60 central norepinephrine concentrations in sensitive areas are 
and her twin are consistent with impaired NET activity. widely used to reduce central sympathetic outflow. The 
These several observations and their consistency between prominent side effects of such agents include fatigue, a 
the proband and her twin were highly suggestive of a genetic common complaint of patients with 01. Acute pharmaco- 
abnormality in the NET gene, which was previously mapped logical blockade of NET causes a decrease in sympathetic 
to chromosome 16q by Bruss, M., et al., Human Genetics 65 outflow, as described by Esler et al., American Journal of 
91 :278-280 (1 993). To confirm such a defect, the structure Physiology (1 991), presumably by increasing norepineph- 
of the proband’s NET gene was examined. One missense rine concentration in central synapses. Similarly, with NET 
Example 7 
Additional hNET Single Nucleotide Polymorphisms 
Discussion of Examples 
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deficiency, one would expect a decrease in the indices of 
sympathetic tone. Yet, in the proband and in many patients 
with 01, central sympathetic tone seems to be increased. 
Thus, chronic NET impairment, or perhaps compensatory 
(e.g., baroreflex) responses to it, is contemplated to further 
complicate phenotype. Peripheral and central impairment of 
NET could disrupt the fine control of autonomic balance. A 
limited capacity to clear synaptic norepinephrine might 
prolong the duration and increase the intensity of adrenore- 
ceptor stimulation resulting from sympathetic nerve electri- 
cal activation. The supranormal and prolonged synaptic 
norepinephrine concentrations interacting with baroreflex- 
mediated withdrawal of sympathetic nerve traffic could 
coarsen blood pressure and heart rate patterns. This coars- 
ening of sympathetic modulation could result in a sponta- 
neous cycle of variability in heart rate and, to a lesser extent, 
vascular tone. Volatility of heart rate in patients with 0 1  has 
not been reported, see Coghlan et al., Am JMed (1979), and 
was evident in the proband (FIG. 1). 
While family members having the A457P mutation had 
physiological and biochemical similarity to the affected 
twins and other patients with 01, not all of them manifested 
the full-blown syndrome. This is contemplated to be attrib- 
utable to the hemizygous nature of the A457P mutation and 
preliminary understanding of complex regulatory control 
over NET mRNA and protein expression. See Appar- 
sundaram et al., JPharm Exp Ther (1998) and Cubells et al., 
J Neurochem (1995). 
The disclosure of the present invention, as indicated in the 
Examples, facilities the discovery of other NET mutations, 
non-genetic NET defects, and other noradrenergic defects 
affecting NET function in patients with 01. Among these are 
autoantibodies to NET or membrane structures essential to 
NET function. The importance of such a role for autoanti- 
bodies is underscored by the preponderance of 0 1  in females 
in whom autoimmune illnesses are more common, but by the 
fact that approximately 50% of patients report an antecedent 
viral illness which could trigger an autoimmune response. 
See Low et al., Neurology (1995). Regardless, the identifi- 
cation of defective norepinephrine transport in patients with 
0 1  shifts attention toward a heretofore unexplored mecha- 
nism of a very common clinical problem. 
TABLE 3 
Orthostatic Blood Pressure, Heart Rate, and Plasma 
Catecholamines Systolic blood pressure (sbp), 
diastolic blood pressure (dbp) and heart rate (hr) 
were determined on multiple occasions in the proband 
and twin and on one occasion in each of eight normal 
volunteers. Norepinephrine (NE), epinephrine (Epi) 
and dihydroxyphenylglycol (DPHG) were determined 
once each in the proband and twin and once in each 
of the eight normal volunteers. Data are presented 
as mean r SEM. 
proband twin normals 
Suuine and Uuright Blood Pressure and Heart Rate 
supine sbp (mmHg) 107 r 2 122 r 6 
dPb (mmHg) 61 r 1 65 r 4  
hr ( b P 4  7 5 r 2  7 2 r 3  
upright sbp (mmHg) 109 r 3 127 r 5 
dPb (mmHg) 6 8 r 2  7 7 r 3  
hr ( b P 4  105 r 3 108 r 6 
Supine and Upright Plasma Catecholamines 
supine NE (pg/ml) 269 199 
DHPG (pg/ml) 824 480 
DHPGFJE 3.06 2.41 
Epi (Pdml) 11 22 
108 r 2  
63 r 2 
65 r 2 
106 r 3  
67 r 3 
83 r 4  
200 r 20 
25 r 3 
1104 r 115 
5.52 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55  
60 
65 
48 
TABLE 3-continued 
Orthostatic Blood Pressure, Heart Rate, and Plasma 
Catecholamines Systolic blood pressure (sbp), 
diastolic blood pressure (dbp) and heart rate (hr) 
were determined on multiple occasions in the proband 
and twin and on one occasion in each of eight normal 
volunteers. Norepinephrine (NE), epinephrine (Epi) 
and dihydroxyphenylglycol (DPHG) were determined 
once each in the proband and twin and once in each 
of the eight normal volunteers. Data are presented 
as mean r SEM. 
proband twin normals 
upright NE (pg/ml) 923 911 485 r 5 0  
Epi (P&l) 23 116 49 r 4 
DHPG (pg/ml) 968 1068 1379 r 133 
DHPGFJE 1.05 1.17 2.84 
TABLE 4 
Urinary Catecholmines and Catecholamine Metabolites 
Norepinephrine (NE), Epinephrine (Epi), noremetanephrine 
(NMN). and metanephrine (MN) in the proband and twin. 
proband twin normal values 
NE ( I d 2 4  hrs) 435 125 0-90 
Epi ( I d 2 4  hrs) 22 53 0-25 
NMN (&24 hrs) 166 236 50-500 
MN (&24 hrs) 122 179 5 0 4 0 0  
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SEQUENCE L I S T I N G  
<160> 
<210> 
<211> 
<212> 
<213> 
<220> 
<221> 
<222> 
<300> 
NUMBER OF SEQ I D  NOS: 40 
SEQ I D  NO 1 
LENGTH: 1854 
TYPE: DNA 
ORGANISM: Homo sapiens 
FEATURE : 
NAME/KEY: CDS 
LOCATION: (1)..(1851) 
PUBLICATION INFORMATION: 
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- con t inued  
< 3 0 1 >  AUTHORS: Porzgen, P. 
Bonisch, H.  
Bruss ,  M .  
of t h e  Human Norepinephr ine  T r a n p o r t e r  Gene 
< 3 0 2 >  TITLE: Molecular  Cloning  and Organ iza t ion  of t h e  Coding Region 
< 3 0 3 >  JOURNAL: Biochem. Biophys.  R e s .  Commun. 
< 3 0 4 >  VOLUME: 2 1 5  
< 3 0 5 >  ISSUE: ( 3 )  
< 3 0 6 >  PAGES: 1 1 4 5 - 1 1 5 0  
< 3 0 7 >  DATE: 1 9 9 5 - 1 0 - 2 4  
< 3 0 8 >  DATABASE ACCESSION NUMBER: x 9 1 1 1 7  
< 3 0 9 >  DATABASE ENTRY DATE: 1 9 9 6 - 0 2 - 2 0  
< 4 0 0 >  SEQUENCE: 1 
a t g  c t t  c t g  gcg cgg a t g  aac  ccg  cag  g t g  cag ccc  gag aac  aac  ggg 
M e t  Leu Leu Ala Arg M e t  Asn P ro  Gln Val Gln P ro  Glu Asn Asn Gly 
1 5 1 0  1 5  
gcg gac acg  g g t  cca  gag cag  ccc  c t t  cgg gcg cgc  aaa  a c t  gcg gag 
Ala Asp Thr Gly P ro  Glu Gln P ro  Leu Arg Ala Arg Lys Thr Ala Glu 
2 0  2 5  3 0  
c t g  c t g  g t g  g t g  aag  gag cgc  aac  ggc g t c  cag t g c  c t g  c t g  gcg ccc  
Leu Leu Val Val Lys Glu Arg Asn Gly Val Gln Cys Leu Leu Ala P ro  
3 5  40  4 5  
cgc  gac ggc gac gcg cag  ccc  cgg gag acc  t g g  ggc aag  aag  a t c  gac 
Arg Asp Gly Asp Ala Gln P ro  Arg Glu Thr Trp Gly Lys Lys I l e  Asp 
5 0  5 5  6 0  
t t c  c t g  c t g  t c c  g t a  g t c  ggc t t c  gca g t g  gac c t g  gcc aac  g t g  t g g  
Phe Leu Leu S e r  Val Val Gly Phe Ala Val Asp Leu Ala Asn Val Trp  
6 5  70  7 5  8 0  
cgc  t t c  ccc  t a c  c t c  t g c  t a c  aag  aac  ggc ggc g g t  gcc t t c  t t g  a t c  
Arg Phe P ro  Tyr Leu Cys Tyr Lys Asn Gly Gly Gly Ala Phe Leu I l e  
8 5  90  9 5  
ccg  t a c  aca  c t g  t t c  c t t  a t c  a t c  gcg ggg a t g  ccc  c t g  t t c  t a c  a t g  
P ro  Tyr Thr Leu Phe Leu I l e  I l e  Ala Gly M e t  P ro  Leu Phe Tyr M e t  
1 0 0  1 0 5  1 1 0  
gag c t g  g c t  c t g  gga cag  t a c  aac  cgg gag ggg g c t  gcc acc  g t t  t g g  
Glu Leu Ala Leu Gly Gln Tyr Asn Arg Glu Gly Ala Ala Thr Val Trp  
1 1 5  1 2 0  1 2 5  
aaa  a t c  t g c  cca  t t c  t t c  aaa  ggc g t t  ggc t a t  g c t  g t c  a t c  c t g  a t c  
Lys I l e  Cys P ro  Phe Phe Lys Gly Val Gly Tyr Ala Val I l e  Leu I l e  
1 3 0  1 3 5  1 4 0  
gcc c t g  t a c  g t t  ggc t t c  t a c  t a c  aac  g t c  a t c  a t c  gcc t g g  t c a  c t c  
Ala Leu Tyr Val Gly Phe Tyr Tyr Asn Val I l e  I l e  Ala Trp  S e r  Leu 
1 4 5  1 5 0  1 5 5  1 6 0  
t a c  t a c  c t c  t t c  t c c  t c c  t t c  acc  c t c  aac  c t g  ccc  t g g  acc  gac t g t  
Tyr Tyr Leu Phe S e r  S e r  Phe Thr Leu Asn Leu P ro  Trp  Thr Asp Cys 
1 6 5  1 7 0  1 7 5  
ggc cac  acc  t g g  aac  agc  ccc  aac  t g t  acc  gac ccc  aag  c t c  c t c  a a t  
Gly H i s  Thr Trp  Asn S e r  P ro  Asn Cys Thr Asp P ro  Lys Leu Leu Asn 
1 8 0  1 8 5  1 9 0  
ggc t c c  g t g  c t t  ggc aac  cac  acc  aag  t a c  t c c  aag  t a c  aag  t t c  acg  
Gly S e r  Val Leu Gly Asn H i s  Thr Lys Tyr Se r  Lys Tyr Lys Phe Thr 
1 9 5  2 0 0  2 0 5  
ccg  gca gcc gag ttt t a t  gag c g t  g g t  g t c  c t g  cac  c t t  cac  gag agc  
P ro  Ala Ala Glu Phe Tyr Glu Arg Gly Val Leu H i s  Leu H i s  Glu S e r  
2 1 0  2 1 5  2 2 0  
agc  ggg a t t  c a t  gac a t c  ggc c t g  ccc  cag  t g g  cag  c t c  t t g  c t c  t g t  
S e r  Gly I l e  H i s  Asp I l e  Gly Leu P ro  Gln Trp Gln Leu Leu Leu Cys 
2 2 5  2 3 0  2 3 5  2 4 0  
c t g  a t g  g t c  g t c  g t c  a t c  g t c  t t g  t a t  ttt agc c t c  t g g  aaa  ggg g t g  
Leu M e t  Val Val Val I l e  Val Leu Tyr Phe Se r  Leu Trp  Lys Gly Val 
2 4 5  2 5 0  2 5 5  
4 8  
9 6  
1 4 4  
1 9 2  
2 4 0  
2 8 8  
3 3 6  
3 8 4  
4 3 2  
4 8 0  
5 2 8  
5 7 6  
6 2 4  
6 7 2  
7 2 0  
7 6 8  
US 7,094,532 B2 
54 
- con t inued  
aag  aca  t c a  gga aag  g t g  g t g  t g g  a t c  aca  gcc acg  c t g  c c t  t a c  t t c  
Lys Thr S e r  Gly Lys Val Val Trp  I l e  Thr Ala Thr Leu P ro  Tyr Phe 
2 6 0  2 6 5  2 7 0  
g t g  c t g  t t c  g t g  c t c  c t g  g t c  c a t  ggc g t c  acg c t g  ccc  gga gcc t c c  
Val Leu Phe Val Leu Leu Val His Gly Val Thr Leu P ro  Gly Ala S e r  
2 7 5  2 8 0  2 8 5  
a a t  ggc a t c  a a t  gcc t a c  c t g  cac  a t c  gac t t c  t a c  cgc  t t g  aaa  gag 
Asn Gly I l e  Asn Ala Tyr Leu His I l e  Asp Phe Tyr Arg Leu Lys Glu 
2 9 0  2 9 5  3 0 0  
gcc acg  g t a  t g g  a t t  g a t  gcc gca a c t  cag  a t a  ttt ttt t c c  t t g  ggg 
Ala Thr Val Trp  I l e  Asp Ala Ala Thr Gln I le  Phe Phe S e r  Leu Gly 
3 0 5  3 1 0  3 1 5  3 2 0  
g c t  gga ttt gga g t a  t t g  a t t  gca ttt gcc a g t  t a c  aac  aaa  ttt gac 
Ala Gly Phe Gly Val Leu I l e  Ala Phe Ala Se r  Tyr Asn Lys Phe Asp 
3 2 5  3 3 0  3 3 5  
aac  aac  t g t  t a c  agg g a t  gcc c t g  c t g  acc  agc agc  a t c  aac  t g t  a t c  
Asn Asn Cys Tyr Arg Asp Ala Leu Leu Thr Se r  S e r  I l e  Asn Cys I l e  
3 4 0  3 4 5  3 5 0  
acc  agc  t t c  g t c  t c t  ggg t t c  gcc a t c  t t c  t c c  a t c  c t t  g g t  t a c  a t g  
Thr S e r  Phe Val S e r  Gly Phe Ala I l e  Phe Se r  I l e  Leu Gly Tyr M e t  
3 5 5  3 6 0  3 6 5  
gcc c a t  gaa cac  aag  g t c  aac  a t t  gag g a t  g t g  gcc aca  gaa gga g c t  
Ala His Glu His Lys Val Asn I l e  Glu Asp Val Ala Thr Glu Gly Ala 
3 7 0  3 7 5  3 8 0  
ggc c t a  g t g  t t c  a t c  c t g  t a t  cca  gag gcc a t t  t c t  acc  c t g  t c t  gga 
Gly Leu Val Phe I l e  Leu Tyr P ro  Glu Ala I le  S e r  Thr Leu S e r  Gly 
3 8 5  3 9 0  3 9 5  400  
t c t  aca  t t c  t g g  g c t  g t t  g t g  ttt t t c  g t c  a t g  c t c  c t g  gcg c t g  ggc 
S e r  Thr Phe Trp  Ala Val Val Phe Phe Val M e t  Leu Leu Ala Leu Gly 
4 0 5  410  4 1 5  
c t t  gac agc  t c a  a t g  gga ggc a t g  gag g c t  g t c  a t c  acg  ggc c t g  gca 
Leu Asp S e r  S e r  M e t  Gly Gly M e t  Glu Ala Val I l e  Thr Gly Leu Ala 
420  4 2 5  4 3 0  
g a t  gac t t c  cag  g t c  c t g  aag  cga  cac  cgg aaa  c t c  t t c  aca  ttt ggc 
Asp Asp Phe Gln Val Leu Lys Arg His Arg Lys Leu Phe Thr Phe Gly 
4 3 5  4 4 0  4 4 5  
g t c  acc  t t c  agc  a c t  t t c  c t t  c t c  gcc c t g  t t c  t g c  a t a  acc  aag  g g t  
Val Thr Phe S e r  Thr Phe Leu Leu Ala Leu Phe Cys I l e  Thr Lys Gly 
4 5 0  4 5 5  4 6 0  
gga a t t  t a c  g t c  t t g  acc  c t c  c t g  gac acc  ttt g c t  gcg ggc acc  t c c  
Gly I l e  Tyr Val Leu Thr Leu Leu Asp Thr Phe Ala Ala Gly Thr S e r  
4 6 5  4 7 0  4 7 5  480  
a t c  c t t  ttt g c t  g t c  c t c  a t g  gaa gcc a t c  gga g t t  t c c  t g g  ttt t a t  
I l e  Leu Phe Ala Val Leu M e t  Glu Ala I l e  Gly Val S e r  Trp  Phe Tyr 
4 8 5  490  4 9 5  
gga g t g  gac agg t t c  agc  aac  gac a t c  cag  cag a t g  a t g  ggg t t c  agg 
Gly Val Asp Arg Phe S e r  Asn Asp I l e  Gln Gln M e t  M e t  Gly Phe Arg 
5 0 0  5 0 5  5 1 0  
ccg  g g t  c t a  t a c  t g g  aga  c t g  t g c  t g g  aag  t t c  g t c  a g t  c c t  gcc t t c  
P ro  Gly Leu Tyr Trp  Arg Leu Cys Trp  Lys Phe Val S e r  P ro  Ala Phe 
5 1 5  5 2 0  5 2 5  
c t c  c t g  t t c  g t g  g t t  g t g  g t c  agc  a t c  a t c  aac  t t c  aag  cca  c t c  acc  
Leu Leu Phe Val Val Val Val S e r  I l e  I l e  Asn Phe Lys P ro  Leu Thr 
5 3 0  5 3 5  5 4 0  
t a c  gac gac t a c  a t c  t t c  ccg  ccc  t g g  gcc aac  t g g  g t g  ggg t g g  ggc 
Tyr Asp Asp Tyr I l e  Phe P ro  P ro  Trp  Ala Asn Trp  Val Gly Trp  Gly 
5 4 5  5 5 0  5 5 5  5 6 0  
a t c  gcc c t g  t c c  t c c  a t g  g t c  c t g  g t g  ccc  a t c  t a c  g t c  a t c  t a t  aag  
I l e  Ala Leu S e r  S e r  M e t  Val Leu Val P ro  I le  Tyr Val I l e  Tyr Lys 
5 6 5  5 7 0  5 7 5  
8 1 6  
8 6 4  
9 1 2  
9 6 0  
1 0 0 8  
1 0 5 6  
1 1 0 4  
1 1 5 2  
1 2 0 0  
1 2 4 8  
1 2 9 6  
1 3 4 4  
1 3 9 2  
1 4 4 0  
1 4 8 8  
1 5 3 6  
1 5 8 4  
1 6 3 2  
1 6 8 0  
1 7 2 8  
US 7,094,532 B2 
56 
- con t inued  
t t c  c t c  agc acg cag ggc t c t  c t t  t g g  gag aga c t g  gcc t a t  ggc a t c  1 7 7 6  
Phe L e u  S e r  T h r  G l n  G l y  S e r  L e u  T r p  G l u  A r g  L e u  A l a  T y r  G l y  I l e  
5 8 0  5 8 5  5 9 0  
acg cca gag aac gag cac cac c t g  g t g  g c t  cag agg gac a t c  aga cag 1 8 2 4  
T h r  P r o  G l u  A s n  G l u  H i s  H i s  L e u  V a l  A l a  G l n  A r g  A s p  I l e  A r g  G l n  
5 9 5  6 0 0  6 0 5  
t t c  cag t t g  caa cac t g g  c t g  gcc a t c  t g a  
Phe G l n  L e u  G l n  H i s  T r p  L e u  A l a  I l e  
6 1 0  6 1 5  
<210>  SEQ I D  NO 2 
<211>  LENGTH: 6 1 7  
<212>  TYPE: PRT 
<213>  ORGANISM: Homo sap iens  
<400>  SEQUENCE: 2 
M e t  L e u  L e u  A l a  A r g  M e t  A s n  P r o  G l n  V a l  G l n  P r o  G l u  A s n  A s n  G l y  
1 5 1 0  1 5  
A l a  A s p  T h r  G l y  P r o  G l u  G l n  P r o  L e u  A r g  A l a  A r g  L y s  T h r  A l a  G l u  
20  2 5  3 0  
L e u  L e u  V a l  V a l  L y s  G l u  A r g  A s n  G l y  V a l  G l n  C y s  L e u  L e u  A l a  P r o  
3 5  4 0  4 5  
A r g  A s p  G l y  A s p  A l a  G l n  P r o  A r g  G l u  T h r  T r p  G l y  L y s  L y s  I l e  A s p  
5 0  5 5  60  
Phe L e u  L e u  S e r  V a l  V a l  G l y  Phe A l a  V a l  A s p  L e u  A l a  A s n  V a l  T r p  
65  7 0  75  8 0  
A r g  Phe P r o  T y r  L e u  C y s  T y r  L y s  A s n  G l y  G l y  G l y  A l a  Phe L e u  I l e  
85  9 0  9 5  
P r o  T y r  T h r  L e u  Phe L e u  I l e  I l e  A l a  G l y  M e t  P r o  L e u  Phe T y r  M e t  
1 0 0  1 0 5  1 1 0  
G l u  L e u  A l a  L e u  G l y  G l n  T y r  A s n  A r g  G l u  G l y  A l a  A l a  T h r  V a l  T r p  
1 1 5  1 2 0  1 2 5  
L y s  I l e  C y s  P r o  Phe Phe L y s  G l y  V a l  G l y  T y r  A l a  V a l  I l e  L e u  I l e  
1 3 0  1 3 5  1 4 0  
A l a  L e u  T y r  V a l  G l y  Phe T y r  T y r  A s n  V a l  I l e  I l e  A l a  T r p  S e r  L e u  
1 4 5  1 5 0  1 5 5  1 6 0  
T y r  T y r  L e u  Phe S e r  S e r  Phe T h r  L e u  A s n  L e u  P r o  T r p  T h r  A s p  C y s  
1 6 5  1 7 0  1 7 5  
G l y  H i s  T h r  T r p  A s n  S e r  P r o  A s n  C y s  T h r  A s p  P r o  L y s  L e u  L e u  A s n  
1 8 0  1 8 5  1 9 0  
G l y  S e r  V a l  L e u  G l y  A s n  H i s  T h r  L y s  T y r  S e r  L y s  T y r  L y s  Phe T h r  
1 9 5  2 0 0  2 0 5  
P r o  A l a  A l a  G l u  Phe T y r  G l u  A r g  G l y  V a l  L e u  H i s  L e u  H i s  G l u  S e r  
2 1 0  2 1 5  2 2 0  
S e r  G l y  I l e  H i s  A s p  I l e  G l y  L e u  P r o  G l n  T r p  G l n  L e u  L e u  L e u  C y s  
2 2 5  2 3 0  2 3 5  2 4 0  
L e u  M e t  V a l  V a l  V a l  I l e  V a l  L e u  T y r  Phe S e r  L e u  T r p  L y s  G l y  V a l  
2 4 5  2 5 0  2 5 5  
L y s  T h r  S e r  G l y  L y s  V a l  V a l  T r p  I l e  T h r  A l a  T h r  L e u  P r o  T y r  Phe 
2 6 0  2 6 5  2 7 0  
V a l  L e u  Phe V a l  L e u  L e u  V a l  H i s  G l y  V a l  T h r  L e u  P r o  G l y  A l a  S e r  
2 7 5  2 8 0  2 8 5  
A s n  G l y  I l e  A s n  A l a  T y r  L e u  H i s  I l e  A s p  Phe T y r  A r g  L e u  L y s  G l u  
2 9 0  2 9 5  3 0 0  
A l a  T h r  V a l  T r p  I l e  A s p  A l a  A l a  T h r  G l n  I l e  Phe Phe S e r  L e u  G l y  
1 8 5 4  
US 7,094,532 B2 
57 58 
- con t inued  
3 0 5  3 1 0  3 1 5  3 2 0  
A l a  G l y  Phe G l y  V a l  L e u  I l e  A l a  Phe A l a  S e r  T y r  A s n  L y s  Phe A s p  
3 2 5  3 3 0  3 3 5  
A s n  A s n  C y s  T y r  A r g  A s p  A l a  L e u  L e u  T h r  S e r  S e r  I l e  A s n  C y s  I l e  
3 4 0  3 4 5  3 5 0  
T h r  S e r  Phe V a l  S e r  G l y  Phe A l a  I l e  Phe S e r  I l e  L e u  G l y  T y r  M e t  
3 5 5  3 6 0  3 6 5  
A l a  H i s  G l u  H i s  L y s  V a l  A s n  I l e  G l u  A s p  V a l  A l a  T h r  G l u  G l y  A l a  
3 7 0  3 7 5  3 8 0  
G l y  L e u  V a l  Phe I l e  L e u  T y r  P r o  G l u  A l a  I l e  S e r  T h r  L e u  S e r  G l y  
3 8 5  3 9 0  3 9 5  400  
S e r  T h r  Phe T r p  A l a  V a l  V a l  Phe Phe V a l  M e t  L e u  L e u  A l a  L e u  G l y  
4 0 5  410  4 1 5  
L e u  A s p  S e r  S e r  M e t  G l y  G l y  M e t  G l u  A l a  V a l  I l e  T h r  G l y  L e u  A l a  
420  4 2 5  4 3 0  
A s p  A s p  Phe G l n  V a l  L e u  L y s  A r g  H i s  A r g  L y s  L e u  Phe T h r  Phe G l y  
4 3 5  4 4 0  4 4 5  
V a l  T h r  Phe S e r  T h r  Phe L e u  L e u  A l a  L e u  Phe C y s  I l e  T h r  L y s  G l y  
4 5 0  4 5 5  4 6 0  
G l y  I l e  T y r  V a l  L e u  T h r  L e u  L e u  A s p  T h r  Phe A l a  A l a  G l y  T h r  S e r  
4 6 5  4 7 0  4 7 5  480  
I l e  L e u  Phe A l a  V a l  L e u  M e t  G l u  A l a  I l e  G l y  V a l  S e r  T r p  Phe T y r  
4 8 5  490  4 9 5  
G l y  V a l  A s p  A r g  Phe S e r  A s n  A s p  I l e  G l n  G l n  M e t  M e t  G l y  Phe A r g  
5 0 0  5 0 5  5 1 0  
P r o  G l y  L e u  T y r  T r p  A r g  L e u  C y s  T r p  L y s  Phe V a l  S e r  P r o  A l a  Phe 
5 1 5  5 2 0  5 2 5  
L e u  L e u  Phe V a l  V a l  V a l  V a l  S e r  I l e  I l e  A s n  Phe L y s  P r o  L e u  T h r  
5 3 0  5 3 5  5 4 0  
T y r  A s p  A s p  T y r  I l e  Phe P r o  P r o  T r p  A l a  A s n  T r p  V a l  G l y  T r p  G l y  
5 4 5  5 5 0  5 5 5  5 6 0  
I l e  A l a  L e u  S e r  S e r  M e t  V a l  L e u  V a l  P r o  I le  T y r  V a l  I l e  T y r  L y s  
5 6 5  5 7 0  5 7 5  
Phe L e u  S e r  T h r  G l n  G l y  S e r  L e u  T r p  G l u  A r g  L e u  A l a  T y r  G l y  I l e  
5 8 0  5 8 5  5 9 0  
T h r  P r o  G l u  A s n  G l u  H i s  H i s  L e u  V a l  A l a  G l n  A r g  A s p  I l e  A r g  G l n  
5 9 5  6 0 0  6 0 5  
Phe G l n  L e u  G l n  H i s  T r p  L e u  A l a  I l e  
6 1 0  6 1 5  
<210>  SEQ I D  NO 3 
<211>  LENGTH: 1 8 5 4  
<212>  TYPE: DNA 
<213>  ORGANISM: Homo sap iens  
<220> FEATURE: 
<221>  NAME/KEY: CDS 
<222> LOCATION: ( 1 ) . . ( 1 8 5 1 )  
<400>  SEQUENCE: 3 
a t g  c t t  c t g  gcg cgg a t g  aac ccg cag g t g  cag ccc gag aac aac ggg 
M e t  L e u  L e u  A l a  A r g  M e t  A s n  P r o  G l n  V a l  G l n  P r o  G l u  A s n  A s n  G l y  
1 5 1 0  1 5  
gcg gac acg g g t  cca gag cag ccc c t t  cgg gcg cgc aaa a c t  gcg gag 
A l a  A s p  T h r  G l y  P r o  G l u  G l n  P r o  L e u  A r g  A l a  A r g  L y s  T h r  A l a  G l u  
20  2 5  3 0  
c t g  c t g  g t g  g t g  aag gag cgc aac ggc g t c  cag t g c  c t g  c t g  gcg ccc 
4 8  
9 6  
1 4 4  
US 7,094,532 B2 
60 
- con t inued  
Leu Leu Val Val Lys Glu Arg Asn Gly Val Gln Cys Leu Leu Ala P ro  
3 5  4 0  4 5  
cgc  gac ggc gac gcg cag  ccc  cgg gag acc  t g g  ggc aag  aag  a t c  gac 
Arg Asp Gly Asp Ala Gln P ro  Arg Glu Thr Trp Gly Lys Lys I l e  Asp 
5 0  5 5  60  
t t c  c t g  c t g  t c c  g t a  g t c  ggc t t c  gca g t g  gac c t g  gcc aac  g t g  t g g  
Phe Leu Leu S e r  Val Val Gly Phe Ala Val Asp Leu Ala Asn Val Trp  
65  7 0  75  8 0  
cgc  t t c  ccc  t a c  c t c  t g c  t a c  aag  aac  ggc ggc g g t  gcc t t c  t t g  a t c  
Arg Phe P ro  Tyr Leu Cys Tyr Lys Asn Gly Gly Gly Ala Phe Leu I l e  
85  9 0  9 5  
ccg  t a c  aca  c t g  t t c  c t t  a t c  a t c  gcg ggg a t g  ccc  c t g  t t c  t a c  a t g  
P ro  Tyr Thr Leu Phe Leu I l e  I l e  Ala Gly M e t  P ro  Leu Phe Tyr M e t  
1 0 0  1 0 5  1 1 0  
gag c t g  g c t  c t g  gga cag  t a c  aac  cgg gag ggg g c t  gcc acc  g t t  t g g  
Glu Leu Ala Leu Gly Gln Tyr Asn Arg Glu Gly Ala Ala Thr Val Trp  
1 1 5  1 2 0  1 2 5  
aaa  a t c  t g c  cca  t t c  t t c  aaa  ggc g t t  ggc t a t  g c t  g t c  a t c  c t g  a t c  
Lys I l e  Cys P ro  Phe Phe Lys Gly Val Gly Tyr Ala Val I l e  Leu I l e  
1 3 0  1 3 5  1 4 0  
gcc c t g  t a c  g t t  ggc t t c  t a c  t a c  aac  g t c  a t c  a t c  gcc t g g  t c a  c t c  
Ala Leu Tyr Val Gly Phe Tyr Tyr Asn Val I l e  I l e  Ala Trp  S e r  Leu 
1 4 5  1 5 0  1 5 5  1 6 0  
t a c  t a c  c t c  t t c  t c c  t c c  t t c  acc  c t c  aac  c t g  ccc  t g g  acc  gac t g t  
Tyr Tyr Leu Phe S e r  S e r  Phe Thr Leu Asn Leu P ro  Trp  Thr Asp Cys 
1 6 5  1 7 0  1 7 5  
ggc cac  acc  t g g  aac  agc  ccc  aac  t g t  acc  gac ccc  aag  c t c  c t c  a a t  
Gly H i s  Thr Trp  Asn S e r  P ro  Asn Cys Thr Asp P ro  Lys Leu Leu Asn 
1 8 0  1 8 5  1 9 0  
ggc t c c  g t g  c t t  ggc aac  cac  acc  aag  t a c  t c c  aag  t a c  aag  t t c  acg  
Gly S e r  Val Leu Gly Asn H i s  Thr Lys Tyr Se r  Lys Tyr Lys Phe Thr 
1 9 5  2 0 0  2 0 5  
ccg  gca gcc gag ttt t a t  gag c g t  g g t  g t c  c t g  cac  c t t  cac  gag agc  
P ro  Ala Ala Glu Phe Tyr Glu Arg Gly Val Leu H i s  Leu H i s  Glu S e r  
2 1 0  2 1 5  2 2 0  
agc  ggg a t t  c a t  gac a t c  ggc c t g  ccc  cag  t g g  cag  c t c  t t g  c t c  t g t  
S e r  Gly I l e  H i s  Asp I l e  Gly Leu P ro  Gln Trp Gln Leu Leu Leu Cys 
2 2 5  2 3 0  2 3 5  2 4 0  
c t g  a t g  g t c  g t c  g t c  a t c  g t c  t t g  t a t  ttt agc c t c  t g g  aaa  ggg g t g  
Leu M e t  Val Val Val I l e  Val Leu Tyr Phe Se r  Leu Trp  Lys Gly Val 
2 4 5  2 5 0  2 5 5  
aag  aca  t c a  gga aag  g t g  g t g  t g g  a t c  aca  gcc acg  c t g  c c t  t a c  t t c  
Lys Thr S e r  Gly Lys Val Val Trp  I l e  Thr Ala Thr Leu P ro  Tyr Phe 
2 6 0  2 6 5  2 7 0  
g t g  c t g  t t c  g t g  c t c  c t g  g t c  c a t  ggc g t c  acg c t g  ccc  gga gcc t c c  
Val Leu Phe Val Leu Leu Val H i s  Gly Val Thr Leu P ro  Gly Ala S e r  
2 7 5  2 8 0  2 8 5  
a a t  ggc a t c  a a t  gcc t a c  c t g  cac  a t c  gac t t c  t a c  cgc  t t g  aaa  gag 
Asn Gly I l e  Asn Ala Tyr Leu H i s  I l e  Asp Phe Tyr Arg Leu Lys Glu 
2 9 0  2 9 5  3 0 0  
gcc acg  g t a  t g g  a t t  g a t  gcc gca a c t  cag  a t a  ttt ttt t c c  t t g  ggg 
Ala Thr Val Trp  I l e  Asp Ala Ala Thr Gln I le  Phe Phe S e r  Leu Gly 
3 0 5  3 1 0  3 1 5  3 2 0  
g c t  gga ttt gga g t a  t t g  a t t  gca ttt gcc a g t  t a c  aac  aaa  ttt gac 
Ala Gly Phe Gly Val Leu I l e  Ala Phe Ala Se r  Tyr Asn Lys Phe Asp 
3 2 5  3 3 0  3 3 5  
aac  aac  t g t  t a c  agg g a t  gcc c t g  c t g  acc  agc agc  a t c  aac  t g t  a t c  
Asn Asn Cys Tyr Arg Asp Ala Leu Leu Thr Se r  S e r  I l e  Asn Cys I l e  
3 4 0  3 4 5  3 5 0  
1 9 2  
2 4 0  
2 8 8  
3 3 6  
3 8 4  
4 3 2  
4 8 0  
5 2 8  
5 7 6  
6 2 4  
6 7 2  
7 2 0  
7 6 8  
8 1 6  
8 6 4  
9 1 2  
9 6 0  
1 0 0 8  
1 0 5 6  
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acc  agc  t t c  g t c  t c t  ggg t t c  gcc a t c  t t c  t c c  a t c  c t t  g g t  t a c  a t g  
Thr S e r  Phe Val S e r  Gly Phe Ala I l e  Phe Se r  I l e  Leu Gly Tyr M e t  
3 5 5  3 6 0  3 6 5  
gcc c a t  gaa cac  aag  g t c  aac  a t t  gag g a t  g t g  gcc aca  gaa gga g c t  
Ala H i s  Glu H i s  Lys Val Asn I l e  Glu Asp Val Ala Thr Glu Gly Ala 
3 7 0  3 7 5  3 8 0  
ggc c t a  g t g  t t c  a t c  c t g  t a t  cca  gag gcc a t t  t c t  acc  c t g  t c t  gga 
Gly Leu Val Phe I l e  Leu Tyr P ro  Glu Ala I le  S e r  Thr Leu S e r  Gly 
3 8 5  3 9 0  3 9 5  400  
t c t  aca  t t c  t g g  g c t  g t t  g t g  ttt t t c  g t c  a t g  c t c  c t g  gcg c t g  ggc 
S e r  Thr Phe Trp  Ala Val Val Phe Phe Val M e t  Leu Leu Ala Leu Gly 
4 0 5  410  4 1 5  
c t t  gac agc  t c a  a t g  gga ggc a t g  gag g c t  g t c  a t c  acg  ggc c t g  gca 
Leu Asp S e r  S e r  M e t  Gly Gly M e t  Glu Ala Val I l e  Thr Gly Leu Ala 
420  4 2 5  4 3 0  
g a t  gac t t c  cag  g t c  c t g  aag  cga  cac  cgg aaa  c t c  t t c  aca  ttt ggc 
Asp Asp Phe Gln Val Leu Lys Arg H i s  Arg Lys Leu Phe Thr Phe Gly 
4 3 5  4 4 0  4 4 5  
g t c  acc  t t c  agc  a c t  t t c  c t t  c t c  ccc  c t g  t t c  t g c  a t a  acc  aag  g g t  
Val Thr Phe S e r  Thr Phe Leu Leu P ro  Leu Phe Cys I l e  Thr Lys Gly 
4 5 0  4 5 5  4 6 0  
gga a t t  t a c  g t c  t t g  acc  c t c  c t g  gac acc  ttt g c t  gcg ggc acc  t c c  
Gly I l e  Tyr Val Leu Thr Leu Leu Asp Thr Phe Ala Ala Gly Thr S e r  
4 6 5  4 7 0  4 7 5  480  
a t c  c t t  ttt g c t  g t c  c t c  a t g  gaa gcc a t c  gga g t t  t c c  t g g  ttt t a t  
I l e  Leu Phe Ala Val Leu M e t  Glu Ala I l e  Gly Val S e r  Trp  Phe Tyr 
4 8 5  490  4 9 5  
gga g t g  gac agg t t c  agc  aac  gac a t c  cag  cag a t g  a t g  ggg t t c  agg 
Gly Val Asp Arg Phe S e r  Asn Asp I l e  Gln Gln M e t  M e t  Gly Phe Arg 
5 0 0  5 0 5  5 1 0  
ccg  g g t  c t a  t a c  t g g  aga  c t g  t g c  t g g  aag  t t c  g t c  a g t  c c t  gcc t t c  
P ro  Gly Leu Tyr Trp  Arg Leu Cys Trp  Lys Phe Val S e r  P ro  Ala Phe 
5 1 5  5 2 0  5 2 5  
c t c  c t g  t t c  g t g  g t t  g t g  g t c  agc  a t c  a t c  aac  t t c  aag  cca  c t c  acc  
Leu Leu Phe Val Val Val Val S e r  I l e  I l e  Asn Phe Lys P ro  Leu Thr 
5 3 0  5 3 5  5 4 0  
t a c  gac gac t a c  a t c  t t c  ccg  ccc  t g g  gcc aac  t g g  g t g  ggg t g g  ggc 
Tyr Asp Asp Tyr I l e  Phe P ro  P ro  Trp  Ala Asn Trp  Val Gly Trp  Gly 
5 4 5  5 5 0  5 5 5  5 6 0  
a t c  gcc c t g  t c c  t c c  a t g  g t c  c t g  g t g  ccc  a t c  t a c  g t c  a t c  t a t  aag  
I l e  Ala Leu S e r  S e r  M e t  Val Leu Val P ro  I le  Tyr Val I l e  Tyr Lys 
5 6 5  5 7 0  5 7 5  
t t c  c t c  agc  acg  cag  ggc t c t  c t t  t g g  gag aga c t g  gcc t a t  ggc a t c  
Phe Leu S e r  Thr Gln Gly S e r  Leu Trp  Glu Arg Leu Ala Tyr Gly I l e  
5 8 0  5 8 5  5 9 0  
acg  cca  gag aac  gag cac  cac  c t g  g t g  g c t  cag agg gac a t c  aga  cag  
Thr P ro  Glu Asn Glu H i s  H i s  Leu Val Ala Gln Arg Asp I l e  Arg Gln 
5 9 5  6 0 0  6 0 5  
t t c  cag  t t g  caa  cac  t g g  c t g  gcc a t c  t g a  
Phe Gln Leu Gln H i s  Trp  Leu Ala I l e  
6 1 0  6 1 5  
<210>  SEQ I D  NO 4 
<211>  LENGTH: 6 1 7  
<212>  TYPE: PRT 
<213>  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 4 
M e t  Leu Leu Ala Arg M e t  Asn P ro  Gln Val Gln P ro  Glu Asn Asn Gly 
1 5 1 0  1 5  
1 1 0 4  
1 1 5 2  
1 2 0 0  
1 2 4 8  
1 2 9 6  
1 3 4 4  
1 3 9 2  
1 4 4 0  
1 4 8 8  
1 5 3 6  
1 5 8 4  
1 6 3 2  
1 6 8 0  
1 7 2 8  
1 7 7 6  
1 8 2 4  
1 8 5 4  
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A l a  A s p  T h r  G l y  P r o  G l u  G l n  P r o  L e u  A r g  A l a  A r g  L y s  T h r  A l a  G l u  
2 0  2 5  3 0  
L e u  L e u  V a l  V a l  L y s  G l u  A r g  A s n  G l y  V a l  G l n  C y s  L e u  L e u  A l a  P r o  
3 5  4 0  4 5  
A r g  A s p  G l y  A s p  A l a  G l n  P r o  A r g  G l u  T h r  T r p  G l y  L y s  L y s  I l e  A s p  
5 0  5 5  60  
Phe L e u  L e u  S e r  V a l  V a l  G l y  Phe A l a  V a l  A s p  L e u  A l a  A s n  V a l  T r p  
65  7 0  75  8 0  
A r g  Phe P r o  T y r  L e u  C y s  T y r  L y s  A s n  G l y  G l y  G l y  A l a  Phe L e u  I l e  
85  9 0  9 5  
P r o  T y r  T h r  L e u  Phe L e u  I l e  I l e  A l a  G l y  M e t  P r o  L e u  Phe T y r  M e t  
1 0 0  1 0 5  1 1 0  
G l u  L e u  A l a  L e u  G l y  G l n  T y r  A s n  A r g  G l u  G l y  A l a  A l a  T h r  V a l  T r p  
1 1 5  1 2 0  1 2 5  
L y s  I l e  C y s  P r o  Phe Phe L y s  G l y  V a l  G l y  T y r  A l a  V a l  I l e  L e u  I l e  
1 3 0  1 3 5  1 4 0  
A l a  L e u  T y r  V a l  G l y  Phe T y r  T y r  A s n  V a l  I l e  I l e  A l a  T r p  S e r  L e u  
1 4 5  1 5 0  1 5 5  1 6 0  
T y r  T y r  L e u  Phe S e r  S e r  Phe T h r  L e u  A s n  L e u  P r o  T r p  T h r  A s p  C y s  
1 6 5  1 7 0  1 7 5  
G l y  H i s  T h r  T r p  A s n  S e r  P r o  A s n  C y s  T h r  A s p  P r o  L y s  L e u  L e u  A s n  
1 8 0  1 8 5  1 9 0  
G l y  S e r  V a l  L e u  G l y  A s n  H i s  T h r  L y s  T y r  S e r  L y s  T y r  L y s  Phe T h r  
1 9 5  2 0 0  2 0 5  
P r o  A l a  A l a  G l u  Phe T y r  G l u  A r g  G l y  V a l  L e u  H i s  L e u  H i s  G l u  S e r  
2 1 0  2 1 5  2 2 0  
S e r  G l y  I l e  H i s  A s p  I l e  G l y  L e u  P r o  G l n  T r p  G l n  L e u  L e u  L e u  C y s  
2 2 5  2 3 0  2 3 5  2 4 0  
L e u  M e t  V a l  V a l  V a l  I l e  V a l  L e u  T y r  Phe S e r  L e u  T r p  L y s  G l y  V a l  
2 4 5  2 5 0  2 5 5  
L y s  T h r  S e r  G l y  L y s  V a l  V a l  T r p  I l e  T h r  A l a  T h r  L e u  P r o  T y r  Phe 
2 6 0  2 6 5  2 7 0  
V a l  L e u  Phe V a l  L e u  L e u  V a l  H i s  G l y  V a l  T h r  L e u  P r o  G l y  A l a  S e r  
2 7 5  2 8 0  2 8 5  
A s n  G l y  I l e  A s n  A l a  T y r  L e u  H i s  I l e  A s p  Phe T y r  A r g  L e u  L y s  G l u  
2 9 0  2 9 5  3 0 0  
A l a  T h r  V a l  T r p  I l e  A s p  A l a  A l a  T h r  G l n  I l e  Phe Phe S e r  L e u  G l y  
3 0 5  3 1 0  3 1 5  3 2 0  
A l a  G l y  Phe G l y  V a l  L e u  I l e  A l a  Phe A l a  S e r  T y r  A s n  L y s  Phe A s p  
3 2 5  3 3 0  3 3 5  
A s n  A s n  C y s  T y r  A r g  A s p  A l a  L e u  L e u  T h r  S e r  S e r  I l e  A s n  C y s  I l e  
3 4 0  3 4 5  3 5 0  
T h r  S e r  Phe V a l  S e r  G l y  Phe A l a  I l e  Phe S e r  I l e  L e u  G l y  T y r  M e t  
3 5 5  3 6 0  3 6 5  
A l a  H i s  G l u  H i s  L y s  V a l  A s n  I l e  G l u  A s p  V a l  A l a  T h r  G l u  G l y  A l a  
3 7 0  3 7 5  3 8 0  
G l y  L e u  V a l  Phe I l e  L e u  T y r  P r o  G l u  A l a  I l e  S e r  T h r  L e u  S e r  G l y  
3 8 5  3 9 0  3 9 5  400  
S e r  T h r  Phe T r p  A l a  V a l  V a l  Phe Phe V a l  M e t  L e u  L e u  A l a  L e u  G l y  
4 0 5  410  4 1 5  
L e u  A s p  S e r  S e r  M e t  G l y  G l y  M e t  G l u  A l a  V a l  I l e  T h r  G l y  L e u  A l a  
420  4 2 5  4 3 0  
A s p  A s p  Phe G l n  V a l  L e u  L y s  A r g  H i s  A r g  L y s  L e u  Phe T h r  Phe G l y  
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4 3 5  4 4 0  4 4 5  
V a l  T h r  Phe S e r  T h r  Phe L e u  L e u  P r o  L e u  Phe C y s  I l e  T h r  L y s  G l y  
4 5 0  4 5 5  4 6 0  
G l y  I l e  T y r  V a l  L e u  T h r  L e u  L e u  A s p  T h r  Phe A l a  A l a  G l y  T h r  S e r  
4 6 5  4 7 0  4 7 5  480  
I l e  L e u  Phe A l a  V a l  L e u  M e t  G l u  A l a  I l e  G l y  V a l  S e r  T r p  Phe T y r  
4 8 5  490  4 9 5  
G l y  V a l  A s p  A r g  Phe S e r  A s n  A s p  I l e  G l n  G l n  M e t  M e t  G l y  Phe A r g  
5 0 0  5 0 5  5 1 0  
P r o  G l y  L e u  T y r  T r p  A r g  L e u  C y s  T r p  L y s  Phe V a l  S e r  P r o  A l a  Phe 
5 1 5  5 2 0  5 2 5  
L e u  L e u  Phe V a l  V a l  V a l  V a l  S e r  I l e  I l e  A s n  Phe L y s  P r o  L e u  T h r  
5 3 0  5 3 5  5 4 0  
T Y r  
5 4 5  
A s p  A s p  T y r  I l e  Phe P r o  P r o  T r p  A l a  A s n  T r p  V a l  G l y  T r p  G l y  
5 5 0  5 5 5  5 6 0  
I l e  A l a  L e u  S e r  S e r  M e t  V a l  L e u  V a l  P r o  I le  T y r  V a l  I l e  T y r  L y s  
5 6 5  5 7 0  5 7 5  
Phe L e u  S e r  T h r  G l n  G l y  S e r  L e u  T r p  G l u  A r g  L e u  A l a  T y r  G l y  I l e  
5 8 0  5 8 5  5 9 0  
T h r  P r o  G l u  A s n  G l u  H i s  H i s  L e u  V a l  A l a  G l n  A r g  A s p  I l e  A r g  G l n  
5 9 5  6 0 0  6 0 5  
Phe G l n  L e u  G l n  H i s  T r p  L e u  A l a  I l e  
6 1 0  6 1 5  
<210>  SEQ I D  NO 5 
<211>  LENGTH: 4 1  
<212>  TYPE: DNA 
<213>  ORGANISM: Homo sap iens  
<400>  SEQUENCE: 5 
c c t t c a g t a c  t t t c c t t c t c  c c c c t g t t c t  gcataaccaa g 
<210>  SEQ I D  NO 6 
<211>  LENGTH: 4 1  
<212>  TYPE: DNA 
<213>  ORGANISM: Homo sap iens  
<400>  SEQUENCE: 6 
c t t g g t t a t g  cagaacaggg ggagaaggaa ag tac tgaag  g 
<210>  SEQ I D  NO 7 
<211>  LENGTH: 1 8  
<212>  TYPE: DNA 
<213>  ORGANISM: Homo sap iens  
<400>  SEQUENCE: 7 
c a t t c t g g g c  t g t t g t g t  
<210>  SEQ I D  NO 8 
<211>  LENGTH: 2 1  
<212>  TYPE: DNA 
<213>  ORGANISM: Homo sap iens  
<400>  SEQUENCE: 8 
g t g g t t g t g g  t c a g c a t c a t  c 
4 1  
4 1  
1 8  
2 1  
<210>  SEQ I D  NO 9 
<211>  LENGTH: 1 5  
<212>  TYPE: DNA 
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<213> ORGANISM: Homo s a p i e n s  
<400> SEQUENCE: 9 
c c t t c t c g c c  c t g t t  
<210> SEQ I D  NO 1 0  
<211> LENGTH: 1 5  
<212> TYPE: DNA 
<213> ORGANISM: Homo s a p i e n s  
<400> SEQUENCE: 1 0  
c c t t c t c c c c  c t g t t  
<210> SEQ I D  NO 11 
<211> LENGTH: 1 8 5 4  
<212> TYPE: DNA 
<213> ORGANISM: Homo s a p i e n s  
<220> FEATURE: 
<221> NAME/KEY: CDS 
<222> LOCATION: ( 1 ) . . ( 1 8 5 1 )  
<400> SEQUENCE: 1 1  
a t g  a t t  c t g  gcg cgg a t g  aac  ccg  cag  g t g  cag ccc  gag aac  aac  ggg 
M e t  I l e  Leu Ala Arg M e t  Asn P ro  Gln Val Gln P ro  Glu Asn Asn Gly 
1 5 1 0  1 5  
gcg gac acg  g g t  cca  gag cag  ccc  c t t  cgg gcg cgc  aaa  a c t  gcg gag 
Ala Asp Thr Gly P ro  Glu Gln P ro  Leu Arg Ala Arg Lys Thr Ala Glu 
20  2 5  3 0  
c t g  c t g  g t g  g t g  aag  gag cgc  aac  ggc g t c  cag t g c  c t g  c t g  gcg ccc  
Leu Leu Val Val Lys Glu Arg Asn Gly Val Gln Cys Leu Leu Ala P ro  
3 5  4 0  4 5  
cgc  gac ggc gac gcg cag  ccc  cgg gag acc  t g g  ggc aag  aag  a t c  gac 
Arg Asp Gly Asp Ala Gln P ro  Arg Glu Thr Trp Gly Lys Lys I l e  Asp 
5 0  5 5  60  
t t c  c t g  c t g  t c c  g t a  g t c  ggc t t c  gca g t g  gac c t g  gcc aac  g t g  t g g  
Phe Leu Leu S e r  Val Val Gly Phe Ala Val Asp Leu Ala Asn Val Trp  
6 5  7 0  7 5  8 0  
cgc  t t c  ccc  t a c  c t c  t g c  t a c  aag  aac  ggc ggc g g t  gcc t t c  t t g  a t c  
Arg Phe P ro  Tyr Leu Cys Tyr Lys Asn Gly Gly Gly Ala Phe Leu I l e  
8 5  9 0  9 5  
ccg  t a c  aca  c t g  t t c  c t t  a t c  a t c  gcg ggg a t g  ccc  c t g  t t c  t a c  a t g  
P ro  Tyr Thr Leu Phe Leu I l e  I l e  Ala Gly M e t  P ro  Leu Phe Tyr M e t  
1 0 0  1 0 5  1 1 0  
gag c t g  g c t  c t g  gga cag  t a c  aac  cgg gag ggg g c t  gcc acc  g t t  t g g  
Glu Leu Ala Leu Gly Gln Tyr Asn Arg Glu Gly Ala Ala Thr Val Trp  
1 1 5  1 2 0  1 2 5  
aaa  a t c  t g c  cca  t t c  t t c  aaa  ggc g t t  ggc t a t  g c t  g t c  a t c  c t g  a t c  
Lys I l e  Cys P ro  Phe Phe Lys Gly Val Gly Tyr Ala Val I l e  Leu I l e  
1 3 0  1 3 5  1 4 0  
gcc c t g  t a c  g t t  ggc t t c  t a c  t a c  aac  g t c  a t c  a t c  gcc t g g  t c a  c t c  
Ala Leu Tyr Val Gly Phe Tyr Tyr Asn Val I l e  I l e  Ala Trp  S e r  Leu 
1 4 5  1 5 0  1 5 5  1 6 0  
t a c  t a c  c t c  t t c  t c c  t c c  t t c  acc  c t c  aac  c t g  ccc  t g g  acc  gac t g t  
Tyr Tyr Leu Phe S e r  S e r  Phe Thr Leu Asn Leu P ro  Trp  Thr Asp Cys 
1 6 5  1 7 0  1 7 5  
ggc cac  acc  t g g  aac  agc  ccc  aac  t g t  acc  gac ccc  aag  c t c  c t c  a a t  
Gly H i s  Thr Trp  Asn S e r  P ro  Asn Cys Thr Asp P ro  Lys Leu Leu Asn 
1 8 0  1 8 5  1 9 0  
ggc t c c  g t g  c t t  ggc aac  cac  acc  aag  t a c  t c c  aag  t a c  aag  t t c  acg  
Gly S e r  Val Leu Gly Asn H i s  Thr Lys Tyr Se r  Lys Tyr Lys Phe Thr 
1 9 5  2 0 0  2 0 5  
1 5  
1 5  
4 8  
9 6  
1 4 4  
1 9 2  
2 4 0  
2 8 8  
3 3 6  
3 8 4  
4 3 2  
4 8 0  
5 2 8  
5 7 6  
6 2 4  
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ccg  gca gcc gag ttt t a t  gag c g t  g g t  g t c  c t g  cac  c t t  cac  gag agc  
P ro  Ala Ala Glu Phe Tyr Glu Arg Gly Val Leu H i s  Leu H i s  Glu S e r  
2 1 0  2 1 5  2 2 0  
agc  ggg a t t  c a t  gac a t c  ggc c t g  ccc  cag  t g g  cag  c t c  t t g  c t c  t g t  
S e r  Gly I l e  H i s  Asp I l e  Gly Leu P ro  Gln Trp Gln Leu Leu Leu Cys 
2 2 5  2 3 0  2 3 5  2 4 0  
c t g  a t g  g t c  g t c  g t c  a t c  g t c  t t g  t a t  ttt agc c t c  t g g  aaa  ggg g t g  
Leu M e t  Val Val Val I l e  Val Leu Tyr Phe Se r  Leu Trp  Lys Gly Val 
2 4 5  2 5 0  2 5 5  
aag  aca  t c a  gga aag  g t g  g t g  t g g  a t c  aca  gcc acg  c t g  c c t  t a c  t t c  
Lys Thr S e r  Gly Lys Val Val Trp  I l e  Thr Ala Thr Leu P ro  Tyr Phe 
2 6 0  2 6 5  2 7 0  
g t g  c t g  t t c  g t g  c t c  c t g  g t c  c a t  ggc g t c  acg c t g  ccc  gga gcc t c c  
Val Leu Phe Val Leu Leu Val H i s  Gly Val Thr Leu P ro  Gly Ala S e r  
2 7 5  2 8 0  2 8 5  
a a t  ggc a t c  a a t  gcc t a c  c t g  cac  a t c  gac t t c  t a c  cgc  t t g  aaa  gag 
Asn Gly I l e  Asn Ala Tyr Leu H i s  I l e  Asp Phe Tyr Arg Leu Lys Glu 
2 9 0  2 9 5  3 0 0  
gcc acg  g t a  t g g  a t t  g a t  gcc gca a c t  cag  a t a  ttt ttt t c c  t t g  ggg 
Ala Thr Val Trp  I l e  Asp Ala Ala Thr Gln I le  Phe Phe S e r  Leu Gly 
3 0 5  3 1 0  3 1 5  3 2 0  
g c t  gga ttt gga g t a  t t g  a t t  gca ttt gcc a g t  t a c  aac  aaa  ttt gac 
Ala Gly Phe Gly Val Leu I l e  Ala Phe Ala Se r  Tyr Asn Lys Phe Asp 
3 2 5  3 3 0  3 3 5  
aac  aac  t g t  t a c  agg g a t  gcc c t g  c t g  acc  agc agc  a t c  aac  t g t  a t c  
Asn Asn Cys Tyr Arg Asp Ala Leu Leu Thr Se r  S e r  I l e  Asn Cys I l e  
3 4 0  3 4 5  3 5 0  
acc  agc  t t c  g t c  t c t  ggg t t c  gcc a t c  t t c  t c c  a t c  c t t  g g t  t a c  a t g  
Thr S e r  Phe Val S e r  Gly Phe Ala I l e  Phe Se r  I l e  Leu Gly Tyr M e t  
3 5 5  3 6 0  3 6 5  
gcc c a t  gaa cac  aag  g t c  aac  a t t  gag g a t  g t g  gcc aca  gaa gga g c t  
Ala H i s  Glu H i s  Lys Val Asn I l e  Glu Asp Val Ala Thr Glu Gly Ala 
3 7 0  3 7 5  3 8 0  
ggc c t a  g t g  t t c  a t c  c t g  t a t  cca  gag gcc a t t  t c t  acc  c t g  t c t  gga 
Gly Leu Val Phe I l e  Leu Tyr P ro  Glu Ala I le  S e r  Thr Leu S e r  Gly 
3 8 5  3 9 0  3 9 5  400  
t c t  aca  t t c  t g g  g c t  g t t  g t g  ttt t t c  g t c  a t g  c t c  c t g  gcg c t g  ggc 
S e r  Thr Phe Trp  Ala Val Val Phe Phe Val M e t  Leu Leu Ala Leu Gly 
4 0 5  410  4 1 5  
c t t  gac agc  t c a  a t g  gga ggc a t g  gag g c t  g t c  a t c  acg  ggc c t g  gca 
Leu Asp S e r  S e r  M e t  Gly Gly M e t  Glu Ala Val I l e  Thr Gly Leu Ala 
420  4 2 5  4 3 0  
g a t  gac t t c  cag  g t c  c t g  aag  cga  cac  cgg aaa  c t c  t t c  aca  ttt ggc 
Asp Asp Phe Gln Val Leu Lys Arg H i s  Arg Lys Leu Phe Thr Phe Gly 
4 3 5  4 4 0  4 4 5  
g t c  acc  t t c  agc  a c t  t t c  c t t  c t c  gcc c t g  t t c  t g c  a t a  acc  aag  g g t  
Val Thr Phe S e r  Thr Phe Leu Leu Ala Leu Phe Cys I l e  Thr Lys Gly 
4 5 0  4 5 5  4 6 0  
gga a t t  t a c  g t c  t t g  acc  c t c  c t g  gac acc  ttt g c t  gcg ggc acc  t c c  
Gly I l e  Tyr Val Leu Thr Leu Leu Asp Thr Phe Ala Ala Gly Thr S e r  
4 6 5  4 7 0  4 7 5  480  
a t c  c t t  ttt g c t  g t c  c t c  a t g  gaa gcc a t c  gga g t t  t c c  t g g  ttt t a t  
I l e  Leu Phe Ala Val Leu M e t  Glu Ala I l e  Gly Val S e r  Trp  Phe Tyr 
4 8 5  490  4 9 5  
gga g t g  gac agg t t c  agc  aac  gac a t c  cag  cag a t g  a t g  ggg t t c  agg 
Gly Val Asp Arg Phe S e r  Asn Asp I l e  Gln Gln M e t  M e t  Gly Phe Arg 
5 0 0  5 0 5  5 1 0  
ccg  g g t  c t a  t a c  t g g  aga  c t g  t g c  t g g  aag  t t c  g t c  a g t  c c t  gcc t t c  
P ro  Gly Leu Tyr Trp  Arg Leu Cys Trp  Lys Phe Val S e r  P ro  Ala Phe 
5 1 5  5 2 0  5 2 5  
6 7 2  
7 2 0  
7 6 8  
8 1 6  
8 6 4  
9 1 2  
9 6 0  
1 0 0 8  
1 0 5 6  
1 1 0 4  
1 1 5 2  
1 2 0 0  
1 2 4 8  
1 2 9 6  
1 3 4 4  
1 3 9 2  
1 4 4 0  
1 4 8 8  
1 5 3 6  
1 5 8 4  
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c t c  c t g  t t c  g t g  g t t  g t g  g t c  agc a t c  a t c  aac t t c  aag cca c t c  acc 1 6 3 2  
L e u  L e u  Phe V a l  V a l  V a l  V a l  S e r  I l e  I l e  A s n  Phe L y s  P r o  L e u  T h r  
5 3 0  5 3 5  5 4 0  
t a c  gac gac t a c  a t c  t t c  ccg ccc t g g  gcc aac t g g  g t g  ggg t g g  ggc 1 6 8 0  
T y r  A s p  A s p  T y r  I l e  Phe P r o  P r o  T r p  A l a  A s n  T r p  V a l  G l y  T r p  G l y  
5 4 5  5 5 0  5 5 5  5 6 0  
a t c  gcc c t g  t c c  t c c  a t g  g t c  c t g  g t g  ccc a t c  t a c  g t c  a t c  t a t  aag 1 7 2 8  
I l e  A l a  L e u  S e r  S e r  M e t  V a l  L e u  V a l  P r o  I le  T y r  V a l  I l e  T y r  L y s  
5 6 5  5 7 0  5 7 5  
t t c  c t c  agc acg cag ggc t c t  c t t  t g g  gag aga c t g  gcc t a t  ggc a t c  1 7 7 6  
Phe L e u  S e r  T h r  G l n  G l y  S e r  L e u  T r p  G l u  A r g  L e u  A l a  T y r  G l y  I l e  
5 8 0  5 8 5  5 9 0  
acg cca gag aac gag cac cac c t g  g t g  g c t  cag agg gac a t c  aga cag 1 8 2 4  
T h r  P r o  G l u  A s n  G l u  H i s  H i s  L e u  V a l  A l a  G l n  A r g  A s p  I l e  A r g  G l n  
5 9 5  6 0 0  6 0 5  
t t c  cag t t g  caa cac t g g  c t g  gcc a t c  t g a  
Phe G l n  L e u  G l n  H i s  T r p  L e u  A l a  I l e  
6 1 0  6 1 5  
<210>  SEQ I D  NO 1 2  
<211>  LENGTH: 6 1 7  
<212>  TYPE: PRT 
<213>  ORGANISM: Homo sap iens  
<400>  SEQUENCE: 1 2  
M e t  I l e  L e u  A l a  A r g  M e t  A s n  P r o  G l n  V a l  G l n  P r o  G l u  A s n  A s n  G l y  
1 5 1 0  1 5  
A l a  A s p  T h r  G l y  P r o  G l u  G l n  P r o  L e u  A r g  A l a  A r g  L y s  T h r  A l a  G l u  
20  2 5  3 0  
L e u  L e u  V a l  V a l  L y s  G l u  A r g  A s n  G l y  V a l  G l n  C y s  L e u  L e u  A l a  P r o  
3 5  4 0  4 5  
A r g  A s p  G l y  A s p  A l a  G l n  P r o  A r g  G l u  T h r  T r p  G l y  L y s  L y s  I l e  A s p  
5 0  5 5  60  
Phe L e u  L e u  S e r  V a l  V a l  G l y  Phe A l a  V a l  A s p  L e u  A l a  A s n  V a l  T r p  
65  7 0  75  8 0  
A r g  Phe P r o  T y r  L e u  C y s  T y r  L y s  A s n  G l y  G l y  G l y  A l a  Phe L e u  I l e  
85  9 0  9 5  
P r o  T y r  T h r  L e u  Phe L e u  I l e  I l e  A l a  G l y  M e t  P r o  L e u  Phe T y r  M e t  
1 0 0  1 0 5  1 1 0  
G l u  L e u  A l a  L e u  G l y  G l n  T y r  A s n  A r g  G l u  G l y  A l a  A l a  T h r  V a l  T r p  
1 1 5  1 2 0  1 2 5  
L y s  I l e  C y s  P r o  Phe Phe L y s  G l y  V a l  G l y  T y r  A l a  V a l  I l e  L e u  I l e  
1 3 0  1 3 5  1 4 0  
A l a  L e u  T y r  V a l  G l y  Phe T y r  T y r  A s n  V a l  I l e  I l e  A l a  T r p  S e r  L e u  
1 4 5  1 5 0  1 5 5  1 6 0  
T y r  T y r  L e u  Phe S e r  S e r  Phe T h r  L e u  A s n  L e u  P r o  T r p  T h r  A s p  C y s  
1 6 5  1 7 0  1 7 5  
G l y  H i s  T h r  T r p  A s n  S e r  P r o  A s n  C y s  T h r  A s p  P r o  L y s  L e u  L e u  A s n  
1 8 0  1 8 5  1 9 0  
G l y  S e r  V a l  L e u  G l y  A s n  H i s  T h r  L y s  T y r  S e r  L y s  T y r  L y s  Phe T h r  
1 9 5  2 0 0  2 0 5  
P r o  A l a  A l a  G l u  Phe T y r  G l u  A r g  G l y  V a l  L e u  H i s  L e u  H i s  G l u  S e r  
2 1 0  2 1 5  2 2 0  
S e r  G l y  I l e  H i s  A s p  I l e  G l y  L e u  P r o  G l n  T r p  G l n  L e u  L e u  L e u  C y s  
2 2 5  2 3 0  2 3 5  2 4 0  
L e u  M e t  V a l  V a l  V a l  I l e  V a l  L e u  T y r  Phe S e r  L e u  T r p  L y s  G l y  V a l  
1 8 5 4  
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2 4 5  2 5 0  2 5 5  
L y s  T h r  S e r  G l y  L y s  V a l  V a l  T r p  I l e  T h r  A l a  T h r  L e u  P r o  T y r  Phe 
2 6 0  2 6 5  2 7 0  
V a l  L e u  Phe V a l  L e u  L e u  V a l  H i s  G l y  V a l  T h r  L e u  P r o  G l y  A l a  S e r  
2 7 5  2 8 0  2 8 5  
A s n  G l y  I l e  A s n  A l a  T y r  L e u  H i s  I l e  A s p  Phe T y r  A r g  L e u  L y s  G l u  
2 9 0  2 9 5  3 0 0  
A l a  T h r  V a l  T r p  I l e  A s p  A l a  A l a  T h r  G l n  I l e  Phe Phe S e r  L e u  G l y  
3 0 5  3 1 0  3 1 5  3 2 0  
A l a  G l y  Phe G l y  V a l  L e u  I l e  A l a  Phe A l a  S e r  T y r  A s n  L y s  Phe A s p  
3 2 5  3 3 0  3 3 5  
A s n  A s n  C y s  T y r  A r g  A s p  A l a  L e u  L e u  T h r  S e r  S e r  I l e  A s n  C y s  I l e  
3 4 0  3 4 5  3 5 0  
T h r  S e r  Phe V a l  S e r  G l y  Phe A l a  I l e  Phe S e r  I l e  L e u  G l y  T y r  M e t  
3 5 5  3 6 0  3 6 5  
A l a  H i s  G l u  H i s  L y s  V a l  A s n  I l e  G l u  A s p  V a l  A l a  T h r  G l u  G l y  A l a  
3 7 0  3 7 5  3 8 0  
G l y  L e u  V a l  Phe I l e  L e u  T y r  P r o  G l u  A l a  I l e  S e r  T h r  L e u  S e r  G l y  
3 8 5  3 9 0  3 9 5  400  
S e r  T h r  Phe T r p  A l a  V a l  V a l  Phe Phe V a l  M e t  L e u  L e u  A l a  L e u  G l y  
4 0 5  410  4 1 5  
L e u  A s p  S e r  S e r  M e t  G l y  G l y  M e t  G l u  A l a  V a l  I l e  T h r  G l y  L e u  A l a  
420  4 2 5  4 3 0  
A s p  A s p  Phe G l n  V a l  L e u  L y s  A r g  H i s  A r g  L y s  L e u  Phe T h r  Phe G l y  
4 3 5  4 4 0  4 4 5  
V a l  T h r  Phe S e r  T h r  Phe L e u  L e u  A l a  L e u  Phe C y s  I l e  T h r  L y s  G l y  
4 5 0  4 5 5  4 6 0  
G l y  I l e  T y r  V a l  L e u  T h r  L e u  L e u  A s p  T h r  Phe A l a  A l a  G l y  T h r  S e r  
4 6 5  4 7 0  4 7 5  480  
I l e  L e u  Phe A l a  V a l  L e u  M e t  G l u  A l a  I l e  G l y  V a l  S e r  T r p  Phe T y r  
4 8 5  490  4 9 5  
G l y  V a l  A s p  A r g  Phe S e r  A s n  A s p  I l e  G l n  G l n  M e t  M e t  G l y  Phe A r g  
5 0 0  5 0 5  5 1 0  
P r o  G l y  L e u  T y r  T r p  A r g  L e u  C y s  T r p  L y s  Phe V a l  S e r  P r o  A l a  Phe 
5 1 5  5 2 0  5 2 5  
L e u  L e u  Phe V a l  V a l  V a l  V a l  S e r  I l e  I l e  A s n  Phe L y s  P r o  L e u  T h r  
5 3 0  5 3 5  5 4 0  
T y r  A s p  A s p  T y r  I l e  Phe P r o  P r o  T r p  A l a  A s n  T r p  V a l  G l y  T r p  G l y  
5 4 5  5 5 0  5 5 5  5 6 0  
I l e  A l a  L e u  S e r  S e r  M e t  V a l  L e u  V a l  P r o  I le  T y r  V a l  I l e  T y r  L y s  
5 6 5  5 7 0  5 7 5  
Phe L e u  S e r  T h r  G l n  G l y  S e r  L e u  T r p  G l u  A r g  L e u  A l a  T y r  G l y  I l e  
5 8 0  5 8 5  5 9 0  
T h r  P r o  G l u  A s n  G l u  H i s  H i s  L e u  V a l  A l a  G l n  A r g  A s p  I l e  A r g  G l n  
5 9 5  6 0 0  6 0 5  
Phe G l n  L e u  G l n  H i s  T r p  L e u  A l a  I l e  
6 1 0  6 1 5  
<210>  SEQ I D  NO 1 3  
<211>  LENGTH: 1 8 5 4  
<212>  TYPE: DNA 
<213>  ORGANISM: Homo sap iens  
<220> FEATURE: 
<221>  NAME/KEY: CDS 
<222> LOCATION: ( 1 ) . . ( 1 8 5 1 )  
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<400>  SEQUENCE: 1 3  
a t g  a t t  c t g  gcg cgg a t g  aac  ccg  cag  g t g  cag ccc  gag aac  aac  ggg 
M e t  I l e  Leu Ala Arg M e t  Asn P ro  Gln Val Gln P ro  Glu Asn Asn Gly 
1 5 1 0  1 5  
gcg gac acg  g g t  cca  gag cag  ccc  c t t  cgg gcg cgc  aaa  a c t  gcg gag 
Ala Asp Thr Gly P ro  Glu Gln P ro  Leu Arg Ala Arg Lys Thr Ala Glu 
c t g  c t g  g t g  g t g  aag  gag cgc  aac  ggc g t c  cag t g c  c t g  c t g  gcg ccc  
Leu Leu Val Val Lys Glu Arg Asn Gly Val Gln Cys Leu Leu Ala P ro  
2 0  2 5  3 0  
3 5  4 0  4 5  
cgc  gac ggc gac gcg cag  ccc  cgg gag acc  t g g  ggc aag  aag  a t c  gac 
Arg Asp Gly Asp Ala Gln P ro  Arg Glu Thr Trp Gly Lys Lys I l e  Asp 
5 0  5 5  60  
t t c  c t g  c t g  t c c  g t a  g t c  ggc t t c  gca g t g  gac c t g  gcc aac  g t g  t g g  
Phe Leu Leu S e r  Val Val Gly Phe Ala Val Asp Leu Ala Asn Val Trp  
65  7 0  75  8 0  
cgc  t t c  ccc  t a c  c t c  t g c  t a c  aag  aac  ggc ggc g g t  gcc t t c  t t g  a t c  
Arg Phe P ro  Tyr Leu Cys Tyr Lys Asn Gly Gly Gly Ala Phe Leu I l e  
85  9 0  9 5  
ccg  t a c  aca  c t g  t t c  c t t  a t c  a t c  gcg ggg a t g  ccc  c t g  t t c  t a c  a t g  
P ro  Tyr Thr Leu Phe Leu I l e  I l e  Ala Gly M e t  P ro  Leu Phe Tyr M e t  
1 0 0  1 0 5  1 1 0  
gag c t g  g c t  c t g  gga cag  t a c  aac  cgg gag ggg g c t  gcc acc  g t t  t g g  
Glu Leu Ala Leu Gly Gln Tyr Asn Arg Glu Gly Ala Ala Thr Val Trp  
1 1 5  1 2 0  1 2 5  
aaa  a t c  t g c  cca  t t c  t t c  aaa  ggc g t t  ggc t a t  g c t  g t c  a t c  c t g  a t c  
Lys I l e  Cys P ro  Phe Phe Lys Gly Val Gly Tyr Ala Val I l e  Leu I l e  
1 3 0  1 3 5  1 4 0  
gcc c t g  t a c  g t t  ggc t t c  t a c  t a c  aac  g t c  a t c  a t c  gcc t g g  t c a  c t c  
Ala Leu Tyr Val Gly Phe Tyr Tyr Asn Val I l e  I l e  Ala Trp  S e r  Leu 
1 4 5  1 5 0  1 5 5  1 6 0  
t a c  t a c  c t c  t t c  t c c  t c c  t t c  acc  c t c  aac  c t g  ccc  t g g  acc  gac t g t  
Tyr Tyr Leu Phe S e r  S e r  Phe Thr Leu Asn Leu P ro  Trp  Thr Asp Cys 
1 6 5  1 7 0  1 7 5  
ggc cac  acc  t g g  aac  agc  ccc  aac  t g t  acc  gac ccc  aag  c t c  c t c  a a t  
Gly H i s  Thr Trp  Asn S e r  P ro  Asn Cys Thr Asp P ro  Lys Leu Leu Asn 
1 8 0  1 8 5  1 9 0  
ggc t c c  g t g  c t t  ggc aac  cac  acc  aag  t a c  t c c  aag  t a c  aag  t t c  acg  
Gly S e r  Val Leu Gly Asn H i s  Thr Lys Tyr Se r  Lys Tyr Lys Phe Thr 
1 9 5  2 0 0  2 0 5  
ccg  gca gcc gag ttt t a t  gag c g t  g g t  g t c  c t g  cac  c t t  cac  gag agc  
P ro  Ala Ala Glu Phe Tyr Glu Arg Gly Val Leu H i s  Leu H i s  Glu S e r  
2 1 0  2 1 5  2 2 0  
agc  ggg a t t  c a t  gac a t c  ggc c t g  ccc  cag  t g g  cag  c t c  t t g  c t c  t g t  
S e r  Gly I l e  H i s  Asp I l e  Gly Leu P ro  Gln Trp Gln Leu Leu Leu Cys 
2 2 5  2 3 0  2 3 5  2 4 0  
c t g  a t g  g t c  g t c  g t c  a t c  g t c  t t g  t a t  ttt agc c t c  t g g  aaa  ggg g t g  
Leu M e t  Val Val Val I l e  Val Leu Tyr Phe Se r  Leu Trp  Lys Gly Val 
2 4 5  2 5 0  2 5 5  
aag  aca  t c a  gga aag  g t g  g t g  t g g  a t c  aca  gcc acg  c t g  c c t  t a c  t t c  
Lys Thr S e r  Gly Lys Val Val Trp  I l e  Thr Ala Thr Leu P ro  Tyr Phe 
2 6 0  2 6 5  2 7 0  
g t g  c t g  t t c  g t g  c t c  c t g  g t c  c a t  ggc g t c  acg c t g  ccc  gga gcc t c c  
Val Leu Phe Val Leu Leu Val H i s  Gly Val Thr Leu P ro  Gly Ala S e r  
2 7 5  2 8 0  2 8 5  
a a t  ggc a t c  a a t  gcc t a c  c t g  cac  a t c  gac t t c  t a c  cgc  t t g  aaa  gag 
Asn Gly I l e  Asn Ala Tyr Leu H i s  I l e  Asp Phe Tyr Arg Leu Lys Glu 
2 9 0  2 9 5  3 0 0  
gcc acg  g t a  t g g  a t t  g a t  gcc gca a c t  cag  a t a  ttt ttt t c c  t t g  ggg 
2 4 0  
2 8 8  
3 3 6  
3 8 4  
4 3 2  
4 8 0  
5 2 8  
5 7 6  
6 2 4  
6 7 2  
7 2 0  
7 6 8  
8 1 6  
8 6 4  
9 1 2  
9 6 0  
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Ala Thr Val Trp  I l e  Asp Ala Ala Thr Gln I le  Phe Phe S e r  Leu Gly 
3 0 5  3 1 0  3 1 5  3 2 0  
g c t  gga ttt gga g t a  t t g  a t t  gca ttt gcc a g t  t a c  aac  aaa  ttt gac 
Ala Gly Phe Gly Val Leu I l e  Ala Phe Ala Se r  Tyr Asn Lys Phe Asp 
3 2 5  3 3 0  3 3 5  
aac  aac  t g t  t a c  agg g a t  gcc c t g  c t g  acc  agc agc  a t c  aac  t g t  a t c  
Asn Asn Cys Tyr Arg Asp Ala Leu Leu Thr Se r  S e r  I l e  Asn Cys I l e  
3 4 0  3 4 5  3 5 0  
acc  agc  t t c  g t c  t c t  ggg t t c  gcc a t c  t t c  t c c  a t c  c t t  g g t  t a c  a t g  
Thr S e r  Phe Val S e r  Gly Phe Ala I l e  Phe Se r  I l e  Leu Gly Tyr M e t  
3 5 5  3 6 0  3 6 5  
gcc c a t  gaa cac  aag  g t c  aac  a t t  gag g a t  g t g  gcc aca  gaa gga g c t  
Ala H i s  Glu H i s  Lys Val Asn I l e  Glu Asp Val Ala Thr Glu Gly Ala 
3 7 0  3 7 5  3 8 0  
ggc c t a  g t g  t t c  a t c  c t g  t a t  cca  gag gcc a t t  t c t  acc  c t g  t c t  gga 
Gly Leu Val Phe I l e  Leu Tyr P ro  Glu Ala I le  S e r  Thr Leu S e r  Gly 
3 8 5  3 9 0  3 9 5  400  
t c t  aca  t t c  t g g  g c t  g t t  g t g  ttt t t c  g t c  a t g  c t c  c t g  gcg c t g  ggc 
S e r  Thr Phe Trp  Ala Val Val Phe Phe Val M e t  Leu Leu Ala Leu Gly 
4 0 5  410  4 1 5  
c t t  gac agc  t c a  a t g  gga ggc a t g  gag g c t  g t c  a t c  acg  ggc c t g  gca 
Leu Asp S e r  S e r  M e t  Gly Gly M e t  Glu Ala Val I l e  Thr Gly Leu Ala 
420  4 2 5  4 3 0  
g a t  gac t t c  cag  g t c  c t g  aag  cga  cac  cgg aaa  c t c  t t c  aca  ttt ggc 
Asp Asp Phe Gln Val Leu Lys Arg H i s  Arg Lys Leu Phe Thr Phe Gly 
4 3 5  4 4 0  4 4 5  
g t c  acc  t t c  agc  a c t  t t c  c t t  c t c  ccc  c t g  t t c  t g c  a t a  acc  aag  g g t  
Val Thr Phe S e r  Thr Phe Leu Leu P ro  Leu Phe Cys I l e  Thr Lys Gly 
4 5 0  4 5 5  4 6 0  
gga a t t  t a c  g t c  t t g  acc  c t c  c t g  gac acc  ttt g c t  gcg ggc acc  t c c  
Gly I l e  Tyr Val Leu Thr Leu Leu Asp Thr Phe Ala Ala Gly Thr S e r  
4 6 5  4 7 0  4 7 5  480  
a t c  c t t  ttt g c t  g t c  c t c  a t g  gaa gcc a t c  gga g t t  t c c  t g g  ttt t a t  
I l e  Leu Phe Ala Val Leu M e t  Glu Ala I l e  Gly Val S e r  Trp  Phe Tyr 
4 8 5  490  4 9 5  
gga g t g  gac agg t t c  agc  aac  gac a t c  cag  cag a t g  a t g  ggg t t c  agg 
Gly Val Asp Arg Phe S e r  Asn Asp I l e  Gln Gln M e t  M e t  Gly Phe Arg 
5 0 0  5 0 5  5 1 0  
ccg  g g t  c t a  t a c  t g g  aga  c t g  t g c  t g g  aag  t t c  g t c  a g t  c c t  gcc t t c  
P ro  Gly Leu Tyr Trp  Arg Leu Cys Trp  Lys Phe Val S e r  P ro  Ala Phe 
5 1 5  5 2 0  5 2 5  
c t c  c t g  t t c  g t g  g t t  g t g  g t c  agc  a t c  a t c  aac  t t c  aag  cca  c t c  acc  
Leu Leu Phe Val Val Val Val S e r  I l e  I l e  Asn Phe Lys P ro  Leu Thr 
5 3 0  5 3 5  5 4 0  
t a c  gac gac t a c  a t c  t t c  ccg  ccc  t g g  gcc aac  t g g  g t g  ggg t g g  ggc 
Tyr Asp Asp Tyr I l e  Phe P ro  P ro  Trp  Ala Asn Trp  Val Gly Trp  Gly 
5 4 5  5 5 0  5 5 5  5 6 0  
a t c  gcc c t g  t c c  t c c  a t g  g t c  c t g  g t g  ccc  a t c  t a c  g t c  a t c  t a t  aag  
I l e  Ala Leu S e r  S e r  M e t  Val Leu Val P ro  I le  Tyr Val I l e  Tyr Lys 
5 6 5  5 7 0  5 7 5  
t t c  c t c  agc  acg  cag  ggc t c t  c t t  t g g  gag aga c t g  gcc t a t  ggc a t c  
Phe Leu S e r  Thr Gln Gly S e r  Leu Trp  Glu Arg Leu Ala Tyr Gly I l e  
5 8 0  5 8 5  5 9 0  
acg  cca  gag aac  gag cac  cac  c t g  g t g  g c t  cag agg gac a t c  aga  cag  
Thr P ro  Glu Asn Glu H i s  H i s  Leu Val Ala Gln Arg Asp I l e  Arg Gln 
5 9 5  6 0 0  6 0 5  
t t c  cag  t t g  caa  cac  t g g  c t g  gcc a t c  t g a  
Phe Gln Leu Gln H i s  Trp  Leu Ala I l e  
6 1 0  6 1 5  
1 0 0 8  
1 0 5 6  
1 1 0 4  
1 1 5 2  
1 2 0 0  
1 2 4 8  
1 2 9 6  
1 3 4 4  
1 3 9 2  
1 4 4 0  
1 4 8 8  
1 5 3 6  
1 5 8 4  
1 6 3 2  
1 6 8 0  
1 7 2 8  
1 7 7 6  
1 8 2 4  
1 8 5 4  
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- con t inued  
<210>  SEQ I D  NO 1 4  
<211>  LENGTH: 6 1 7  
<212>  TYPE: PRT 
<213>  ORGANISM: Homo sap iens  
<400>  SEQUENCE: 1 4  
M e t  I l e  L e u  A l a  A r g  M e t  A s n  P r o  G l n  V a l  G l n  P r o  G l u  A s n  A s n  G l y  
1 5 1 0  1 5  
A l a  A s p  T h r  G l y  P r o  G l u  G l n  P r o  L e u  A r g  A l a  A r g  L y s  T h r  A l a  G l u  
20  2 5  3 0  
L e u  L e u  V a l  V a l  L y s  G l u  A r g  A s n  G l y  V a l  G l n  C y s  L e u  L e u  A l a  P r o  
3 5  4 0  4 5  
A r g  A s p  G l y  A s p  A l a  G l n  P r o  A r g  G l u  T h r  T r p  G l y  L y s  L y s  I l e  A s p  
5 0  5 5  60  
Phe L e u  L e u  S e r  V a l  V a l  G l y  Phe A l a  V a l  A s p  L e u  A l a  A s n  V a l  T r p  
65  7 0  75  8 0  
A r g  Phe P r o  T y r  L e u  C y s  T y r  L y s  A s n  G l y  G l y  G l y  A l a  Phe L e u  I l e  
85  9 0  9 5  
P r o  T y r  T h r  L e u  Phe L e u  I l e  I l e  A l a  G l y  M e t  P r o  L e u  Phe T y r  M e t  
1 0 0  1 0 5  1 1 0  
G l u  L e u  A l a  L e u  G l y  G l n  T y r  A s n  A r g  G l u  G l y  A l a  A l a  T h r  V a l  T r p  
1 1 5  1 2 0  1 2 5  
L y s  I l e  C y s  P r o  Phe Phe L y s  G l y  V a l  G l y  T y r  A l a  V a l  I l e  L e u  I l e  
1 3 0  1 3 5  1 4 0  
A l a  L e u  T y r  V a l  G l y  Phe T y r  T y r  A s n  V a l  I l e  I l e  A l a  T r p  S e r  L e u  
1 4 5  1 5 0  1 5 5  1 6 0  
T y r  T y r  L e u  Phe S e r  S e r  Phe T h r  L e u  A s n  L e u  P r o  T r p  T h r  A s p  C y s  
1 6 5  1 7 0  1 7 5  
G l y  H i s  T h r  T r p  A s n  S e r  P r o  A s n  C y s  T h r  A s p  P r o  L y s  L e u  L e u  A s n  
1 8 0  1 8 5  1 9 0  
G l y  S e r  V a l  L e u  G l y  A s n  H i s  T h r  L y s  T y r  S e r  L y s  T y r  L y s  Phe T h r  
1 9 5  2 0 0  2 0 5  
P r o  A l a  A l a  G l u  Phe T y r  G l u  A r g  G l y  V a l  L e u  H i s  L e u  H i s  G l u  S e r  
2 1 0  2 1 5  2 2 0  
S e r  G l y  I l e  H i s  A s p  I l e  G l y  L e u  P r o  G l n  T r p  G l n  L e u  L e u  L e u  C y s  
2 2 5  2 3 0  2 3 5  2 4 0  
L e u  M e t  V a l  V a l  V a l  I l e  V a l  L e u  T y r  Phe S e r  L e u  T r p  L y s  G l y  V a l  
2 4 5  2 5 0  2 5 5  
L y s  T h r  S e r  G l y  L y s  V a l  V a l  T r p  I l e  T h r  A l a  T h r  L e u  P r o  T y r  Phe 
2 6 0  2 6 5  2 7 0  
V a l  L e u  Phe V a l  L e u  L e u  V a l  H i s  G l y  V a l  T h r  L e u  P r o  G l y  A l a  S e r  
2 7 5  2 8 0  2 8 5  
A s n  G l y  I l e  A s n  A l a  T y r  L e u  H i s  I l e  A s p  Phe T y r  A r g  L e u  L y s  G l u  
2 9 0  2 9 5  3 0 0  
A l a  T h r  V a l  T r p  I l e  A s p  A l a  A l a  T h r  G l n  I l e  Phe Phe S e r  L e u  G l y  
3 0 5  3 1 0  3 1 5  3 2 0  
A l a  G l y  Phe G l y  V a l  L e u  I l e  A l a  Phe A l a  S e r  T y r  A s n  L y s  Phe A s p  
3 2 5  3 3 0  3 3 5  
A s n  A s n  C y s  T y r  A r g  A s p  A l a  L e u  L e u  T h r  S e r  S e r  I l e  A s n  C y s  I l e  
3 4 0  3 4 5  3 5 0  
T h r  S e r  Phe V a l  S e r  G l y  Phe A l a  I l e  Phe S e r  I l e  L e u  G l y  T y r  M e t  
3 5 5  3 6 0  3 6 5  
A l a  H i s  G l u  H i s  L y s  V a l  A s n  I l e  G l u  A s p  V a l  A l a  T h r  G l u  G l y  A l a  
3 7 0  3 7 5  3 8 0  
US 7,094,532 B2 
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G l y  L e u  V a l  Phe I l e  L e u  T y r  P r o  G l u  A l a  I l e  S e r  T h r  L e u  S e r  G l y  
3 8 5  3 9 0  3 9 5  400  
S e r  T h r  Phe T r p  A l a  V a l  V a l  Phe Phe V a l  M e t  L e u  L e u  A l a  L e u  G l y  
4 0 5  410  4 1 5  
L e u  A s p  S e r  S e r  M e t  G l y  G l y  M e t  G l u  A l a  V a l  I l e  T h r  G l y  L e u  A l a  
420  4 2 5  4 3 0  
A s p  A s p  Phe G l n  V a l  L e u  L y s  A r g  H i s  A r g  L y s  L e u  Phe T h r  Phe G l y  
4 3 5  4 4 0  4 4 5  
V a l  T h r  Phe S e r  T h r  Phe L e u  L e u  P r o  L e u  Phe C y s  I l e  T h r  L y s  G l y  
4 5 0  4 5 5  4 6 0  
G l y  I l e  T y r  V a l  L e u  T h r  L e u  L e u  A s p  T h r  Phe A l a  A l a  G l y  T h r  S e r  
4 6 5  4 7 0  4 7 5  480  
I l e  L e u  Phe A l a  V a l  L e u  M e t  G l u  A l a  I l e  G l y  V a l  S e r  T r p  Phe T y r  
4 8 5  490  4 9 5  
G l y  V a l  A s p  A r g  Phe S e r  A s n  A s p  I l e  G l n  G l n  M e t  M e t  G l y  Phe A r g  
5 0 0  5 0 5  5 1 0  
P r o  G l y  L e u  T y r  T r p  A r g  L e u  C y s  T r p  L y s  Phe V a l  S e r  P r o  A l a  Phe 
5 1 5  5 2 0  5 2 5  
L e u  L e u  Phe V a l  V a l  V a l  V a l  S e r  I l e  I l e  A s n  Phe L y s  P r o  L e u  T h r  
5 3 0  5 3 5  5 4 0  
T y r  A s p  A s p  T y r  I l e  Phe P r o  P r o  T r p  A l a  A s n  T r p  V a l  G l y  T r p  G l y  
5 4 5  5 5 0  5 5 5  5 6 0  
I l e  A l a  L e u  S e r  S e r  M e t  V a l  L e u  V a l  P r o  I le  T y r  V a l  I l e  T y r  L y s  
5 6 5  5 7 0  5 7 5  
Phe L e u  S e r  T h r  G l n  G l y  S e r  L e u  T r p  G l u  A r g  L e u  A l a  T y r  G l y  I l e  
5 8 0  5 8 5  5 9 0  
T h r  P r o  G l u  A s n  G l u  H i s  H i s  L e u  V a l  A l a  G l n  A r g  A s p  I l e  A r g  G l n  
5 9 5  6 0 0  6 0 5  
Phe G l n  L e u  G l n  H i s  T r p  L e u  A l a  I l e  
6 1 0  6 1 5  
< 2 1 0 >  SEQ I D  NO 1 5  
< 2 1 1 >  LENGTH: 9 8 0  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n  
<220> FEATURE: 
< 2 2 1 >  NAME/KEY:  exon 
<222> LOCATION: ( 1 2 9 ) . . ( 2 5 7  
< 2 2 1 >  NAME/KEY:  gene 
<222> LOCATION: ( 1 2 9 ) . . ( 8 0 0  
< 2 2 1 >  NAME/KEY:  exon 
<222> LOCATION: ( 7 0 1 ) . . ( 8 0 2  
< 3 0 0 >  PUBLICATION INFORMATI 
< 3 0 1 >  AUTHORS: P o r z g e n ,  P .  
B o n i s c h ,  H. 
B r u s s ,  M .  
N: 
< 3 0 2 >  TITLE:  Molecular C l o n i n g  and O r g a n i z a t i o n  of t h e  C o d i n g  R e g i o n  
< 3 0 3 >  JOURNAL: B i o c h e m .  B i o p h y s .  R e s .  Commun. 
< 3 0 4 >  VOLUME: 2 1 5  
< 3 0 5 >  ISSUE:  ( 3 )  
< 3 0 6 >  PAGES: 1 1 4 5 - 1 1 5 0  
< 3 0 7 >  DATE: 1 9 9 5 - 1 0 - 2 4  
< 3 0 8 >  DATABASE ACCESSION NUMBER: x 9 1 1 1 7  
< 3 0 9 >  DATABASE ENTRY DATE: 1 9 9 6 - 0 2 - 2 0  
< 4 0 0 >  SEQUENCE: 1 5  
t t t c t c g a g a  gaggcaaggc agcc taca tg  ag tcc tgggc  tgcaggaggc tc taggaacc  6 0  
c tggggcctg  agac tgaggt  ccagggagac c c t a a t t c c t  gcaccccacc c c t c c t g g t t  1 2 0  
ccctccag a t g  gga ggc a t g  gag g c t  g t c  a t c  acg ggc c t g  gca g a t  gac 1 7 0  
of t h e  Human N o r e p i n e p h r i n e  T r a n p o r t e r  G e n e  
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- con t inued  
t t c  cag  g t c  c t g  aag  cga  cac  cgg aaa  c t c  t t c  aca  ttt ggc g t c  acc  
t t c  agc  a c t  t t c  c t t  c t c  gcc c t g  t t c  t g c  a t a  acc  aag  g tgag taggg  
g c t g g g c t c t  ggg tcacc tg  ggggcc tc tg  a g g c c g c a t t  t c a a t a a a g t  c a a a c a t t c c  
t a g c c t t a g a  ac tgggc tga  gc tcagggag aacaa tgcag  g a t c c a g c a t  c c t c a a t t c a  
gcggcc tgac  c c a c t a g g g t  t a g g c c c a g t  a g t c t t c t t c  c a t c t c t g a s  s c t g a g g a t t  
c c a t t c a g c c  c t g t t a a t t g  c c t t a t t g a c  t t g a g g g s c a  gcaaaag tcc  c t t t g g a a c c  
c a t c t a a c t c  t t t a t t g g c t  gaaac tgagg t g a c t g t a a c  g t c a a t a c a a  cagcaccaca  
g c c c t a t g c c  c t g g g t t t t c  a a a t a g a g c t  ccgagcaagt  gggacagggg gcaggtaaga  
g t t g a c a g a c  a c a a c a a t c a  g t t c c c a c g t  t t g a c c a a a g  a g g g c c t c t t  g g c t t c t t c t  
c t c c c t g t g c  cag  g g t  gga a t t  t a c  g t c  t t g  acc  c t c  c t g  gac acc  ttt 
g c t  gcg ggc acc  t c c  a t c  c t t  ttt g c t  g t c  c t c  a t g  gaa gcc a t c  gga 
g t t  t c c  t g g  ttt t a t  g g t  a t g t g a g t g t  g tggaaaagc  c t c a g c t c c c  
a g t c c t c c t a  g a a t c c t g c a  cc tggagg tg  tgcagggagg c c t t c c a t t t  ccaggacagc  
c a c c t a a a a t  t c c a g a g t c c  agcaag tcac  t t a t t g g g a a  c a a a t c t c a a  t c c t c g g c t c  
a t c t t t g g a t  gaacc tgccc  t t a a c a g g  
<210> SEQ I D  NO 16 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Homo s a p i e n s  
<400> SEQUENCE: 16 
aggaccggta  a a g t t c c t c t  cg 
<210> SEQ I D  NO 17 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Homo s a p i e n s  
<400> SEQUENCE: 17 
t c c g t g t g t a  t t c c a g c t c c  t g  
<210> SEQ I D  NO 18 
<211> LENGTH: 21 
<212> TYPE: DNA 
<213> ORGANISM: Homo s a p i e n s  
<400> SEQUENCE: 18 
g a t t g c t g c g  c g t c g c c t t t  g 
<210> SEQ I D  NO 19 
<211> LENGTH: 21 
<212> TYPE: DNA 
<213> ORGANISM: Homo s a p i e n s  
<400> SEQUENCE: 19 
c c t t a g a t c t  caccac tgga  g 
218 
267 
327 
387 
447 
507 
567 
627 
687 
736 
784 
832 
892 
952 
980 
2 2  
2 2  
21 
21 
<210> SEQ I D  NO 2 0  
<211> LENGTH: 20  
<212> TYPE: DNA 
<213> ORGANISM: Homo s a p i e n s  
<400> SEQUENCE: 2 0  
US 7,094,532 B2 
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- con t inued  
ca tgcgacag  g t c a c t g g t g  
< 2 1 0 >  SEQ I D  NO 2 1  
< 2 1 1 >  LENGTH: 22 
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 2 1  
t a g t g t t t g g  c t c a g g t c a t  a c  
< 2 1 0 >  SEQ I D  NO 2 2  
< 2 1 1 >  LENGTH: 20  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 2 2  
agagtggcca  g g t c c t g t c t  
< 2 1 0 >  SEQ I D  NO 2 3  
< 2 1 1 >  LENGTH: 22 
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 2 3  
c t t g c a c t t c  c a g c t c c a t c  tt 
< 2 1 0 >  SEQ I D  NO 2 4  
< 2 1 1 >  LENGTH: 2 3  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 2 4  
t g g c t t c a g g  g c c t t g c c t a  gag 
< 2 1 0 >  SEQ I D  NO 2 5  
< 2 1 1 >  LENGTH: 2 3  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 2 5  
acaagcc tgg  c c c a a g g c t t  gg t  
< 2 1 0 >  SEQ I D  NO 2 6  
< 2 1 1 >  LENGTH: 2 4  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 2 6  
c t g c c c a t c t  c t g g t t c a g a  c c a t  
< 2 1 0 >  SEQ I D  NO 2 7  
< 2 1 1 >  LENGTH: 2 3  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 2 7  
ggagag t tgg  c t t c c a g a c c  aga 
< 2 1 0 >  SEQ I D  NO 2 8  
< 2 1 1 >  LENGTH: 22 
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 2 8  
2 0  
2 2  
2 0  
2 2  
2 3  
2 3  
2 4  
2 3  
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- con t inued  
g t a t c c a t g t  ggcagcagga gc 2 2  
< 2 1 0 >  SEQ I D  NO 2 9  
< 2 1 1 >  LENGTH: 22 
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
< 4 0 0 >  SEQUENCE: 2 9  
cacggaagag cca tgcagcc  a a  
< 2 1 0 >  SEQ I D  NO 3 0  
< 2 1 1 >  LENGTH: 2 6  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
< 4 0 0 >  SEQUENCE: 3 0  
c t a t c a t g t g  cagc tcagac  c a a t g g  
< 2 1 0 >  SEQ I D  NO 3 1  
< 2 1 1 >  LENGTH: 27  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
< 4 0 0 >  SEQUENCE: 3 1  
g t c t g c a a t t  t a a a t a g g g c  c t t c t g g  
< 2 1 0 >  SEQ I D  NO 3 2  
< 2 1 1 >  LENGTH: 2 4  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
< 4 0 0 >  SEQUENCE: 3 2  
caaggcagcc t a c a t g a g t c  c t g g  
< 2 1 0 >  SEQ I D  NO 33  
< 2 1 1 >  LENGTH: 2 5  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
< 4 0 0 >  SEQUENCE: 33  
t a a c a g g g c t  g a a t g g a a t c  c t c a g  
< 2 1 0 >  SEQ I D  NO 3 4  
< 2 1 1 >  LENGTH: 2 4  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
< 4 0 0 >  SEQUENCE: 3 4  
gg tgcaggat  t c t a g g a g g a  c t g g  
< 2 1 0 >  SEQ I D  NO 35 
< 2 1 1 >  LENGTH: 2 4  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
< 4 0 0 >  SEQUENCE: 35 
c a t c t t g c c t  c a c t g c c c t g  c t c t  
2 2  
2 6  
2 7  
2 4  
2 5  
2 4  
2 4  
< 2 1 0 >  SEQ I D  NO 3 6  
< 2 1 1 >  LENGTH: 2 6  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
US 7,094,532 B2 
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<400>  SEQUENCE: 3 6  
t t g a c c c t a g  t g t c t g t g t c  c t t c t g  
< 2 1 0 >  SEQ I D  NO 3 7  
< 2 1 1 >  LENGTH: 2 4  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 3 7  
g c t g c a g g a t  caaa tagcag  g t g g  
< 2 1 0 >  SEQ I D  NO 38  
< 2 1 1 >  LENGTH: 2 4  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 38  
t g c t c c t c t c  c t c t g a g c t a  acag  
< 2 1 0 >  SEQ I D  NO 3 9  
< 2 1 1 >  LENGTH: 2 3  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 3 9  
g g a g g t g c t t  g g a g a t c a t t  t g g  
< 2 1 0 >  SEQ I D  NO 4 0  
< 2 1 1 >  LENGTH: 2 3  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: Homo s a p i e n s  
<400>  SEQUENCE: 4 0  
g c t t c a g t c t  c a c a t t a g c g  agg 
2 6  
2 4  
2 4  
2 3  
2 3  
40 What is claimed is: 
1. Amethod of screening for susceptibility to sub-optimal 
norepinephrine (NE) transport resulting in decreased NE 
clearance in a subject, the method comprising: 
amino acid 457 of SEQ ID NO: 1, the presence of the 
polymorphism indicating the susceptibility of the sub- 
ject to sub-optimal norepinephrine transport resulting 
in decreased NE clearance. 
(a) obtaining a biological sample from the subject, 45 3. The method of claim 2, wherein the polymorphism is 
wherein the biological sample comprises a nucleic acid detected by amplifying a target nucleic acid in the nucleic 
sample; and acid sample from the subject using an amplification tech- 
(b) detecting a polymorphism of a NE transporter gene in nique. 
the biological sample from the subject, wherein the 4. The method of claim 3, wherein the polymorphism is 
polymorphism of the NE transporter gene comprises a 5o detected by amplifying a target nucleic acid in the nucleic 
G to C transversion within NE transporter exon 9 acid sample from the subject using an oligonucleotide pair, 
(nucleotides 129-257 of SEQ ID NO: 15), the presence wherein a first oligonucleotide of the pair hybridizes to a first 
of the polymorphism indicating the susceptibility of the portion of the NE transporter gene, wherein the first portion 
subject to sub-optimal norepinephrine transport result- 
ing in decreased NE clearance. 
2. Amethod of screening for susceptibility to sub-optimal 
norepinephrine (NE) transport resulting in decreased NE 
clearance in a subject, the method comprising: 
(a) obtaining a biological sample from the subject, 
wherein the biological sample comprises a nucleic acid 
sample; and 
(b) detecting a polymorphism of a NE transporter gene in 
the biological sample from the subject, wherein the 
polymorphism of the NE transporter gene comprises a 
G to C transversion within NE transporter exon 9 
(nucleotides 129-257 of SEQ ID NO: 15) and encodes 
includes the polymorphism of the NE transporter gene, and 
55 wherein the second of the oligonucleotide pair hybridizes to 
a second portion of the NE transporter gene that is adjacent 
to the first portion. 
5. A method of screening for susceptibility to sub-optimal 
norepinephrine (NE) transport resulting in decreased NE 
(a) obtaining a biological sample from the subject, 
wherein the biological sample comprises a nucleic acid 
sample; and 
(b) detecting a polymorphism of a NE transporter gene 
65 encoding an amino acid change in the biological 
sample from the subject, wherein the polymorphism of 
60 clearance in a subject, the method comprising: 
a NE transporter polypeptide having a proline moiety at the NE transporter gene is detected by amplifying a 
US 7,094, 
91 
target nucleic acid in the nucleic acid sample from the 
subject using an oligonucleotide pair, wherein a first 
oligonucleotide of the pair hybridizes to a first portion 
of the NE transporter gene including exon 9 (nucle- 
otides 129-257 of SEQ ID NO: 15) and the polymor- 5 
phism of the NE transporter gene, and wherein the 
second oligonucleotide of the pair hybridizes to a 
second portion of the NE transporter gene that is 
adjacent to the first portion, the presence of the poly- 
morphism indicating the susceptibility of the subject to i o  
sub-optimal norepinephrine transport resulting in 
decreased NE clearance. 
6. The method of claim 4, wherein the first and the second 
oligonucleotides each further comprise a detectable label, 
and wherein the label of the first oligonucleotide is distin- 15 
guishable from the label of the second oligonucleotide. 
7. The method of claim 6, wherein said label of said first 
oligonucleotide is a radiolabel, and wherein said label of 
said second oligonucleotide is a biotin label. 
is detected by sequencing a target nucleic acid in the nucleic 
acid sample from the subject. 
9. The method of claim 8, wherein the sequencing com- 
prises dideoxy sequencing. 
10. A method of screening for susceptibility to sub- 25 
optimal norepinephrine (NE) transport resulting in 
8. The method of claim 1 or 2, wherein the polymorphism 20 
532 B2 
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presence of the NE transporter polymorphism and 
detecting the reagent, wherein the reagent detects a G 
to C transversion within NE transporter exon 9 (nucle- 
otides 129-257 of SEQ ID NO: 15), the presence of the 
polymorphism indicating the susceptibility of the sub- 
ject to sub-optimal norepinephrine transport resulting 
in decreased NE clearance. 
11. A method of screening for susceptibility to sub- 
optimal norepinephrine (NE) transport resulting in 
decreased NE clearance in a subject, the method comprising: 
(a) obtaining a biological sample from the subject, 
wherein the biological sample comprises a nucleic acid 
sample; and 
(b) detecting a polymorphism of a NE transporter gene in 
the biological sample from the subject, wherein the 
polymorphism of the NE transporter gene is detected 
by contacting a target nucleic acid in the nucleic acid 
sample from the subject with a reagent that detects the 
presence of the NE transporter polymorphism and 
detecting the reagent, wherein the reagent is an oligo- 
nucleotide primer as set forth in SEQ ID NO:9 or SEQ 
ID NO:10, the presence of the polymorphism indicat- 
ing the susceptibility of the subject to sub-optimal 
norepinephrine transport resulting in decreased NE 
clearance. 
12. The method of claim 1, wherein the subject is a human 
decreased NE cle&ance in a subject, the method comp&ing: 
(a) obtaining a biological sample from the subject, 
wherein the biological sample comprises a nucleic acid 
sample; and 
(b) detecting a polymorphism of a NE transporter gene in 
the biological sample from the subject, wherein the 
polymorphism of the NE transporter gene is detected 
by contacting a target nucleic acid in the nucleic acid 
sample from the subject with a reagent that detects the 
subject. 
13. The method of claim 2, wherein the susceptibility of 
the subject to sub-optimal NE transport is further charac- 
14. The method of claim 2, wherein the polymorphism 
results in a norepinephrine transporter comprising an amino 
acid sequence as set forth in SEQ ID NO: 4. 
30 terized as susceptibility to orthostatic intolerance. 
* * * * *  
